Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

LNTH

Lantheus Holdings Inc

May 01 • 04:00PM ET

67.39

Dollar change +0.85
Percentage change 1.28	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IJH VTI VB IWM VXF VBK IWO IJK SCHA VTWO

Index	RUT	P/E	14.51	EPS (ttm)	4.64	Insider Own	2.37%	Shs Outstand	69.86M	Perf Week	3.34%
Market Cap	4.62B	Forward P/E	10.11	EPS next Y	6.67	Insider Trans	-	Shs Float	66.92M	Perf Month	14.47%
Income	326.66M	PEG	0.38	EPS next Q	1.54	Inst Own	102.34%	Short Float	6.95%	Perf Quarter	29.77%
Sales	1.30B	P/S	3.56	EPS this Y	5.55%	Inst Trans	-1.01%	Short Ratio	5.43	Perf Half Y	9.43%
Book/sh	11.68	P/B	5.77	EPS next Y	1.37%	ROA	21.98%	Short Interest	4.65M	Perf Year	-19.17%
Cash/sh	10.41	P/C	6.47	EPS next 5Y	37.73%	ROE	51.73%	52W Range	50.20 - 100.85	Perf YTD	8.69%
Dividend Est.	-	P/FCF	17.86	EPS past 5Y	35.30%	ROI	22.81%	52W High	-33.18%	Beta	0.52
Dividend TTM	-	Quick Ratio	5.45	Sales past 5Y	36.54%	Gross Margin	65.38%	52W Low	34.24%	ATR (14)	2.08
Dividend Ex-Date	-	Current Ratio	5.80	EPS Y/Y TTM	1065.78%	Oper. Margin	38.06%	RSI (14)	68.31	Volatility	2.93% 3.17%
Employees	834	Debt/Eq	0.76	Sales Y/Y TTM	38.65%	Profit Margin	25.20%	Recom	1.18	Target Price	97.50
Option/Short	Yes / Yes	LT Debt/Eq	0.76	EPS Q/Q	184.77%	Payout	0.00%	Rel Volume	1.72	Prev Close	66.54
Sales Surprise	4.25%	EPS Surprise	22.29%	Sales Q/Q	34.52%	Earnings	May 02 BMO	Avg Volume	856.82K	Price	67.39
SMA20	7.91%	SMA50	8.87%	SMA200	3.03%	Trades		Volume	1,473,745	Change	1.28%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-18-23	Downgrade	William Blair	Outperform → Mkt Perform
Dec-04-23	Initiated	TD Cowen	Outperform	$100
Sep-29-23	Initiated	William Blair	Outperform
Mar-08-23	Initiated	JMP Securities	Mkt Outperform	$120
Nov-30-22	Initiated	SVB Leerink	Outperform
Oct-13-22	Initiated	Mizuho	Buy	$105
May-09-22	Initiated	B. Riley Securities	Buy	$91
Apr-13-22	Initiated	Truist	Buy	$77
Feb-01-21	Initiated	SVB Leerink	Outperform	$24
Jun-29-20	Resumed	Jefferies	Buy	$29
Aug-16-19	Upgrade	CJS Securities	Market Perform → Market Outperform
Nov-02-17	Upgrade	Wells Fargo	Market Perform → Outperform
Nov-08-16	Reiterated	RBC Capital Mkts	Outperform	$6 → $12
Sep-23-16	Resumed	Credit Suisse	Neutral
Feb-24-16	Reiterated	RBC Capital Mkts	Outperform	$9 → $6
Dec-11-15	Downgrade	Credit Suisse	Outperform → Neutral
Sep-30-15	Downgrade	Wells Fargo	Outperform → Market Perform
Jul-20-15	Initiated	Wells Fargo	Outperform
Jul-20-15	Initiated	Robert W. Baird	Outperform	$10
Jul-20-15	Initiated	RBC Capital Mkts	Outperform	$10

Show Previous Ratings

Apr-30-24 02:39PM	Here's Why You Should Hold Lantheus (LNTH) in Your Portfolio Now (Zacks)
Apr-26-24 05:50PM	Here's Why Lantheus Holdings (LNTH) Gained But Lagged the Market Today (Zacks)
01:12PM	Factors Setting the Tone For Lantheus' (LNTH) Q1 Earnings (Zacks)
Apr-25-24 10:01AM	Lantheus Holdings (LNTH) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-24-24 06:00PM	Lantheus Holdings (LNTH) Outpaces Stock Market Gains: What You Should Know (Zacks)
09:00AM	Loading…
09:00AM	Lantheus Holdings, Inc. (LNTH) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Apr-23-24 09:45AM	Why Lantheus Holdings (LNTH) is a Top Growth Stock for the Long-Term (Zacks)
09:40AM	Is Lantheus (LNTH) Stock Undervalued Right Now? (Zacks)
Apr-19-24 12:10PM	Will Lantheus Holdings (LNTH) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Apr-18-24 08:00AM	Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time (GlobeNewswire)
Apr-15-24 06:00PM	Lantheus Holdings (LNTH) Stock Moves -0.89%: What You Should Know (Zacks)
09:50AM	Here's Why Lantheus Holdings (LNTH) is a Strong Momentum Stock (Zacks)
Apr-13-24 12:12PM	10 Most Undervalued Value Stocks To Buy Now (Insider Monkey)
Apr-11-24 09:00AM	Lantheus Holdings, Inc. (LNTH) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Apr-10-24 02:18PM	Wall Street Favorites: 3 Russell 2000 Stocks With Strong Buy Ratings for April 2024 (InvestorPlace)
06:00PM	Loading…
Apr-09-24 06:00PM	Lantheus Holdings (LNTH) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
Apr-05-24 09:00AM	Is Trending Stock Lantheus Holdings, Inc. (LNTH) a Buy Now? (Zacks)
Apr-03-24 05:45PM	Lantheus Holdings (LNTH) Exceeds Market Returns: Some Facts to Consider (Zacks)
Mar-28-24 10:04AM	Here's Why You Should Add Lantheus (LNTH) to Your Portfolio (Zacks)
07:30AM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results (GlobeNewswire)
Mar-26-24 05:45PM	Lantheus Holdings (LNTH) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
Mar-25-24 09:00AM	Is Most-Watched Stock Lantheus Holdings, Inc. (LNTH) Worth Betting on Now? (Zacks)
Mar-22-24 09:30AM	Lantheus (LNTH) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Mar-20-24 05:45PM	Why Lantheus Holdings (LNTH) Outpaced the Stock Market Today (Zacks)
Mar-14-24 05:45PM	Lantheus Holdings (LNTH) Rises As Market Takes a Dip: Key Facts (Zacks)
09:50AM	Why Lantheus Holdings (LNTH) is a Top Momentum Stock for the Long-Term (Zacks)
Mar-13-24 04:30PM	The 7 Most Undervalued Mid-Cap Stocks to Buy in March 2024 (InvestorPlace)
Mar-12-24 09:00AM	Lantheus Holdings, Inc. (LNTH) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Mar-11-24 07:01PM	Insider Sell: President Paul Blanchfield Sells Shares of Lantheus Holdings Inc (LNTH) (GuruFocus.com)
Mar-08-24 05:45PM	Lantheus Holdings (LNTH) Stock Moves -0.11%: What You Should Know (Zacks)
03:00AM	Loading…
03:00AM	Director Sam Leno Sells Shares of Lantheus Holdings Inc (LNTH) (GuruFocus.com)
Mar-07-24 09:40AM	Is Lantheus (LNTH) a Great Value Stock Right Now? (Zacks)
Mar-06-24 09:55AM	Wall Street Analysts See a 44.13% Upside in Lantheus Holdings (LNTH): Can the Stock Really Move This High? (Zacks)
09:30AM	Wall Street Analysts See Lantheus Holdings (LNTH) as a Buy: Should You Invest? (Zacks)
Mar-05-24 10:15AM	Lantheus' (LNTH) DEFINITY Approved by FDA for Pediatric Use (Zacks)
08:30AM	Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
08:00AM	Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility (GlobeNewswire)
Mar-04-24 08:30AM	Lantheus Announces the FDA Approval of DEFINITY (Perflutren Lipid Microsphere) for Pediatric Patients (GlobeNewswire)
Feb-28-24 08:30AM	Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer (GlobeNewswire)
Feb-27-24 09:00AM	Lantheus Holdings, Inc. (LNTH) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Feb-26-24 11:00AM	Here's Why You Should Add Lantheus (LNTH) to Your Portfolio (Zacks)
08:30AM	Lantheus to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-23-24 11:00AM	Lantheus (LNTH) Q4 Earnings Surpass Estimates, Gross Margin Up (Zacks)
10:48AM	Lantheus Holdings, Inc. (NASDAQ:LNTH) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:30AM	Lantheus Holdings (LNTH) Recently Broke Out Above the 50-Day Moving Average (Zacks)
Feb-22-24 09:30AM	Lantheus Holdings (LNTH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +14.71%
08:30AM	Lantheus Holdings (LNTH) Q4 Earnings and Revenues Beat Estimates (Zacks)
08:12AM	Lantheus Holdings Inc Reports Robust Revenue Growth and Strong Earnings in Q4 and Full Year 2023 (GuruFocus.com)
07:33AM	Lantheus Holdings: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
03:55AM	11 Best Small-Cap Growth Stocks to Invest In (Insider Monkey)
Feb-19-24 09:55AM	Wall Street Analysts Think Lantheus Holdings (LNTH) Could Surge 58.6%: Read This Before Placing a Bet (Zacks)
09:30AM	Should You Invest in Lantheus Holdings (LNTH) Based on Bullish Wall Street Views? (Zacks)
08:30AM	Lantheus (LNTH) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-16-24 05:45PM	Lantheus Holdings (LNTH) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Feb-15-24 10:00AM	Lantheus Holdings (LNTH) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-13-24 01:36PM	15 Best Strong Buy Stocks To Invest In (Insider Monkey)
08:30AM	Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging (GlobeNewswire)
Feb-08-24 05:45PM	Lantheus Holdings (LNTH) Exceeds Market Returns: Some Facts to Consider (Zacks)
08:00AM	Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time (GlobeNewswire)
Feb-06-24 09:00AM	Lantheus Holdings, Inc. (LNTH) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Feb-02-24 05:45PM	Lantheus Holdings (LNTH) Outperforms Broader Market: What You Need to Know (Zacks)
Jan-26-24 05:45PM	Lantheus Holdings (LNTH) Increases Despite Market Slip: Here's What You Need to Know (Zacks)
Jan-23-24 12:10PM	Will Lantheus Holdings (LNTH) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:00AM	Lantheus Holdings, Inc. (LNTH) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
07:45AM	Lantheus Announces CEO Succession Plan (GlobeNewswire)
Jan-18-24 05:45PM	Lantheus Holdings (LNTH) Stock Dips While Market Gains: Key Facts (Zacks)
Jan-12-24 05:45PM	Lantheus Holdings (LNTH) Stock Sinks As Market Gains: What You Should Know (Zacks)
09:37AM	14 High Growth NASDAQ Stocks That Are Profitable (Insider Monkey)
09:23AM	16 Best Mid-Cap Growth Stocks To Buy Now (Insider Monkey)
Jan-11-24 08:00AM	Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA (Lutetium Lu 177 Dotatate) (GlobeNewswire)
Jan-10-24 09:00AM	Lantheus Holdings, Inc. (LNTH) is Attracting Investor Attention: Here is What You Should Know (Zacks) -5.99%
Jan-09-24 08:00AM	Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability (GlobeNewswire)
08:00AM	Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics (GlobeNewswire)
07:55AM	Lantheus Reports Preliminary Fiscal Year 2023 Revenue (GlobeNewswire)
Jan-08-24 09:51AM	17 High Growth Non-Tech Stocks That Are Profitable (Insider Monkey)
Jan-05-24 05:45PM	Lantheus Holdings (LNTH) Exceeds Market Returns: Some Facts to Consider (Zacks)
Jan-03-24 08:30AM	Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-01-24 12:52PM	New Year, New Gains: The 3 Best AI Stocks to Buy in 2024 (InvestorPlace)
09:30AM	Is It Worth Investing in Lantheus Holdings (LNTH) Based on Wall Street's Bullish Views? (Zacks)
Dec-29-23 05:45PM	Lantheus Holdings (LNTH) Declines More Than Market: Some Information for Investors (Zacks)
09:00AM	Lantheus Holdings, Inc. (LNTH) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Dec-27-23 06:41PM	13 Most Promising Future Stocks To Buy According To Hedge Funds (Insider Monkey)
Dec-20-23 08:00AM	Lantheus Holdings Is Charting a Path to Sustainable Growth and Value (GuruFocus.com)
Dec-18-23 07:30AM	Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire) -26.88%
Dec-15-23 09:30AM	Lantheus Holdings (LNTH) Crossed Above the 200-Day Moving Average: What That Means for Investors (Zacks)
Dec-12-23 09:00AM	Lantheus Holdings, Inc. (LNTH) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Dec-11-23 09:35AM	Lantheus Holdings (LNTH) Recently Broke Out Above the 20-Day Moving Average (Zacks)
Nov-29-23 09:00AM	Investors Heavily Search Lantheus Holdings, Inc. (LNTH): Here is What You Need to Know (Zacks)
Nov-17-23 09:00AM	Here is What to Know Beyond Why Lantheus Holdings, Inc. (LNTH) is a Trending Stock (Zacks)
Nov-08-23 08:00AM	Lantheus to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-06-23 09:00AM	Is Trending Stock Lantheus Holdings, Inc. (LNTH) a Buy Now? (Zacks)
Nov-04-23 12:53PM	Lantheus Holdings, Inc. (NASDAQ:LNTH) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 09:30AM	Compared to Estimates, Lantheus Holdings (LNTH) Q3 Earnings: A Look at Key Metrics (Zacks) -5.95%
09:16AM	Lantheus Holdings Inc (LNTH) Reports 33.7% Increase in Q3 2023 Revenue and Doubled Net Income (GuruFocus.com)
07:38AM	Lantheus Holdings: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Lantheus Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-01-23 11:59AM	Lantheus (LNTH) to Report Q3 Earnings: What's in the Cards? (Zacks)
Oct-30-23 03:39PM	7 Low-Risk Stock Picks to Double Your Money (InvestorPlace) -7.86%
Oct-26-23 05:45PM	Lantheus Holdings (LNTH) Stock Moves -1.02%: What You Should Know (Zacks)

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sabens Andrea	Chief Accounting Officer	Apr 15 '24	Sale	61.24	341	20,883	63,239	Apr 17 04:30 PM
Marshall Robert J. Jr.	CFO and Treasurer	Mar 15 '24	Sale	60.00	20,000	1,200,000	113,749	Mar 19 04:30 PM
Sabens Andrea	Chief Accounting Officer	Mar 13 '24	Sale	60.48	341	20,624	63,204	Mar 15 04:30 PM
Blanchfield Paul	President	Mar 07 '24	Sale	61.96	18,023	1,116,705	103,357	Mar 11 04:30 PM
LENO SAM R	Director	Mar 06 '24	Option Exercise	16.30	2,045	33,334	59,982	Mar 07 04:30 PM
Lantheus Alpha Therapy, LLC	10% Owner	Mar 06 '24	Buy	0.95	60,431,039	57,409,487	116,773,394	Mar 08 11:24 AM
LENO SAM R	Director	Mar 06 '24	Sale	63.50	2,045	129,857	57,937	Mar 07 04:30 PM
LENO SAM R	Director	Mar 05 '24	Option Exercise	16.30	2,045	33,334	59,982	Mar 07 04:30 PM
LENO SAM R	Director	Mar 05 '24	Sale	64.62	2,045	132,148	57,937	Mar 07 04:30 PM
LENO SAM R	Director	Mar 04 '24	Option Exercise	19.85	22,389	444,499	80,326	Mar 06 05:15 PM
Heino Mary Anne	Director	Mar 04 '24	Sale	65.31	93,863	6,129,889	251,643	Mar 05 08:28 PM
LENO SAM R	Director	Mar 04 '24	Sale	65.42	22,389	1,464,749	57,937	Mar 06 05:15 PM
Sabens Andrea	Chief Accounting Officer	Feb 13 '24	Sale	55.31	341	18,861	58,403	Feb 15 04:30 PM
Sabens Andrea	Chief Accounting Officer	Jan 16 '24	Sale	56.01	341	19,099	58,744	Jan 18 04:30 PM
Marshall Robert J. Jr.	CFO and Treasurer	Dec 15 '23	Sale	78.24	10,000	782,400	103,170	Dec 19 05:00 PM
Sabens Andrea	Chief Accounting Officer	Dec 13 '23	Sale	75.62	341	25,786	59,085	Dec 15 04:30 PM
Blanchfield Paul	President	Nov 16 '23	Sale	67.96	1,500	101,940	88,651	Nov 20 04:30 PM
Heino Mary Anne	CEO	Nov 13 '23	Sale	63.72	11,780	750,611	317,687	Nov 15 04:32 PM
Sabens Andrea	Chief Accounting Officer	Nov 13 '23	Sale	63.57	341	21,677	59,426	Nov 15 04:30 PM
Niedzwiecki Daniel	See Remarks	Sep 15 '23	Option Exercise	17.79	2,846	50,630	69,141	Sep 19 04:30 PM
Niedzwiecki Daniel	See Remarks	Sep 15 '23	Sale	66.43	2,846	189,060	66,295	Sep 19 04:30 PM
Blanchfield Paul	President	Aug 21 '23	Sale	66.10	408	26,969	90,067	Aug 23 04:30 PM
Blanchfield Paul	President	Aug 18 '23	Sale	65.19	1,500	97,785	90,475	Aug 22 04:30 PM
Marshall Robert J. Jr.	CFO and Treasurer	Aug 15 '23	Sale	68.52	10,000	685,200	108,298	Aug 17 04:30 PM
Heino Mary Anne	CEO	Aug 11 '23	Sale	68.58	10,950	750,981	329,467	Aug 15 05:35 PM
Niedzwiecki Daniel	See Remarks	Aug 11 '23	Sale	67.93	4,297	291,895	66,295	Aug 15 04:54 PM
Sabens Andrea	Chief Accounting Officer	Jul 19 '23	Sale	90.87	1,752	159,209	59,767	Jul 21 04:30 PM
Baylor-Henry Minnie	Director	Jun 02 '23	Sale	86.22	6	517	16	Oct 13 05:03 PM
Blanchfield Paul	President	May 18 '23	Sale	97.93	1,500	146,895	92,743	May 22 06:47 PM
Marshall Robert J. Jr.	CFO and Treasurer	May 15 '23	Sale	99.36	10,000	993,600	118,298	May 17 04:30 PM
Sabens Andrea	Chief Accounting Officer	May 15 '23	Sale	99.36	385	38,254	61,519	May 17 04:31 PM
Niedzwiecki Daniel	See Remarks	May 11 '23	Sale	98.82	6,113	604,087	72,058	May 15 06:34 PM

Open in Screener

NEOG

Neogen Corp.

May 01 • 04:00PM ET

12.25

Dollar change -0.08
Percentage change -0.65	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB IJH IWM VXF VBK IWN IJJ VTWO SCHA

Index	RUT	P/E	1701.39	EPS (ttm)	0.01	Insider Own	0.18%	Shs Outstand	216.25M	Perf Week	-0.97%
Market Cap	2.65B	Forward P/E	816.67	EPS next Y	0.01	Insider Trans	16.42%	Shs Float	216.22M	Perf Month	-15.46%
Income	1.57M	PEG	170.14	EPS next Q	-0.01	Inst Own	103.40%	Short Float	8.17%	Perf Quarter	-20.97%
Sales	929.24M	P/S	2.86	EPS this Y	70.83%	Inst Trans	88.57%	Short Ratio	8.84	Perf Half Y	-18.66%
Book/sh	14.52	P/B	0.84	EPS next Y	142.86%	ROA	0.03%	Short Interest	17.66M	Perf Year	-29.15%
Cash/sh	0.78	P/C	15.75	EPS next 5Y	10.00%	ROE	0.05%	52W Range	11.46 - 24.09	Perf YTD	-39.09%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	0.04%	52W High	-49.16%	Beta	1.17
Dividend TTM	-	Quick Ratio	2.66	Sales past 5Y	17.12%	Gross Margin	50.83%	52W Low	6.89%	ATR (14)	0.55
Dividend Ex-Date	-	Current Ratio	3.82	EPS Y/Y TTM	-76.68%	Oper. Margin	8.09%	RSI (14)	38.02	Volatility	3.80% 4.40%
Employees	2640	Debt/Eq	0.28	Sales Y/Y TTM	28.93%	Profit Margin	0.17%	Recom	2.00	Target Price	17.00
Option/Short	Yes / Yes	LT Debt/Eq	0.28	EPS Q/Q	-124.60%	Payout	-	Rel Volume	1.06	Prev Close	12.33
Sales Surprise	-0.35%	EPS Surprise	-166.67%	Sales Q/Q	4.84%	Earnings	Apr 09 BMO	Avg Volume	2.00M	Price	12.25
SMA20	-3.22%	SMA50	-16.87%	SMA200	-30.91%	Trades		Volume	2,114,817	Change	-0.65%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-16-23	Initiated	Wells Fargo	Overweight	$22
Nov-22-22	Upgrade	William Blair	Mkt Perform → Outperform
Jul-12-22	Initiated	Piper Sandler	Neutral	$25
May-23-19	Initiated	Guggenheim	Neutral
Dec-05-17	Resumed	ROTH Capital	Neutral	$82
Jul-14-17	Initiated	CL King	Neutral
Jun-05-14	Initiated	William Blair	Mkt Perform
Mar-31-11	Upgrade	Hilliard Lyons	Underperform → Neutral
Sep-25-09	Reiterated	Roth Capital	Buy	$33 → $36
Jul-22-09	Reiterated	Roth Capital	Buy	$29 → $33
Mar-20-09	Reiterated	Roth Capital	Buy	$32 → $28
Jan-07-09	Reiterated	Roth Capital	Buy	$33 → $32
Sep-25-08	Reiterated	Roth Capital	Buy	$30 → $33
Jan-04-08	Reiterated	Roth Capital	Buy	$28 → $30
Sep-28-07	Reiterated	Roth Capital	Buy	$23.33 → $28
Jul-25-07	Reiterated	Roth Capital	Buy	$33 → $35
Jul-09-07	Reiterated	Roth Capital	Buy	$27 → $33
May-08-07	Initiated	Susquehanna Financial	Positive

Show Previous Ratings

Today 08:45AM	Neogen Petrifilm Celebrates 40 Years! (PR Newswire)
Apr-30-24 08:45AM	Neogen Launches New Molecular Method for Detection of Two Salmonella Serotypes (PR Newswire)
Apr-28-24 06:32PM	11 Oversold Growth Stocks to Buy Right Now (Insider Monkey)
Apr-24-24 09:31AM	Latest Insider Trading Activity: 5 Stocks Executives and Directors are Buying (Insider Monkey)
Apr-22-24 10:44AM	Neogen (NEOG) Inks Genomics Deal to Aid in Food Tracing (Zacks)
08:45AM	Loading…
Apr-18-24 08:45AM	Neogen Forms Genomics Relationship with Performance Food Group (PR Newswire)
Apr-17-24 03:00PM	Insider Buying: Neogen Corp (NEOG) COO Douglas Jones Acquires 10,000 Shares (GuruFocus.com)
Apr-11-24 01:48PM	Hedge Fund and Insider Trading News: Bill Ackman, Paul Marshall, John Paulson, Larry Robbins, Mason Capital Management, Neogen Corp (NEOG), Broadcom Inc. (AVGO), and More (Insider Monkey)
08:45AM	Neogen Farm Fluid MAX Disinfectant Launches Across Great Britain Livestock & Poultry Markets (PR Newswire)
03:24AM	Neogen Corp (NEOG) CEO John Adent Acquires 23,000 Shares (GuruFocus.com)
Apr-10-24 09:40AM	Neogen Corporation (NASDAQ:NEOG) Q3 2024 Earnings Call Transcript (Insider Monkey)
08:06AM	Neogen (NEOG) Q3 Earnings Miss Estimates, Gross Margin Expands (Zacks)
03:01AM	Neogen Corp (NEOG) Q3 2024 Earnings Call Transcript Highlights: Steady Growth Amidst ... (GuruFocus.com)
Apr-09-24 09:54PM	Q3 2024 Neogen Corp Earnings Call (Thomson Reuters StreetEvents) -9.32%
05:30PM	Here's What Key Metrics Tell Us About Neogen (NEOG) Q3 Earnings (Zacks)
12:40PM	Loading…
12:40PM	Food And Animal Safety-Focused Neogen Cuts Guidance, Stock Falls (Benzinga)
12:38PM	BlackBerry, Alkermes rise; Neogen, Tilray Brands fall, Tuesday, 4/9/2024 (Associated Press Finance)
11:52AM	NEOG Stock Earnings: Neogen Misses EPS, Misses Revenue for Q3 2024 (InvestorPlace)
11:39AM	Neogen Stock Is Tumbling. Revenue Guidance Was Cut. (Barrons.com)
08:11AM	Neogen Corp (NEOG) Posts Q3 Net Loss, Adjusts Full-Year Outlook (GuruFocus.com)
08:10AM	Neogen (NEOG) Q3 Earnings and Revenues Lag Estimates (Zacks)
07:16AM	Neogen Q3 Adj. Profit Slightly Declines - Quick Facts (RTT News)
07:07AM	Neogen: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Neogen Announces Third-Quarter 2024 Results (PR Newswire)
Apr-04-24 09:15AM	Neogen (NEOG) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks)
Mar-19-24 04:30PM	Neogen Announces Third-Quarter Earnings Release Date (PR Newswire)
Mar-07-24 07:29AM	Here's Why You Should Hold on to Neogen (NEOG) Stock Now (Zacks)
Feb-08-24 11:30AM	Why Is Neogen (NEOG) Down 14.6% Since Last Earnings Report? (Zacks)
Feb-06-24 04:30PM	Neogen Announces James Walter as Vice President, Global Operations (PR Newswire)
Jan-30-24 01:51PM	Here's Why You Should Retain Neogen (NEOG) Stock for Now (Zacks)
08:45AM	Loading…
Jan-17-24 08:45AM	Neogen Releases SureKill Gel Bait Pro Applicator (PR Newswire) -6.17%
Jan-15-24 08:45AM	Neogen Releases Provecta Pro Flea & Tick Collar for Dogs** (PR Newswire)
Jan-11-24 08:16AM	Neogen Corporation (NASDAQ:NEOG) Q2 2024 Earnings Call Transcript (Insider Monkey)
Jan-10-24 12:52PM	Neogen's (NEOG) Q2 Earnings Miss Estimates, 2024 View Down (Zacks)
Jan-09-24 10:09PM	Q2 2024 Neogen Corp Earnings Call (Thomson Reuters StreetEvents) -8.37%
05:30PM	Neogen (NEOG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:03PM	Neogen Corp (NEOG) Reports Mixed Second-Quarter 2024 Results Amidst Integration Progress (GuruFocus.com)
12:51PM	NEOG Stock Earnings: Neogen Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace)
12:12PM	Acuity Brands, Urban Outfitters rise; Neogen, Unity Software fall, Tuesday, 1/9/2024 (Associated Press Finance)
07:07AM	Neogen: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Neogen Announces Second-Quarter 2024 Results (PR Newswire)
Dec-21-23 08:45AM	Neogen to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-19-23 08:45AM	Neogen Announces Second-Quarter Earnings Release Date (PR Newswire)
Dec-15-23 12:13PM	Neogen (NEOG) to Advance Feline DNA Testing With New Pact (Zacks)
08:55AM	Here's Why You Should Buy Neogen (NEOG) Stock Now (Zacks)
Dec-14-23 08:45AM	Neogen, Cat Fanciers' Association Collaborate to Advance Feline DNA Testing (PR Newswire)
Dec-06-23 08:16AM	Neogen (NEOG) to Offer Biosecurity Products With New Pact (Zacks)
Dec-05-23 08:45AM	Neogen Announces Biosecurity Partnership with TerraNova (PR Newswire)
Dec-01-23 11:01AM	Neogen (NEOG) Unveils New Assay for Walnut Allergens Detection (Zacks)
Nov-30-23 08:45AM	Neogen Launches Highly Sensitive Quantitative ELISA Assay for the Detection of Walnut Allergens (PR Newswire)
04:10AM	12 Best Pet Stocks to Buy Now (Insider Monkey)
Nov-21-23 08:45AM	Neogen to Participate in the Piper Sandler 35th Annual Healthcare Conference (PR Newswire)
Nov-17-23 11:23AM	Neogen's (NEOG) Innovation Aids, Currency Headwind Stays (Zacks)
Nov-09-23 11:30AM	Neogen (NEOG) Up 3.6% Since Last Earnings Report: Can It Continue? (Zacks)
Oct-26-23 01:03PM	Insider Buying: Douglas Jones Acquires 10,000 Shares of Neogen Corp (GuruFocus.com)
Oct-11-23 11:01PM	Insider Buying: CFO David Naemura Acquires 10,000 Shares of Neogen Corp (GuruFocus.com) -6.79%
12:43PM	Neogen's (NEOG) Q1 Earnings Miss Estimates, Margins Rise (Zacks)
09:42AM	Neogen Corporation (NASDAQ:NEOG) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:39AM	Company News for Oct 11, 2023 (Zacks)
Oct-10-23 09:33PM	Q1 2024 Neogen Corp Earnings Call (Thomson Reuters StreetEvents) -5.31%
08:00PM	Neogen (NEOG) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
02:02PM	Neogen Corp (NEOG) Reports First-Quarter 2024 Results: Revenue Soars by 73% (GuruFocus.com)
12:10PM	PepsiCo, Palantir rise; Neogen, Akero Therapeutics fall, Tuesday, 10/10/2023 (Associated Press Finance)
11:41AM	Unveiling Neogen (NEOG)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
09:35AM	Here's Why Neogen (NEOG) is Poised for a Turnaround After Losing -14.43% in 4 Weeks (Zacks)
08:15AM	Neogen (NEOG) Lags Q1 Earnings and Revenue Estimates (Zacks)
07:24AM	Neogen Q1 Results Miss Estimates; Backs FY24 Outlook (RTT News)
07:10AM	Neogen: Fiscal Q1 Earnings Snapshot (AP Finance)
07:00AM	Neogen Announces First-Quarter 2024 Results (PR Newswire)
Oct-04-23 11:29AM	Here's Why You Should Invest in Neogen (NEOG) Stock Now (Zacks)
Sep-27-23 09:12AM	Neogen (NEOG) Gains From Strong Segmental Sales, Innovation (Zacks)
Sep-26-23 08:45AM	Neogen Announces First-Quarter Earnings Release Date (PR Newswire)
Sep-08-23 09:35AM	Down -12.39% in 4 Weeks, Here's Why Neogen (NEOG) Looks Ripe for a Turnaround (Zacks)
Sep-07-23 03:49PM	Why Shares of Neogen Are Slumping This Week (Motley Fool) -13.18%
11:51AM	Neogen (NEOG)'s Hidden Bargain: An In-Depth Look at the 25% Margin of Safety Based on its Valuation (GuruFocus.com)
Sep-06-23 06:01AM	Is Neogen Corporation (NEOG) an Attractive Investment? (Insider Monkey)
Sep-04-23 09:00AM	Neogen (NEOG) Launches SureKill Evolve SC Pest Management Tool (Zacks)
Sep-01-23 08:45AM	Neogen® Releases New Professional Pest Management Solution (PR Newswire)
Aug-31-23 08:45AM	Neogen® To Participate in 2023 Wells Fargo Healthcare Conference (PR Newswire)
07:06AM	Here's Why You Should Invest in Neogen (NEOG) Stock Now (Zacks)
Aug-30-23 08:45AM	Neogen® Wins Best Innovative Luminol-Based Substrate Award (PR Newswire)
Aug-24-23 04:00PM	3 Short Squeeze Stocks up 50% or More in 2023 (InvestorPlace)
Aug-17-23 09:09AM	Neogen (NEOG) Introduces New Genomic Data Management Tool (Zacks)
Aug-16-23 05:05PM	Neogen Says Iran Sanctions Probe Concluded Without Fine (The Wall Street Journal)
Aug-15-23 08:45AM	Neogen® Launches Igenity® Enhanced Dairy (PR Newswire)
Aug-11-23 07:03AM	3 Medical Product Stocks Set to Outpace Q2 Earnings Estimates (Zacks)
Aug-08-23 08:45AM	Neogen® Unveils Over 100 New Genetic Tests (PR Newswire)
Jul-29-23 08:10AM	Is It Time To Consider Buying Neogen Corporation (NASDAQ:NEOG)? (Simply Wall St.)
Jul-28-23 08:14AM	Neogen (NEOG) Q4 Earnings Beat Estimates, Gross Margin Up (Zacks)
Jul-27-23 08:35AM	Neogen (NEOG) Q4 Earnings and Revenues Top Estimates (Zacks)
07:39AM	Neogen: Fiscal Q4 Earnings Snapshot (AP Finance)
07:00AM	Neogen Announces Fourth-Quarter 2023 Results (PR Newswire)
Jul-20-23 10:02AM	Earnings Preview: Neogen (NEOG) Q4 Earnings Expected to Decline (Zacks)
Jul-19-23 10:00AM	Best Momentum Stocks to Buy for July 19th (Zacks)
Jul-14-23 08:46AM	Buy These 4 Stocks Following New Analyst Coverage (Zacks)
Jul-11-23 08:45AM	Neogen Announces Fourth-Quarter Earnings Release Date (PR Newswire)
Jul-05-23 09:56AM	Cintas (CTAS) to Post Q4 Earnings: Will Cost Woes Mar Results? (Zacks)
Jul-03-23 09:35AM	Here's Why You Should Invest in Neogen (NEOG) Stock Now (Zacks)
Jun-30-23 12:20PM	Earnings Estimates Moving Higher for Neogen (NEOG): Time to Buy? (Zacks)
12:00PM	What Makes Neogen (NEOG) a New Buy Stock (Zacks)

Neogen Corp. engages in the development, manufacture, and marketing of food and animal safety products. It operates through the Food Safety and Animal Safety segments. The Food Safety segment consists of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens, drug residues, and levels of general sanitation. The Animal Safety segment includes a line of consumable products marketed to veterinarians and animal health product distributors. The company was founded on June 30, 1981 and is headquartered in Lansing, MI.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ADENT JOHN EDWARD	CEO	Apr 25 '24	Option Exercise	11.96	2,113	25,271	171,979	Apr 26 12:50 PM
Jones Douglas Edward	Chief Operating Officer	Apr 25 '24	Option Exercise	11.96	845	10,106	46,976	Apr 26 12:38 PM
Rocklin Amy M	Chief Legal Officer	Apr 25 '24	Option Exercise	11.96	563	6,733	10,456	Apr 26 09:48 AM
Jones Douglas Edward	Chief Operating Officer	Apr 17 '24	Buy	12.36	10,000	123,590	46,131	Apr 17 12:04 PM
BOREL JAMES C	Director	Apr 11 '24	Buy	13.06	7,500	97,986	21,392	Apr 11 11:40 AM
ADENT JOHN EDWARD	CEO	Apr 10 '24	Buy	12.36	23,000	284,190	152,389	Apr 10 02:25 PM
Naemura David H.	CFO	Apr 10 '24	Buy	12.51	12,500	156,321	30,040	Apr 10 04:18 PM
BOEHM WILLIAM T	Director	Nov 03 '23	Buy	16.05	2,000	32,110	26,509	Nov 03 01:59 PM
Jones Douglas Edward	Chief Operating Officer	Oct 25 '23	Buy	15.17	10,000	151,727	36,131	Oct 26 08:01 AM
Lilly Jason Warren	Vice President	Oct 13 '23	Sale	15.10	351	5,300	26,744	Oct 17 10:06 AM
Tobin James P	Director	Oct 12 '23	Buy	15.19	3,000	45,567	20,392	Oct 12 04:01 PM
Naemura David H.	CFO	Oct 11 '23	Buy	15.03	10,000	150,333	10,000	Oct 11 04:21 PM
BOEHM WILLIAM T	Director	Oct 11 '23	Sale	15.61	2,591	40,456	24,509	Oct 12 11:54 AM
Lilly Jason Warren	Vice President	Oct 11 '23	Sale	15.69	1,917	30,087	25,944	Oct 12 11:25 AM
BOEHM WILLIAM T	Director	Aug 18 '23	Option Exercise	15.62	1,500	23,430	26,009	Aug 22 10:57 AM
BOEHM WILLIAM T	Director	Aug 18 '23	Sale	22.59	1,500	33,891	24,509	Aug 22 10:57 AM

Open in Screener

OCX

Oncocyte Corporation

May 01 • 04:00PM ET

2.55

Dollar change +0.06
Percentage change 2.41	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

OCX Oncocyte Corporation daily Stock Chart

Held by: VTI VXF DFSV

Index	-	P/E	-	EPS (ttm)	-23.74	Insider Own	23.00%	Shs Outstand	8.26M	Perf Week	3.66%
Market Cap	21.09M	Forward P/E	-	EPS next Y	-1.98	Insider Trans	129.19%	Shs Float	6.37M	Perf Month	-12.97%
Income	-29.13M	PEG	-	EPS next Q	-0.67	Inst Own	85.90%	Short Float	3.66%	Perf Quarter	-17.74%
Sales	1.50M	P/S	14.06	EPS this Y	36.27%	Inst Trans	-33.77%	Short Ratio	4.07	Perf Half Y	9.21%
Book/sh	2.48	P/B	1.03	EPS next Y	17.29%	ROA	-	Short Interest	0.23M	Perf Year	-53.62%
Cash/sh	1.14	P/C	2.24	EPS next 5Y	-	ROE	-	52W Range	2.08 - 6.20	Perf YTD	2.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	14.72%	ROI	-104.79%	52W High	-58.87%	Beta	0.80
Dividend TTM	-	Quick Ratio	1.49	Sales past 5Y	16.25%	Gross Margin	-56.62%	52W Low	22.60%	ATR (14)	0.15
Dividend Ex-Date	-	Current Ratio	1.49	EPS Y/Y TTM	-81.28%	Oper. Margin	-1482.24%	RSI (14)	40.84	Volatility	5.99% 6.41%
Employees	46	Debt/Eq	0.11	Sales Y/Y TTM	-	Profit Margin	-1938.06%	Recom	1.67	Target Price	4.42
Option/Short	No / Yes	LT Debt/Eq	0.09	EPS Q/Q	-21.67%	Payout	-	Rel Volume	0.08	Prev Close	2.49
Sales Surprise	39.56%	EPS Surprise	-224.29%	Sales Q/Q	-69.12%	Earnings	Apr 12 BMO	Avg Volume	57.33K	Price	2.55
SMA20	-4.61%	SMA50	-11.19%	SMA200	-19.84%	Trades		Volume	4,697	Change	2.41%

Date	Action	Analyst	Rating Change	Price Target Change
May-24-22	Downgrade	Stephens	Overweight → Equal-Weight
Mar-14-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Jan-07-22	Initiated	Stephens	Overweight	$3.10
Jan-06-22	Resumed	Piper Sandler	Overweight	$3.10
Mar-17-21	Resumed	Needham	Buy	$8
Jan-07-21	Upgrade	The Benchmark Company	Speculative Buy → Buy	$6
Dec-16-20	Upgrade	Piper Sandler	Neutral → Overweight	$2 → $4
Nov-30-20	Initiated	BTIG Research	Buy	$5
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$5
Jul-30-20	Reiterated	The Benchmark Company	Speculative Buy	$7 → $6
Jul-01-20	Downgrade	Piper Sandler	Overweight → Neutral
Jun-30-20	Downgrade	Chardan Capital Markets	Buy → Neutral	$2
Jun-02-20	Initiated	Needham	Buy	$4
Feb-13-19	Initiated	Piper Jaffray	Overweight	$6
Jan-29-19	Upgrade	Janney	Neutral → Buy
Dec-19-18	Resumed	Lake Street	Buy

Show Previous Ratings

Apr-12-24 10:52AM	OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -8.60%
06:00AM	Oncocyte Reports Full Year 2023 Financial Results (GlobeNewswire)
Apr-11-24 09:46PM	Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
05:30PM	Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay (GlobeNewswire)
Apr-09-24 04:05PM	Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
08:00AM	Loading…
Jan-16-24 08:00AM	Oncocyte to Present at the Sequire Investor Summit in Puerto Rico (GlobeNewswire)
Dec-06-23 08:00AM	Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays (GlobeNewswire)
Nov-09-23 08:27AM	OncoCyte Corp (OCX) Reports Q3 2023 Financial Results with Key Product Launches on the Horizon (GuruFocus.com) +29.71%
07:00AM	Oncocyte Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-03-23 08:30AM	Oncocyte to Announce Third Quarter 2023 Financial Results (GlobeNewswire) +8.09%
Sep-18-23 08:00AM	Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier (ACCESSWIRE) +5.49%
Sep-06-23 08:00AM	Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (ACCESSWIRE)
Aug-28-23 08:30AM	Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage (ACCESSWIRE)
Aug-10-23 07:00AM	Oncocyte Reports Second Quarter 2023 Financial Results (ACCESSWIRE)
Aug-09-23 08:00AM	Oncocyte Regains Compliance With Nasdaq Listing Requirements (ACCESSWIRE)
08:30AM	Loading…
Aug-08-23 08:30AM	Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference (ACCESSWIRE) -5.29%
Aug-03-23 08:00AM	Oncocyte To Announce Second Quarter 2023 Financial Results (ACCESSWIRE)
Jul-25-23 09:08AM	VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients (GlobeNewswire)
Jul-24-23 01:35PM	Oncocyte Announces 1-For-20 Reverse Stock Split (GlobeNewswire) -9.57%
Jun-27-23 08:30AM	Oncocyte Begins Manufacturing Transplant Blood Test (GlobeNewswire)
Jun-01-23 04:15PM	Oncocyte Corporation to Present at the LD Micro Invitational XIII (Newsfile) +6.55%
May-11-23 08:00AM	Oncocyte Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-27-23 04:59PM	Oncocyte To Announce First Quarter 2023 Financial Results (GlobeNewswire) +9.86%
Apr-18-23 08:45AM	Oncocyte Presents New Data at AACR (GlobeNewswire)
Apr-12-23 04:15PM	Oncocyte Announces Reduction in Force (GlobeNewswire)
Apr-07-23 08:24AM	Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer (GlobeNewswire)
Apr-03-23 08:00AM	Oncocyte Pricing of $13.86 Million Public Offering of Common Stock (GlobeNewswire) -10.41%
Mar-31-23 05:00PM	Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K (GlobeNewswire) +26.57%
Mar-29-23 04:01PM	Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call (GlobeNewswire) +5.52%
Mar-15-23 04:01PM	Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -20.00%
09:00AM	Loading…
Mar-02-23 09:00AM	Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer (GlobeNewswire)
Feb-22-23 08:00AM	Oncocyte Completes Razor Genomics Transaction (GlobeNewswire)
Dec-16-22 08:19AM	Oncocyte cuts 40% of staff (MarketWatch) -21.95%
08:00AM	Oncocyte Announces Initiatives to Focus Corporate Strategy (GlobeNewswire)
Nov-30-22 06:05PM	Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors (GlobeNewswire)
06:00PM	Oncocyte Announces Executive Leadership Changes (GlobeNewswire)
Nov-10-22 04:30PM	Oncocyte Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-27-22 04:01PM	Oncocyte to Announce Third Quarter 2022 Financial Results (GlobeNewswire) -13.50%
Oct-06-22 08:00AM	DetermaIO Clinical Test to be used in SWOG Cancer Research Network Biomarker Study for Breast Cancer (GlobeNewswire)
Sep-07-22 08:00AM	Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on DetermaRx to CMS (GlobeNewswire)
Aug-31-22 04:01PM	Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference (GlobeNewswire)
Aug-30-22 04:27PM	Oncocyte Announces Five-Year VA Contract for DetermaRx (GlobeNewswire) -6.93%
Aug-24-22 08:00AM	Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer (GlobeNewswire)
Aug-10-22 04:05PM	Oncocyte Reports Second Quarter 2022 Financial Results (GlobeNewswire) +10.57%
Aug-03-22 04:01PM	Oncocyte to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-01-22 11:33AM	The past year for OncoCyte (NASDAQ:OCX) investors has not been profitable (Simply Wall St.)
05:00AM	Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022 (GlobeNewswire)
Jul-27-22 04:01PM	Oncocyte to Announce Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-13-22 08:00AM	Oncocyte Announces Market Entry and Early Adopter Program for Transplant Rejection Monitoring Business (GlobeNewswire) +5.75%
Jul-06-22 08:00AM	Oncocyte Presents DetermaIO Data in Podium Presentation at ESMO World Congress on Gastrointestinal Cancer 2022 (GlobeNewswire)
Jun-22-22 08:00AM	Oncocyte Hosting Key Opinion Webinar on the Role of DetermaIO and the Tumor Microenvironment in Clinical Practice (GlobeNewswire)
Jun-15-22 07:15AM	How Much Of OncoCyte Corporation (NASDAQ:OCX) Do Insiders Own? (Simply Wall St.)
May-26-22 05:00PM	Oncocyte Presents DetermaIO Data at ASCO 2022 Supporting the Tests Potential to Expand the Clinical Use of Immunotherapy (GlobeNewswire)
May-11-22 04:05PM	Oncocyte Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-05-22 08:00AM	Oncocyte Completes Validation of TheraSure Transplant Monitor Test (GlobeNewswire)
Apr-28-22 04:01PM	Oncocyte to Announce First Quarter 2022 Financial Results (GlobeNewswire)
Apr-27-22 04:30PM	Oncocyte to Present New Data at ASCO 2022 Underpinning Pan-Cancer Clinical Utility of DetermaIO (GlobeNewswire)
Apr-22-22 09:26AM	A number of insiders bought OncoCyte Corporation (NASDAQ:OCX) stock last year, which is great news for shareholders (Simply Wall St.)
Apr-13-22 10:01PM	Oncocyte Corporation Announces Pricing of Public Offering of Common Stock and Warrants (GlobeNewswire)
05:12PM	Oncocyte Corporation Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
05:10PM	Oncocyte Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock (GlobeNewswire)
Apr-11-22 08:00AM	Oncocyte Presents Confirmatory Data for DetermaIO at the American Association for Cancer Research Annual Meeting 2022 (GlobeNewswire)
Mar-28-22 08:00AM	Oncocyte to Present New Data Confirming Association of IO Score with Response to Immunotherapy Treatment for Bladder Cancer at the American Association for Cancer Research Annual Meeting 2022 (GlobeNewswire)
Mar-10-22 04:05PM	Oncocyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +7.69%
Mar-01-22 04:05PM	Oncocyte to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday March 10 (GlobeNewswire)
Feb-21-22 07:26AM	Shareholders in OncoCyte (NASDAQ:OCX) have lost 78%, as stock drops 12% this past week (Simply Wall St.)
Feb-10-22 08:00AM	Oncocyte to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (GlobeNewswire)
Jan-18-22 04:05PM	Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision Oncology (GlobeNewswire) +15.87%
Jan-06-22 09:43AM	What Type Of Shareholders Make Up OncoCyte Corporation's (NASDAQ:OCX) Share Registry? (Simply Wall St.)
Jan-04-22 08:00AM	Oncocyte Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer (GlobeNewswire)
Dec-09-21 06:00PM	Spotlight Poster Presentation at San Antonio Breast Cancer Symposium SABCS 2021 Shows Oncocytes DetermaIO Clinical Test Predicts Response to Immunotherapy in Triple Negative Breast Cancer (GlobeNewswire) -9.81%
Dec-08-21 08:00AM	Oncocyte and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled Distribution of DetermaRx in China (GlobeNewswire) +10.42%
Dec-06-21 08:00AM	Oncocyte Corporation Hosting Business Update Call (GlobeNewswire)
Dec-02-21 08:00AM	Oncocyte to Present New Data on DetermaIO Clinical Test for Immunotherapy Response in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium 2021 (GlobeNewswire)
Nov-22-21 06:14AM	Is OncoCyte (NASDAQ:OCX) Using Too Much Debt? (Simply Wall St.) -5.43%
Nov-09-21 04:05PM	Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-21 08:00AM	Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test (GlobeNewswire)
Nov-02-21 03:02PM	Will OncoCyte (OCX) Report Negative Earnings Next Week? What You Should Know (Zacks)
Oct-27-21 08:00AM	Oncocyte Strengthens Transplant Intellectual Property Portfolio with US Patent Covering Digital PCR Technology for Early Detection of Organ Transplant Rejection (GlobeNewswire) -5.00%
Oct-26-21 04:05PM	Oncocyte to Report Third Quarter 2021 Financial Results on Tuesday, November 9th (GlobeNewswire)
Oct-08-21 09:46AM	A OncoCyte Corporation (NASDAQ:OCX) insider increased their holdings by 11% last year (Simply Wall St.)
Oct-07-21 08:00AM	Oncocyte Appoints Gisela A. Paulsen as Chief Operating Officer (GlobeNewswire)
Sep-30-21 08:00AM	Oncocyte Publishes Study Demonstrating Predictive Potential for DetermaIO® Test in Triple Negative Breast Cancer (GlobeNewswire)
Sep-20-21 11:35AM	Oncocyte Announces Oral Presentation of New Data on Its DetermaIO Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting (GlobeNewswire)
08:00AM	Oncocyte Hosting Two-Part Key Opinion Leader Event Series (GlobeNewswire)
Sep-16-21 08:00AM	Modern Healthcare Recognizes Oncocyte as One of the 2021 Best Places to Work in Healthcare (GlobeNewswire)
Sep-13-21 08:00AM	Oncocyte to Present New Data on DetermaIO from NeoTRIPaPDL1 Trial in Oral Presentation from Late-Breaking Abstract at ESMO 2021 (GlobeNewswire)
Sep-07-21 04:05PM	Oncocyte to Participate in the 5th Annual Lake Street Capital Markets Best Ideas Growth Conference (GlobeNewswire)
Aug-23-21 09:13AM	Investors in OncoCyte (NASDAQ:OCX) have made a strong return of 202% over the past year (Simply Wall St.)
Aug-18-21 08:49AM	Is the Options Market Predicting a Spike in OncoCyte (OCX) Stock? (Zacks)
Aug-17-21 08:00AM	Oncocyte Launches First Real-World Evidence (RWE) Registry to Evaluate Biomarker Impact on Early-Stage Lung Cancer Treatment Decisions and Outcomes (GlobeNewswire)
Aug-10-21 04:01PM	Oncocyte Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-09-21 08:00AM	Oncocyte to Participate in Upcoming Investor Events (GlobeNewswire)
Aug-03-21 03:00PM	Will OncoCyte (OCX) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jul-27-21 10:35AM	Oncocyte to Report Second Quarter 2021 Financial Results on Tuesday, August 10 (GlobeNewswire)
Jul-08-21 05:34AM	Here's What OncoCyte Corporation's (NASDAQ:OCX) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Jun-22-21 08:00AM	Oncocyte Celebrates Women Thoracic Surgeons in #ShesMySurgeon Campaign (GlobeNewswire)
Jun-15-21 08:03AM	EchelonDx and Oncocyte Announce Collaboration to Create Seamless Informatics Software to Scale Proprietary Clinical Test Offerings (Business Wire)
Jun-03-21 08:00AM	Oncocyte Announces Collaboration with Gruppo Oncologico del Nord Ovest to Evaluate Oncocytes DetermaIO Test in Colorectal Cancer, the Second Leading Cause of Cancer Mortality Globally (GlobeNewswire) +7.97%
Jun-01-21 08:00AM	Oncocyte Selected as New Day One Launch Site for QIAGENs Companion Diagnostics Test to Identify Patients for Amgens Newly FDA-Approved Drug LUMAKRAS (Sotorasib) For Advanced Stage Lung Cancer (GlobeNewswire)

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BROADWOOD PARTNERS, L.P.	10% Owner	Apr 11 '24	Buy	2.92	2,420,000	7,057,688	4,929,066	Apr 15 07:21 PM
Arno Andrew	Director	Apr 11 '24	Buy	2.95	33,898	99,999	69,054	Apr 15 06:02 AM
Riggs Josh	CEO and President	Apr 11 '24	Buy	2.95	3,390	10,000	3,505	Apr 15 06:04 AM
KINGSLEY ALFRED D	Director	Jun 14 '23	Buy	0.21	30,000	6,447	469,111	Jun 15 08:13 PM

Open in Screener

CATX

Perspective Therapeutics Inc

May 01 • 04:00PM ET

1.70

Dollar change +0.02
Percentage change 1.19	%

Healthcare • Medical Devices • USA • AMEX

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

CATX Perspective Therapeutics Inc daily Stock Chart

Index	-	P/E	-	EPS (ttm)	-0.09	Insider Own	20.55%	Shs Outstand	586.92M	Perf Week	0.59%
Market Cap	997.76M	Forward P/E	-	EPS next Y	-0.09	Insider Trans	105.64%	Shs Float	466.28M	Perf Month	16.44%
Income	-23.91M	PEG	-	EPS next Q	-0.02	Inst Own	13.09%	Short Float	2.24%	Perf Quarter	109.90%
Sales	8.84M	P/S	112.87	EPS this Y	48.53%	Inst Trans	-1.05%	Short Ratio	2.42	Perf Half Y	559.68%
Book/sh	0.35	P/B	4.83	EPS next Y	2.86%	ROA	-27.07%	Short Interest	10.43M	Perf Year	176.78%
Cash/sh	0.03	P/C	55.49	EPS next 5Y	-	ROE	-29.53%	52W Range	0.20 - 1.77	Perf YTD	322.89%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-7.69%	ROI	-23.50%	52W High	-3.95%	Beta	1.43
Dividend TTM	-	Quick Ratio	2.55	Sales past 5Y	-	Gross Margin	27.13%	52W Low	729.27%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	2.67	EPS Y/Y TTM	-45.00%	Oper. Margin	-346.50%	RSI (14)	66.64	Volatility	6.35% 8.60%
Employees	119	Debt/Eq	0.03	Sales Y/Y TTM	-19.63%	Profit Margin	-270.46%	Recom	1.00	Target Price	1.68
Option/Short	No / Yes	LT Debt/Eq	0.03	EPS Q/Q	-29.02%	Payout	-	Rel Volume	0.91	Prev Close	1.68
Sales Surprise	-83.33%	EPS Surprise	20.00%	Sales Q/Q	27.26%	Earnings	Mar 28 BMO	Avg Volume	4.31M	Price	1.70
SMA20	11.11%	SMA50	34.22%	SMA200	168.36%	Trades		Volume	3,912,348	Change	1.19%

Apr-30-24 07:00AM	Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT- -NET in NETs (GlobeNewswire)
07:00AM	Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-a-NET in NETs (GlobeNewswire)
Apr-08-24 08:00AM	Perspective Therapeutics to Participate at Upcoming April Investor Conferences (GlobeNewswire)
Mar-30-24 05:31AM	Perspective Therapeutics Inc (CATX) Reports Fiscal Year 2023 Financial Results (GuruFocus.com)
Mar-28-24 07:30AM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results (GlobeNewswire)
10:39AM	Loading…
Mar-19-24 10:39AM	Heard on the Street: Pharma Goes Radioactive as AstraZeneca Announces Fusion Deal (The Wall Street Journal) +16.06%
Mar-18-24 08:00AM	Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma (GlobeNewswire) -9.81%
Mar-11-24 08:00AM	Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024 (GlobeNewswire)
Mar-05-24 08:00AM	Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility (GlobeNewswire)
Mar-04-24 09:45AM	Perspective Therapeutics Announces $87.4 Million Private Placement (GlobeNewswire) +11.72%
Feb-26-24 08:00AM	Perspective Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire) -6.25%
Feb-20-24 06:30AM	These Drug Companies Are Going Nuclear to Fight Cancer (The Wall Street Journal)
Feb-12-24 08:00AM	Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) -7.79%
Feb-08-24 10:00AM	Earnings Preview: Perspective Therapeutics (CATX) Q4 Earnings Expected to Decline (Zacks) -5.72%
Feb-01-24 08:00AM	Perspective Therapeutics Introduces Pre-Targeting Theranostic Technology Platform (GlobeNewswire)
04:05PM	Loading…
Jan-22-24 04:05PM	Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement (GlobeNewswire)
Jan-18-24 07:00AM	Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement (GlobeNewswire) +26.12%
Jan-17-24 04:05PM	Perspective Therapeutics Announces Proposed Public Offering (GlobeNewswire)
08:00AM	Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT--NET and [(212)Pb]VMT01 (GlobeNewswire)
Jan-09-24 08:00AM	Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability (GlobeNewswire) +9.15%
08:00AM	Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics (GlobeNewswire)
Jan-05-24 08:00AM	Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment (GlobeNewswire) +8.77%
Jan-02-24 08:00AM	Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-23 08:00AM	Perspective Therapeutics Divests Brachytherapy Business (GlobeNewswire) -5.24%
Dec-07-23 08:00AM	Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT--NET to Treat Refractory or Relapsed Neuroendocrine Tumors (GlobeNewswire)
Nov-28-23 08:00AM	Perspective Therapeutics Announces First Ever Human SPECT Imaging of Pb-212 with VMT--NET by Clinical Collaborators in Germany (GlobeNewswire)
Nov-27-23 08:00AM	Perspective Therapeutics Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals (GlobeNewswire)
Nov-16-23 08:00AM	Perspective Therapeutics Completes Initial Dose Escalation Cohort for Second Novel Targeted Alpha Therapy (GlobeNewswire)
Nov-14-23 04:25PM	Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights (GlobeNewswire)
Nov-08-23 08:00AM	Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Study of [(212)Pb]VMT--NET for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors (GlobeNewswire)
08:00AM	Loading…
Oct-16-23 08:00AM	Perspective Therapeutics Completes Recruitment for First Patient Cohort in Phase 1/2a Dose Escalation Trial of VMT01 in Malignant Melanoma (GlobeNewswire)
Oct-10-23 08:00AM	Perspective Therapeutics VMT--NET Protocols Presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium (GlobeNewswire)
Oct-05-23 04:05PM	Perspective Therapeutics Cesium-131 Featured at the American Society for Radiation Oncologys Annual Conference (GlobeNewswire)
Sep-12-23 08:00AM	Perspective Announces Presentation of Positive Early Clinical Data for VMT--NET at the 36th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire)
Sep-11-23 08:00AM	Perspective Therapeutics Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire)
Aug-30-23 08:17AM	Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023 (GlobeNewswire)
Aug-28-23 08:00AM	Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire)
Aug-11-23 09:15AM	Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:11AM	Perspective Therapeutics: Q2 Earnings Snapshot (AP Finance)
08:05AM	Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma (GlobeNewswire)
08:00AM	Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights (GlobeNewswire)
Aug-09-23 08:05AM	Perspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique Cesium-131 Based Brain Cancer Treatment (GlobeNewswire)
Jun-27-23 08:00AM	Perspective Therapeutics Cesium-131 Featured at the American Brachytherapy Societys Annual Conference (GlobeNewswire)
Jun-21-23 08:00AM	Perspective Therapeutics Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates (GlobeNewswire)
Jun-16-23 08:00AM	Perspective Therapeutics Cesium-131 to be Featured in Presentations at the 2023 American Brachytherapy Societys Annual Meeting (GlobeNewswire) +24.37%
Jun-08-23 08:00AM	Perspective Therapeutics to Present at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging Conference (GlobeNewswire)
May-28-23 06:36PM	The Best Penny Stock to Buy Now ZH vs CATX vs LMFA (InvestorPlace)
May-24-23 08:10AM	Perspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS) (GlobeNewswire)
May-16-23 05:02AM	Perspective Therapeutics: Fiscal Q3 Earnings Snapshot (AP Finance) -21.54%
May-15-23 08:22PM	Perspective Therapeutics Reports First Quarter Fiscal 2023 Results (GlobeNewswire)
05:35PM	Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:49PM	Perspective Therapeutics Announces Changes to the Board of Directors (GlobeNewswire)

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1998 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Austin Mark John	VP Finance/Prin Fin&Acct Offic	Apr 23 '24	Option Exercise	0.36	30,000	10,800	84,030	Apr 24 04:35 PM
Lantheus Alpha Therapy, LLC	10% Owner	Mar 06 '24	Buy	0.95	60,431,039	57,409,487	116,773,394	Mar 08 11:24 AM
Williamson Robert F III	Director	Jan 30 '24	Buy	0.71	127,206	90,710	338,761	Feb 01 04:53 PM
Williamson Robert F III	Director	Jan 29 '24	Buy	0.64	25,266	16,170	211,555	Jan 30 04:57 PM
Williamson Robert F III	Director	Jan 26 '24	Buy	0.56	110,613	62,304	186,289	Jan 30 04:57 PM
Williamson Robert F III	Director	Jan 25 '24	Buy	0.49	22,134	10,846	75,676	Jan 26 05:38 PM
Puhlmann Markus	Chief Medical Officer	Jan 24 '24	Buy	0.50	280,000	139,888	1,375,425	Jan 26 05:40 PM
Williamson Robert F III	Director	Jan 24 '24	Buy	0.49	29,862	14,632	53,542	Jan 26 05:38 PM
Williamson Robert F III	Director	Dec 21 '23	Buy	0.33	3,663	1,203	3,663	Dec 26 05:00 PM
Puhlmann Markus	Chief Medical Officer	Dec 19 '23	Buy	0.34	400,000	137,000	1,095,425	Dec 19 07:09 PM
Williamson Robert F III	Director	Dec 19 '23	Buy	0.32	13,680	4,378	23,680	Dec 19 07:10 PM
Hunt Jonathan Robert	Chief Financial Officer	Dec 18 '23	Buy	0.26	125,000	32,338	316,710	Dec 19 07:11 PM
Puhlmann Markus	Chief Medical Officer	Dec 18 '23	Buy	0.26	60,419	15,461	695,425	Dec 19 07:09 PM
Williamson Robert F III	Director	Dec 18 '23	Buy	0.26	10,000	2,600	10,000	Dec 19 07:10 PM
Woods Lori A	Director	Dec 15 '23	Buy	0.27	152,962	41,284	1,519,738	Dec 18 04:16 PM
Puhlmann Markus	Chief Medical Officer	Dec 15 '23	Buy	0.27	135,006	36,276	635,006	Dec 19 07:09 PM
Woods Lori A	Director	Dec 14 '23	Buy	0.27	32,238	8,704	1,366,776	Dec 18 04:16 PM

Open in Screener

IDXX

Idexx Laboratories, Inc.

May 01 • 04:00PM ET

468.04

Dollar change -24.72
Percentage change -5.02	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

IDXX Idexx Laboratories, Inc. daily Stock Chart

Held by: VTI VOO QQQ VO VUG IVV IHI IWP VOT VHT

Index	NDX, S&P 500	P/E	46.51	EPS (ttm)	10.06	Insider Own	0.99%	Shs Outstand	83.03M	Perf Week	-5.30%
Market Cap	38.89B	Forward P/E	36.77	EPS next Y	12.73	Insider Trans	-8.03%	Shs Float	82.27M	Perf Month	-10.28%
Income	845.04M	PEG	3.88	EPS next Q	2.97	Inst Own	89.82%	Short Float	2.08%	Perf Quarter	-9.13%
Sales	3.66B	P/S	10.62	EPS this Y	10.78%	Inst Trans	-0.23%	Short Ratio	4.01	Perf Half Y	18.08%
Book/sh	17.88	P/B	26.18	EPS next Y	14.21%	ROA	28.14%	Short Interest	1.71M	Perf Year	-4.40%
Cash/sh	5.46	P/C	85.67	EPS next 5Y	12.00%	ROE	80.74%	52W Range	372.50 - 583.39	Perf YTD	-15.68%
Dividend Est.	-	P/FCF	50.32	EPS past 5Y	18.76%	ROI	38.29%	52W High	-19.77%	Beta	1.27
Dividend TTM	-	Quick Ratio	1.11	Sales past 5Y	10.69%	Gross Margin	59.73%	52W Low	25.65%	ATR (14)	13.17
Dividend Ex-Date	-	Current Ratio	1.51	EPS Y/Y TTM	25.28%	Oper. Margin	29.88%	RSI (14)	31.63	Volatility	3.24% 2.37%
Employees	11000	Debt/Eq	0.72	Sales Y/Y TTM	8.72%	Profit Margin	23.08%	Recom	2.31	Target Price	620.06
Option/Short	Yes / Yes	LT Debt/Eq	0.49	EPS Q/Q	12.80%	Payout	0.00%	Rel Volume	2.38	Prev Close	492.76
Sales Surprise	-0.11%	EPS Surprise	4.15%	Sales Q/Q	8.81%	Earnings	May 01 BMO	Avg Volume	427.23K	Price	468.04
SMA20	-6.10%	SMA50	-11.54%	SMA200	-7.09%	Trades		Volume	1,017,078	Change	-5.02%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-24	Downgrade	Piper Sandler	Overweight → Neutral	$525
Dec-07-23	Initiated	Exane BNP Paribas	Outperform	$602
Dec-04-23	Upgrade	Cleveland Research	Neutral → Buy
Aug-02-23	Downgrade	Atlantic Equities	Overweight → Neutral	$610
Jul-25-22	Downgrade	Stifel	Buy → Hold	$415
Jul-21-22	Upgrade	Goldman	Neutral → Buy	$530 → $435
Jul-12-22	Initiated	Piper Sandler	Overweight	$440
May-05-22	Downgrade	BofA Securities	Buy → Neutral	$550 → $470
Feb-08-22	Initiated	Atlantic Equities	Overweight	$650
Nov-18-21	Initiated	Morgan Stanley	Overweight
Aug-05-21	Resumed	Credit Suisse	Outperform	$735
Jul-12-21	Downgrade	Guggenheim	Buy → Neutral
Feb-17-21	Initiated	Barclays	Overweight	$600
Sep-09-19	Initiated	Goldman	Neutral	$277
May-23-19	Initiated	Guggenheim	Buy	$276
Nov-02-18	Reiterated	BofA/Merrill	Buy	$275 → $235
May-07-18	Reiterated	Stifel	Buy	$215 → $225
Jan-16-18	Initiated	Piper Jaffray	Overweight	$200
Aug-23-17	Upgrade	BofA/Merrill	Neutral → Buy
Jul-28-17	Upgrade	CL King	Neutral → Buy

Show Previous Ratings

Today 02:31PM	Furry Tech Boom: 3 Pet Stocks Unleashing the Power of AI (InvestorPlace) -5.02%
10:41AM	IDEXX (IDXX) Q1 Earnings Surpass Estimates, 2024 View Slashed (Zacks)
09:30AM	Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics (Zacks)
08:11AM	IDEXX Labs cuts 2024 revenue forecast on lagging vet visits, strong dollar (Reuters)
07:52AM	IDEXX Laboratories Inc (IDXX) Q1 Earnings: Exceeds Revenue Estimates, EPS Surpasses Expectations (GuruFocus.com)
07:40AM	Loading…
07:40AM	Idexx Laboratories (IDXX) Tops Q1 Earnings Estimates (Zacks)
07:10AM	IDEXX Laboratories' Q1 Earnings, Revenue Increase (MT Newswires)
06:38AM	Idexx: Q1 Earnings Snapshot (Associated Press Finance)
06:30AM	IDEXX Laboratories Announces First Quarter Results (Business Wire)
Apr-30-24 10:02AM	BofA Securities Cuts Price Target on IDEXX Laboratories to $595 From $600, Maintains Neutral Rating (MT Newswires)
Apr-28-24 06:32PM	11 Oversold Growth Stocks to Buy Right Now (Insider Monkey)
Apr-26-24 09:15AM	Seeking Clues to Idexx (IDXX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Apr-24-24 12:01PM	Eaton Vance Worldwide Health Sciences Fund Bolsters Position in IDEXX Laboratories (GuruFocus.com)
Apr-19-24 07:56AM	What Lies Ahead of IDEXX Laboratories (IDXX) in Q1 Earnings? (Zacks)
Apr-12-24 01:53PM	New AI Bot Predicts These 7 Stocks Will Mint Millionaires (InvestorPlace)
06:00PM	Loading…
Apr-09-24 06:00PM	Idexx Laboratories (IDXX) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
12:00PM	All You Need to Know About Idexx (IDXX) Rating Upgrade to Buy (Zacks)
Apr-05-24 12:10PM	Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Apr-04-24 04:30PM	IDEXX Laboratories to Release 2024 First Quarter Financial Results (Business Wire)
Apr-02-24 08:31AM	Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now (Zacks)
Mar-29-24 02:15AM	IDEXX Laboratories (IDXX) Gained 27% on Improved Operating Margins (Insider Monkey)
Mar-21-24 05:42AM	Strong Fiscal Q3 Earnings Pushed IDEXX Laboratories (IDXX) in Q4 (Insider Monkey)
Mar-08-24 03:01AM	Executive Vice President James Polewaczyk Sells Shares of IDEXX Laboratories Inc (IDXX) (GuruFocus.com)
Mar-06-24 11:30AM	Idexx (IDXX) Down 1.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-05-24 03:05AM	Guidewire Software (GWRE) was Up 21.2% in Q4 (Insider Monkey)
Feb-22-24 03:46AM	IDEXX Laboratories (IDXX) Rebounded After Significant Drawdown From July Highs (Insider Monkey)
Feb-20-24 02:00PM	IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences (Business Wire)
Feb-18-24 01:26PM	25 Most Valuable Medical Device Companies in the US (Insider Monkey)
Feb-16-24 12:56PM	IDEXX (IDXX) Unveils Pet Owner Engagement Software Solution (Zacks)
Feb-15-24 11:53AM	Here's Why You Should Retain IDEXX (IDXX) Stock for Now (Zacks)
07:00AM	Loading…
07:00AM	IDEXX Launches Vello, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect (PR Newswire)
Feb-10-24 02:07AM	IDEXX Laboratories Inc Insider Sells Shares (GuruFocus.com)
Feb-09-24 03:35PM	Analyst Report: IDEXX Laboratories, Inc. (Morningstar Research)
Feb-08-24 10:34AM	IDEXX's (IDXX) Global Growth Continues, Currency Woes Persist (Zacks)
Feb-06-24 02:25PM	IDEXX Laboratories Stock Sees RS Rating Move Higher On Earnings Beat (Investor's Business Daily)
08:46AM	IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q4 2023 Earnings Call Transcript (Insider Monkey)
02:05AM	Q4 2023 IDEXX Laboratories Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-05-24 10:31PM	Analyst Report: IDEXX Laboratories, Inc. (Morningstar Research) +8.53%
10:37AM	IDEXX (IDXX) Q4 Earnings Surpass Estimates, Margins Fall (Zacks)
09:30AM	Idexx (IDXX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:45AM	IDEXX Laboratories sees 2024 revenue above estimates (Reuters)
07:40AM	Idexx Laboratories (IDXX) Q4 Earnings and Revenues Top Estimates (Zacks)
06:53AM	IDEXX Laboratories Inc (IDXX) Reports Solid Growth in Q4 and Full Year Earnings (GuruFocus.com)
06:39AM	Idexx: Q4 Earnings Snapshot (Associated Press Finance)
06:30AM	IDEXX Announces Fourth Quarter and Full Year Results (Business Wire)
Feb-02-24 08:46AM	Should You Buy IDEXX Laboratories (IDXX) Ahead of Earnings? (Zacks)
Jan-31-24 09:15AM	Unveiling Idexx (IDXX) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
07:29AM	Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now (Zacks)
Jan-30-24 12:10PM	Why Idexx (IDXX) is Poised to Beat Earnings Estimates Again (Zacks)
Jan-29-24 11:58AM	IDEXX Laboratories (IDXX) to Post Q4 Earnings: What's in Store? (Zacks)
Jan-25-24 07:18AM	Here's How IDEXX Laboratories (IDXX) is Delivering Robust Financial Results (Insider Monkey)
Jan-23-24 03:30PM	IDEXX Laboratories to Release 2023 Fourth Quarter and Full Year Financial Results (Business Wire)
Jan-19-24 07:14AM	IDEXX Laboratories (IDXX) Surged in 2023 (Insider Monkey)
Jan-15-24 11:33AM	IDEXX (IDXX) Enhances Fecal Dx Antigen Testing Platform (Zacks)
Jan-12-24 07:05AM	IDEXX Expands Fecal Dx Antigen Testing Platform with Cystoisospora Detection, Marking the Second Platform Expansion in Less than Two Years (PR Newswire)
07:00AM	IDEXX Announces Revolutionary Slide-Free Cellular Analyzer, IDEXX inVue Dx Transforming In-Clinic Workflows (PR Newswire)
Jan-11-24 09:48PM	3 Purrfect Stocks to Buy for the Booming Pet Care Industry (InvestorPlace)
Dec-18-23 07:40AM	Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now (Zacks)
05:19AM	Should You Add IDEXX Laboratories (IDXX) to Your Portfolio? (Insider Monkey)
Dec-09-23 01:05AM	Insider Sell: Executive Vice President James Polewaczyk Sells Shares of IDEXX Laboratories Inc (GuruFocus.com)
Dec-07-23 09:16PM	Insider Sell: President and CEO Jonathan Mazelsky Sells Shares of IDEXX Laboratories Inc (IDXX) (GuruFocus.com)
04:15PM	IDEXX Laboratories Schedules Two Institutional Investor Events (Business Wire)
Dec-06-23 03:25PM	IDEXX Laboratories Stock Earns IBD Stock Rating Upgrade (Investor's Business Daily)
Dec-04-23 08:12PM	Analyst Report: IDEXX Laboratories, Inc. (Morningstar Research) +7.05%
Dec-01-23 11:31AM	Idexx (IDXX) Up 11.1% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-16-23 09:28AM	IDEXX Laboratories (IDXX) Declined on Weak Clinical Visits Across the Industry (Insider Monkey)
Nov-13-23 06:10AM	IDEXX's (IDXX) Upcoming Launch to Detect Canine Leishmaniosis (Zacks)
Nov-11-23 12:00PM	IDEXX Laboratories (IDXX) Fell on Investors Concerns (Insider Monkey)
Nov-09-23 07:48AM	Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now (Zacks)
Nov-08-23 07:00AM	IDEXX Expands SNAP Platform with Leish 4Dx Test to Support Veterinarians Globally in Diagnosing Vector-borne Diseases (PR Newswire)
Nov-02-23 06:55PM	IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q3 2023 Earnings Call Transcript (Insider Monkey) +6.09%
08:52AM	Zoetis cuts annual sales forecast as inflation weights on pet spending (Reuters)
01:10AM	The IDEXX Laboratories Inc (IDXX) Company: A Short SWOT Analysis (GuruFocus.com)
12:45AM	Q3 2023 IDEXX Laboratories Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-01-23 10:00PM	Compared to Estimates, Idexx (IDXX) Q3 Earnings: A Look at Key Metrics (Zacks)
02:52PM	Analyst Report: IDEXX Laboratories, Inc. (Morningstar Research)
09:53AM	IDEXX (IDXX) Q3 Earnings Top Estimates, '23 Sales View Down (Zacks)
09:28AM	IDEXX Laboratories Inc (IDXX) Reports 9% Revenue Growth in Q3 2023 (GuruFocus.com)
08:46AM	IDEXX cuts annual sales forecast as pet owners remain cautious on vet visits (Reuters)
06:40AM	Idexx: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	IDEXX Laboratories Announces Third Quarter Results (Business Wire)
Oct-31-23 11:25AM	MedTech Stocks' Q3 Earnings Due on Nov 1: IDXX, EXAS & More (Zacks)
Oct-25-23 10:02AM	Idexx Laboratories (IDXX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-23-23 06:19AM	IDEXX Laboratories (IDXX) to Post Q3 Earnings: What's in Store? (Zacks)
Oct-13-23 11:40AM	IART vs. IDXX: Which Stock Is the Better Value Option? (Zacks)
Oct-06-23 07:30AM	T2 Biosystems (TTOO) vs. IDEXX Laboratories (IDXX): Which Medical Stock Is Poised for More October Gains? (Entrepreneur: Stocks)
Oct-05-23 04:00PM	IDEXX Laboratories to Release 2023 Third Quarter Financial Results (Business Wire)
Sep-28-23 10:12AM	3 Stocks Ready to Rocket on These Global Mega Trends (InvestorPlace)
Sep-19-23 01:08PM	Here's Why You Should Hold on to IDEXX (IDXX) Stock Right Now (Zacks)
Sep-13-23 07:39PM	Analyst Report: IDEXX Laboratories, Inc. (Morningstar Research)
Sep-08-23 12:04PM	Unveiling the Investment Potential of IDEXX Laboratories Inc (IDXX): A Comprehensive Analysis ... (GuruFocus.com)
Sep-06-23 11:14AM	12 Best Healthcare ETFs To Buy (Insider Monkey)
Aug-31-23 11:31AM	Idexx (IDXX) Down 1.6% Since Last Earnings Report: Can It Rebound? (Zacks)
07:14AM	Heres Why You Should Hold IDEXX Laboratories (IDXX) for the Long-Term (Insider Monkey)
04:35AM	20 Most Dog Friendly Cities in the US (Insider Monkey)
Aug-29-23 12:06PM	Unpacking the Financial Strength and Growth Potential of IDEXX Laboratories Inc (IDXX) (GuruFocus.com)
11:35AM	Unveiling IDEXX Laboratories (IDXX)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
Aug-27-23 08:44AM	15 Most Undervalued Large Cap Stocks to Buy According to Wall Street Analysts (Insider Monkey)
Aug-25-23 04:30AM	VolitionRx (VNRX): Review of 2Q 2023; Distribution Footprint of Nu.Q Vet Cancer Test is expanding. Prolific Schedule of Clinical Papers & Posters. (Zacks Small Cap Research)
Aug-23-23 09:26AM	15 Highest Paying Countries for Veterinarians (Insider Monkey)

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
POLEWACZYK JAMES F	Executive Vice President	Mar 06 '24	Option Exercise	422.45	8,104	3,423,547	18,815	Mar 07 05:00 PM
POLEWACZYK JAMES F	Executive Vice President	Mar 06 '24	Sale	558.44	8,104	4,525,596	10,711	Mar 07 05:00 PM
Vandebroek Sophie V.	Director	Mar 05 '24	Option Exercise	245.79	1,404	345,089	2,620	Mar 07 05:00 PM
Vandebroek Sophie V.	Director	Mar 05 '24	Sale	562.98	1,404	790,427	1,216	Mar 07 05:00 PM
MAZELSKY JONATHAN JAY	President and CEO	Feb 21 '24	Option Exercise	206.94	483	99,952	82,047	Feb 22 05:02 PM
Underberg Sharon E.	EVP, GC & Corporate Secretary	Feb 16 '24	Option Exercise	206.94	483	99,952	5,595	Feb 20 05:01 PM
MCKEON BRIAN P	EVP, CFO and Treasurer	Feb 15 '24	Option Exercise	206.94	483	99,952	30,835	Feb 20 05:00 PM
Smith Martin Alexander	Executive Vice President	Feb 14 '24	Option Exercise	0.00	337	0	583	Feb 16 05:58 PM
Schreck Michael	Executive Vice President	Feb 14 '24	Option Exercise	0.00	368	0	903	Feb 16 05:58 PM
Johnson Michael Perkins	EVP and CHRO	Feb 14 '24	Option Exercise	0.00	176	0	243	Feb 16 05:56 PM
Lane Michael	Executive Vice President	Feb 14 '24	Option Exercise	0.00	939	0	6,726	Feb 16 05:56 PM
MAZELSKY JONATHAN JAY	President and CEO	Feb 14 '24	Option Exercise	0.00	4,156	0	83,403	Feb 16 05:56 PM
Erickson Michael G	Executive Vice President	Feb 14 '24	Option Exercise	0.00	462	0	10,801	Feb 16 05:54 PM
FENNELL GEORGE	SVP, Chief Revenue Officer	Feb 14 '24	Option Exercise	0.00	370	0	7,082	Feb 16 05:55 PM
Hunt Nimrata	Executive Vice President	Feb 14 '24	Option Exercise	0.00	664	0	11,731	Feb 16 05:55 PM
MCKEON BRIAN P	EVP, CFO and Treasurer	Feb 14 '24	Option Exercise	0.00	1,731	0	31,449	Feb 16 05:57 PM
POLEWACZYK JAMES F	Executive Vice President	Feb 14 '24	Option Exercise	0.00	927	0	10,990	Feb 16 05:57 PM
FENNELL GEORGE	SVP, Chief Revenue Officer	Feb 08 '24	Option Exercise	62.00	9,810	608,220	14,910	Feb 09 05:03 PM
FENNELL GEORGE	SVP, Chief Revenue Officer	Feb 08 '24	Sale	573.87	8,198	4,704,559	6,712	Feb 09 05:03 PM
MCKEON BRIAN P	EVP, CFO and Treasurer	Feb 07 '24	Option Exercise	141.60	23,326	3,302,962	53,044	Feb 09 05:01 PM
MAZELSKY JONATHAN JAY	President and CEO	Feb 07 '24	Option Exercise	67.85	12,000	814,200	91,247	Feb 09 05:00 PM
MCKEON BRIAN P	EVP, CFO and Treasurer	Feb 07 '24	Sale	570.01	23,326	13,295,975	29,718	Feb 09 05:01 PM
MAZELSKY JONATHAN JAY	President and CEO	Feb 07 '24	Sale	572.61	12,000	6,871,319	79,247	Feb 09 05:00 PM
POLEWACZYK JAMES F	Executive Vice President	Dec 07 '23	Option Exercise	253.92	11,636	2,954,645	21,686	Dec 08 05:00 PM
POLEWACZYK JAMES F	Executive Vice President	Dec 07 '23	Sale	521.79	11,636	6,071,500	10,050	Dec 08 05:00 PM
MAZELSKY JONATHAN JAY	President and CEO	Dec 04 '23	Option Exercise	79.54	13,424	1,067,745	86,361	Dec 06 05:01 PM
MAZELSKY JONATHAN JAY	President and CEO	Dec 04 '23	Sale	513.05	7,128	3,657,049	79,233	Dec 06 05:01 PM
Lane Michael	Executive Vice President	Nov 07 '23	Option Exercise	133.76	1,728	231,142	5,774	Nov 08 05:09 PM
Smith Martin Alexander	Executive Vice President	Sep 01 '23	Option Exercise	0.00	19	0	226	Sep 06 05:01 PM
MAZELSKY JONATHAN JAY	President and CEO	Aug 31 '23	Option Exercise	79.54	13,424	1,067,745	86,349	Sep 05 05:01 PM
MAZELSKY JONATHAN JAY	President and CEO	Aug 31 '23	Sale	512.01	13,424	6,873,267	72,925	Sep 05 05:01 PM
POLEWACZYK JAMES F	Executive Vice President	Aug 29 '23	Option Exercise	144.21	16,909	2,438,478	32,947	Aug 31 05:17 PM
POLEWACZYK JAMES F	Executive Vice President	Aug 29 '23	Sale	510.56	22,909	11,696,446	10,038	Aug 31 05:17 PM
MAZELSKY JONATHAN JAY	President and CEO	Aug 05 '23	Option Exercise	0.00	384	0	73,095	Aug 08 05:59 PM
MCKEON BRIAN P	EVP, CFO and Treasurer	Aug 05 '23	Option Exercise	0.00	192	0	29,809	Aug 08 05:59 PM
Lane Michael	Executive Vice President	Aug 03 '23	Option Exercise	187.47	16,027	3,004,598	20,061	Aug 07 05:04 PM
Lane Michael	Executive Vice President	Aug 03 '23	Sale	510.00	16,027	8,173,770	4,034	Aug 07 05:04 PM
AYERS JONATHAN W	Director	May 19 '23	Option Exercise	79.54	10,000	795,400	147,039	May 22 05:00 PM
AYERS JONATHAN W	Director	May 19 '23	Sale	491.35	10,000	4,913,502	137,039	May 22 05:00 PM
AYERS JONATHAN W	Director	May 18 '23	Option Exercise	79.54	10,000	795,400	147,039	May 22 05:00 PM
AYERS JONATHAN W	Director	May 18 '23	Sale	489.23	10,000	4,892,268	137,039	May 22 05:00 PM
Vandebroek Sophie V.	Director	May 11 '23	Option Exercise	0.00	344	0	1,216	May 15 05:32 PM
COLLINS Asha	Director	May 11 '23	Option Exercise	0.00	344	0	522	May 15 05:31 PM
ESSIG STUART	Director	May 11 '23	Option Exercise	0.00	344	0	1,717	May 15 05:31 PM
Kingsley Lawrence D	Director	May 11 '23	Option Exercise	0.00	464	0	8,544	May 15 05:32 PM
SZOSTAK M ANNE	Director	May 11 '23	Option Exercise	0.00	344	0	1,604	May 15 05:32 PM
AYERS JONATHAN W	Director	May 11 '23	Option Exercise	0.00	344	0	140,553	May 15 05:31 PM
AYERS JONATHAN W	Director	May 10 '23	Option Exercise	178.26	560	99,826	141,894	May 11 05:01 PM
Underberg Sharon E.	EVP, GC & Corporate Secretary	May 05 '23	Option Exercise	206.94	483	99,952	4,245	May 08 05:04 PM
MCKEON BRIAN P	EVP, CFO and Treasurer	May 05 '23	Option Exercise	178.26	560	99,826	29,605	May 08 05:02 PM
SZOSTAK M ANNE	Director	May 05 '23	Sale	474.89	2,000	949,789	4,700	May 08 05:03 PM
Lane Michael	Executive Vice President	May 05 '23	Sale	484.00	1,000	484,000	4,022	May 08 05:01 PM
Vandebroek Sophie V.	Director	May 04 '23	Option Exercise	206.62	2,187	451,878	3,059	May 05 06:01 PM
MAZELSKY JONATHAN JAY	President and CEO	May 04 '23	Option Exercise	178.26	560	99,826	73,301	May 05 06:00 PM
Vandebroek Sophie V.	Director	May 04 '23	Sale	469.02	2,187	1,025,740	872	May 05 06:01 PM

Open in Screener

ACHV

Achieve Life Sciences Inc.

May 01 • 04:00PM ET

4.52

Dollar change +0.13
Percentage change 2.96	%

Healthcare • Biotechnology • Canada • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

ACHV Achieve Life Sciences Inc. daily Stock Chart

Held by: VTI VXF SURI

Index	-	P/E	-	EPS (ttm)	-1.53	Insider Own	15.37%	Shs Outstand	34.25M	Perf Week	-0.44%
Market Cap	154.81M	Forward P/E	-	EPS next Y	-1.00	Insider Trans	0.38%	Shs Float	28.99M	Perf Month	0.89%
Income	-29.82M	PEG	-	EPS next Q	-0.24	Inst Own	19.73%	Short Float	2.46%	Perf Quarter	-8.32%
Sales	0.00M	P/S	-	EPS this Y	27.89%	Inst Trans	1.44%	Short Ratio	7.58	Perf Half Y	13.57%
Book/sh	-0.07	P/B	-	EPS next Y	7.55%	ROA	-120.85%	Short Interest	0.71M	Perf Year	-47.38%
Cash/sh	0.45	P/C	9.96	EPS next 5Y	15.00%	ROE	-869.88%	52W Range	3.03 - 10.30	Perf YTD	9.71%
Dividend Est.	-	P/FCF	-	EPS past 5Y	53.91%	ROI	-	52W High	-56.12%	Beta	1.26
Dividend TTM	-	Quick Ratio	0.82	Sales past 5Y	0.00%	Gross Margin	-	52W Low	49.17%	ATR (14)	0.21
Dividend Ex-Date	-	Current Ratio	0.82	EPS Y/Y TTM	62.37%	Oper. Margin	0.00%	RSI (14)	51.46	Volatility	4.64% 4.24%
Employees	22	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	19.29
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	68.82%	Payout	-	Rel Volume	4.85	Prev Close	4.39
Sales Surprise	-	EPS Surprise	16.13%	Sales Q/Q	-	Earnings	May 09 AMC	Avg Volume	94.09K	Price	4.52
SMA20	1.07%	SMA50	2.08%	SMA200	-1.12%	Trades		Volume	456,396	Change	2.96%

Date	Action	Analyst	Rating Change	Price Target Change
May-10-23	Reiterated	Maxim Group	Buy	$8 → $20
Jun-23-21	Initiated	Oppenheimer	Outperform	$23

Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-25-24 08:00AM	Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024 (GlobeNewswire)
Apr-11-24 08:00AM	Achieve Life Sciences to Present at Life Science Innovation Northwest 2024 Conference (GlobeNewswire)
Apr-01-24 03:30PM	Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 06:24AM	Q4 2023 Achieve Life Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
08:53PM	Loading…
Mar-28-24 08:53PM	ACHV Stock Earnings: Achieve Life Sciences Beats EPS for Q4 2023 (InvestorPlace)
05:32PM	Achieve Life Sciences Inc Reports Year-End Loss, Progresses Towards FDA Approval (GuruFocus.com)
04:01PM	Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update (GlobeNewswire)
Mar-20-24 08:00AM	Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting (GlobeNewswire)
Mar-14-24 08:00AM	Achieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call and Webcast on March 28, 2024 (GlobeNewswire)
Mar-08-24 08:35AM	Life Science Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Mar-06-24 08:00AM	Achieve Life Sciences Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Mar-05-24 08:35AM	Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024 (GlobeNewswire)
Feb-29-24 08:01AM	Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission (GlobeNewswire) -9.19%
08:00AM	Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire)
08:35AM	Loading…
Dec-15-23 08:35AM	Life Science Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
Dec-13-23 08:00AM	TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors (GlobeNewswire) +5.40%
Dec-12-23 01:02PM	Life Science Investor Forum Agenda Announced for December 14th, 2023 (GlobeNewswire) -42.20%
09:10AM	Why Is Achieve Life Sciences (ACHV) Stock Down 25% Today? (InvestorPlace)
Dec-11-23 04:30PM	Achieve Life Sciences Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Nov-11-23 10:36AM	Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 10:01AM	Q3 2023 Achieve Life Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-09-23 04:00PM	Achieve Life Sciences Reports Financial Results for Third Quarter and Provides Corporate Update (GlobeNewswire)
Oct-26-23 08:00AM	Achieve Life Sciences to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 9, 2023 (GlobeNewswire)
Oct-03-23 08:00AM	Achieve Life Sciences Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Sep-11-23 08:00AM	Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting (GlobeNewswire)
Sep-07-23 08:00AM	Achieve Life Sciences Announces Participation at Upcoming Investor Conferences (GlobeNewswire) -5.24%
Aug-16-23 10:30AM	ACHV: 2Q:23 Results (Zacks)
Aug-15-23 10:25PM	Q2 2023 Achieve Life Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 04:00PM	Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update (GlobeNewswire)
08:00AM	Loading…
Aug-01-23 08:00AM	Achieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast (GlobeNewswire)
Jul-18-23 08:00AM	Achieve Life Sciences Announces Presentation at 2023 American Society of Pharmacognosy Annual Meeting (GlobeNewswire)
Jul-11-23 11:23AM	Achieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA) (GlobeNewswire)
May-25-23 09:00AM	Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering (GlobeNewswire) -6.07%
07:16AM	ACHV: ORCA-3 Topline (Zacks Small Cap Research)
May-24-23 06:10AM	Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) Shift From Loss To Profit (Simply Wall St.)
May-23-23 02:46PM	Can't Kick the Bud? Achieve's Cytisinicline Proves Promising in Phase 3 Smoking Cessation Trial (Benzinga) -23.80%
06:00AM	Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial (GlobeNewswire)
May-17-23 08:00AM	Achieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley Bank (GlobeNewswire)
May-10-23 09:08AM	ACHV: First Quarter Results (Zacks Small Cap Research) +12.71%
05:57AM	Q1 2023 Achieve Life Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
May-09-23 04:05PM	Achieve Life Sciences Reports Financial Results for First Quarter 2023 and Provides Corporate Update (GlobeNewswire)
Apr-26-23 08:00AM	Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023 (GlobeNewswire)
Apr-24-23 05:27AM	ACHV: ORCA-V1 Readout (Zacks Small Cap Research)
Apr-20-23 02:22PM	Want To Quit Smoking? Achieve Life Sciences Reports Successful E-Cigarette Cessation Benefit With Cytisinicline Treatment (Benzinga)
08:00AM	Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline (GlobeNewswire)
Apr-14-23 08:00AM	Achieve Life Sciences to Present at Life Science Innovation Northwest 2023 Conference (GlobeNewswire)
Mar-30-23 08:00AM	Achieve Life Sciences Announces Refresh to Board of Directors (GlobeNewswire) +5.86%
Mar-29-23 08:00AM	Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation (GlobeNewswire) +7.57%
Mar-20-23 10:46PM	Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q4 2022 Earnings Call Transcript (Insider Monkey)
05:27AM	ACHV: 2022 Financial and Operational Results (Zacks Small Cap Research)
Mar-17-23 08:00AM	Achieve Life Sciences Announces Granting of New Hire Inducement Award (GlobeNewswire)
05:48AM	Q4 2022 Achieve Life Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-16-23 04:05PM	Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update (GlobeNewswire)
Mar-08-23 08:00AM	Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation (GlobeNewswire)
Mar-03-23 08:00AM	Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting (GlobeNewswire) +7.79%
Mar-02-23 08:00AM	Achieve Life Sciences to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call and Webcast on March 16, 2023 (GlobeNewswire)
Feb-15-23 05:42AM	Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) top owners are individual investors with 56% stake, while 43% is held by institutions (Simply Wall St.) -15.52%
Feb-07-23 08:00AM	Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation (GlobeNewswire)
Feb-02-23 08:00AM	Achieve Life Sciences to Participate at the 2023 SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-27-23 04:30PM	Achieve Life Sciences Announces Granting of New Hire Inducement Award (GlobeNewswire)
Jan-09-23 08:00AM	Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation (GlobeNewswire) +7.28%
Dec-29-22 06:02AM	Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-21-22 08:00AM	Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation (GlobeNewswire)
Nov-21-22 06:01AM	ACHV: 3Q:22 Results: Target Enrollments Reached (Zacks Small Cap Research)
Nov-15-22 08:00AM	Achieve Life Sciences Announces Private Placement of $18.9 Million (GlobeNewswire) +5.45%
Nov-14-22 04:05PM	Achieve Reports Financial Results for Third Quarter 2022 and Provides Corporate Update (GlobeNewswire)
Nov-08-22 08:00AM	Achieve Announces Early Completion of Target Enrollment in Cytisinicline e-Cigarette Cessation Trial (GlobeNewswire)
Oct-31-22 08:00AM	Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 14, 2022 (GlobeNewswire)
Sep-27-22 08:00AM	Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation (GlobeNewswire) -7.42%
Sep-07-22 08:00AM	Achieve Life Sciences Announces Participation at Fall Investor Conferences (GlobeNewswire)
Aug-15-22 06:16AM	ACHV: Autumn Enrollment Completion for ORCA-3 (Zacks Small Cap Research) +12.80%
Aug-11-22 04:05PM	Achieve Reports Financial Results for Second Quarter 2022 and Provides Corporate Update (GlobeNewswire)
Jul-28-22 08:00AM	Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11, 2022 (GlobeNewswire)
Jul-01-22 04:05PM	Achieve Life Sciences Announces Granting of New Hire Inducement Awards (GlobeNewswire)
Jun-29-22 08:00AM	Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation (GlobeNewswire)
Jun-21-22 08:00AM	Achieve Life Sciences Announces Participation at H.C. Wainwright 1st Annual Mental Health Conference (GlobeNewswire)
Jun-01-22 08:00AM	Achieve Life Sciences Awarded Grant from the National Institutes of Health to Conduct Phase 2 Trial of Cytisinicline in Nicotine e-cigarette Users (GlobeNewswire)
May-26-22 08:00AM	Achieve Life Sciences Announces Participation at LD Micro Invitational Conference (GlobeNewswire)
May-16-22 01:20PM	36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022 (ACCESSWIRE)
May-13-22 08:00AM	Achieve Life Sciences Announces Participation at Best Ideas Virtual Investor Conference (GlobeNewswire)
06:30AM	ACHV: First Quarter 2022 Results (Zacks Small Cap Research)
May-12-22 04:00PM	Achieve Reports Financial Results for First Quarter 2022 and Provides Corporate Update (GlobeNewswire)
May-05-22 02:59PM	Health Check: How Prudently Does Achieve Life Sciences (NASDAQ:ACHV) Use Debt? (Simply Wall St.)
Apr-28-22 05:22AM	ACHV: Topline Data from ORCA-2 Smoking Cessation Trial (Zacks Small Cap Research) -6.46%
Apr-27-22 09:40AM	Achieve Life Sciences Aces Pivotal Cytisinicline Study In Smoking Cessation (Benzinga) +7.68%
08:00AM	Achieve Life Sciences Announces Successful, Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers (GlobeNewswire)
Apr-21-22 08:00AM	Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 12, 2022 (GlobeNewswire)
Mar-15-22 08:00AM	Achieve Life Sciences Announces Cytisinicline Presentation at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting (GlobeNewswire)
Mar-14-22 08:00AM	Achieve Life Sciences Announces Appointment of Dr. Vaughn Himes to Board of Directors (GlobeNewswire)
Mar-11-22 08:06AM	ACHV: 2021 Results: ORCA-3 Underway, ORCA-V1 Soon to Start (Zacks Small Cap Research)
08:00AM	Achieve Life Sciences Announces Expansion of Manufacturing & Quality Operations Team and Granting of Inducement Award (GlobeNewswire)
Mar-10-22 08:00AM	Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2021 and Provides Corporate Update (GlobeNewswire)
Mar-08-22 08:00AM	Achieve Life Sciences Announces Participation in March Investor Conferences (GlobeNewswire)
Feb-24-22 08:00AM	Achieve Life Sciences to Announce Fourth Quarter and Year-End 2021 Financial Results and Host Conference Call and Webcast on March 10, 2022 (GlobeNewswire)
Feb-04-22 04:37AM	ACHV: The Final Phase III Begins (Zacks Small Cap Research)
Feb-03-22 08:00AM	Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Award (GlobeNewswire)
Feb-02-22 08:00AM	Achieve Life Sciences Announces Participation in February Investor Conferences (GlobeNewswire)
Jan-28-22 10:07AM	36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022 (ACCESSWIRE)
Jan-25-22 11:08AM	Achieve Life Sciences Initiates Pivotal Trial Of Cytisinicline For Smoking Cessation (Benzinga)

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wan Jerry	Principal Accounting Officer	Apr 19 '24	Option Exercise	0.00	5,625	0	12,057	Apr 23 04:39 PM
JACOBS CINDY	President & CMO	Apr 19 '24	Option Exercise	0.00	16,250	0	34,511	Apr 23 04:35 PM
Stewart Richard Alistair	Executive Chairman	Apr 19 '24	Option Exercise	0.00	22,500	0	61,001	Apr 23 04:31 PM
Bencich John	CEO	Apr 19 '24	Option Exercise	0.00	25,000	0	101,724	Apr 23 04:26 PM
Stewart Richard Alistair	Executive Chairman	Mar 04 '24	Buy	4.58	10,000	45,850	38,501	Mar 06 04:49 PM
Bencich John	CEO	Mar 04 '24	Buy	4.58	10,000	45,850	76,724	Mar 06 04:43 PM
Bencich John	CEO	May 30 '23	Buy	5.50	5,000	27,500	66,730	Jun 01 05:42 PM

Open in Screener

NTLA

Intellia Therapeutics Inc

May 01 • 04:00PM ET

22.50

Dollar change +1.10
Percentage change 5.14	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

NTLA Intellia Therapeutics Inc daily Stock Chart

Held by: ARKK VTI VB ARKG IWM VXF VBK IWN IBB XT

Index	RUT	P/E	-	EPS (ttm)	-5.42	Insider Own	2.33%	Shs Outstand	96.44M	Perf Week	6.28%
Market Cap	2.17B	Forward P/E	-	EPS next Y	-5.64	Insider Trans	-2.33%	Shs Float	94.19M	Perf Month	-10.36%
Income	-481.19M	PEG	-	EPS next Q	-1.37	Inst Own	88.81%	Short Float	15.49%	Perf Quarter	-5.54%
Sales	36.27M	P/S	59.83	EPS this Y	-1.29%	Inst Trans	-0.30%	Short Ratio	9.68	Perf Half Y	-5.58%
Book/sh	11.29	P/B	1.99	EPS next Y	-2.69%	ROA	-34.11%	Short Interest	14.59M	Perf Year	-40.38%
Cash/sh	9.46	P/C	2.38	EPS next 5Y	30.00%	ROE	-42.10%	52W Range	19.37 - 47.48	Perf YTD	-26.21%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-22.30%	ROI	-41.96%	52W High	-52.61%	Beta	1.85
Dividend TTM	-	Quick Ratio	8.67	Sales past 5Y	12.09%	Gross Margin	75.26%	52W Low	16.16%	ATR (14)	1.31
Dividend Ex-Date	-	Current Ratio	8.67	EPS Y/Y TTM	12.31%	Oper. Margin	-1420.51%	RSI (14)	44.72	Volatility	6.72% 4.90%
Employees	526	Debt/Eq	0.11	Sales Y/Y TTM	-30.40%	Profit Margin	-1326.51%	Recom	1.54	Target Price	69.57
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	-4.64%	Payout	-	Rel Volume	1.12	Prev Close	21.40
Sales Surprise	-115.04%	EPS Surprise	-1.49%	Sales Q/Q	-114.12%	Earnings	Feb 22 BMO	Avg Volume	1.51M	Price	22.50
SMA20	-1.78%	SMA50	-14.34%	SMA200	-25.96%	Trades		Volume	1,684,893	Change	5.14%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-23-24	Downgrade	Goldman	Buy → Neutral	$136 → $32
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy	$66
Mar-21-23	Initiated	Bernstein	Outperform	$54
Mar-14-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$54 → $57
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$67
Jan-24-23	Upgrade	Citigroup	Sell → Neutral	$48 → $39
Jan-19-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Oct-11-22	Initiated	Morgan Stanley	Overweight	$84
Sep-21-22	Initiated	JP Morgan	Overweight	$85
Sep-01-22	Initiated	Citigroup	Sell	$50
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$54
Jun-16-22	Initiated	BofA Securities	Buy	$70
Apr-28-22	Initiated	Credit Suisse	Outperform	$100
Feb-18-22	Initiated	William Blair	Outperform	$144
Feb-07-22	Upgrade	Oppenheimer	Perform → Outperform	$145 → $150
Jan-31-22	Initiated	Cowen	Outperform
Jan-07-22	Initiated	Piper Sandler	Overweight	$171
Oct-05-21	Initiated	Guggenheim	Buy	$170
Sep-24-21	Initiated	Stifel	Buy	$173

Show Previous Ratings

Apr-29-24 07:30AM	Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024 (GlobeNewswire) +5.88%
Apr-25-24 11:21AM	Intellia (NTLA) to Report Q1 Earnings: What's in the Cards? (Zacks) -5.43%
10:01AM	Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline (Zacks)
Apr-14-24 05:55AM	2 Stocks Down 30% to Buy Right Now (Motley Fool)
Apr-12-24 04:50AM	Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week. (Motley Fool)
04:50AM	Loading…
Apr-09-24 04:50AM	Bull Market and Beyond: 3 Stocks Just Waiting to Soar (Motley Fool)
Mar-28-24 05:55AM	Better Cathie Wood Stock: Moderna vs. Intellia (Motley Fool)
Mar-21-24 05:29PM	Hot Stocks: The 3 Best Opportunities for Investing in Biotech (InvestorPlace)
04:19PM	3 Stocks That Could Be the Next Big Thing in Gene Editing (InvestorPlace)
Mar-19-24 01:06PM	Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study (Zacks)
Mar-18-24 07:30AM	Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy (GlobeNewswire)
Mar-09-24 09:45AM	Is Intellia Therapeutics Stock a Buy Now? (Motley Fool)
Mar-06-24 10:35AM	Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst (Motley Fool)
Mar-01-24 01:43PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
Feb-29-24 05:50AM	A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now (Motley Fool)
09:30AM	Loading…
Feb-28-24 09:30AM	Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks) +5.74%
Feb-27-24 11:55AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool) +12.15%
09:35AM	Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving Average (Zacks)
Feb-23-24 12:22PM	Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript (Insider Monkey)
11:12AM	Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update (Zacks)
09:55AM	Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High? (Zacks)
Feb-22-24 10:53PM	Q4 2023 Intellia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
08:12AM	Intellia Therapeutics Inc (NTLA) Reports Full-Year 2023 Financial Results and Operational Progress (GuruFocus.com)
07:30AM	Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Feb-20-24 05:02AM	Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought (Motley Fool)
Feb-17-24 01:59AM	Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen? (Motley Fool)
Feb-15-24 10:00AM	Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
07:30AM	Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis (GlobeNewswire)
06:20AM	Intellia, ReCode partner on genetic medicines for cystic fibrosis (BioPharma Dive)
Feb-14-24 07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates (GlobeNewswire) +6.92%
06:05AM	Loading…
Feb-13-24 06:05AM	3 Gene Editing Stocks With Unprecedented Surge Potential (InvestorPlace) -10.67%
Feb-10-24 05:09PM	Top 11 CRISPR Stocks To Invest In (Insider Monkey)
Feb-08-24 01:15PM	The 3 Most Undervalued Biotech Stocks to Buy in February 2024 (InvestorPlace) +5.37%
Feb-07-24 11:50AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Feb-05-24 05:25AM	A Bull Market Is Here: 2 Top Growth Stocks to Buy Hand Over Fist (Motley Fool)
Jan-31-24 05:00PM	Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine (GlobeNewswire)
12:28PM	3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential (InvestorPlace)
Jan-30-24 05:10AM	History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does. (Motley Fool) -6.07%
Jan-29-24 09:35AM	Down -19.06% in 4 Weeks, Here's Why Intellia Therapeutics, Inc. (NTLA) Looks Ripe for a Turnaround (Zacks) +6.08%
Jan-27-24 01:25PM	2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street (Motley Fool)
08:55AM	Is It Too Late to Buy Intellia Therapeutics Stock? (Motley Fool)
Jan-24-24 07:00AM	SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa (GlobeNewswire)
Jan-22-24 05:41PM	3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024 (InvestorPlace)
Jan-21-24 08:00AM	Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics (Motley Fool)
Jan-18-24 11:50AM	Is it a Good Idea to Invest in Intellia (NTLA) Stock Now? (Zacks)
Jan-13-24 06:05AM	The Top Healthcare Stocks to Buy With $100 (Motley Fool)
Jan-12-24 08:44AM	Is Intellia Therapeutics (NTLA) Stock a Solid Choice Right Now? (Zacks)
Jan-08-24 07:45AM	Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics (Motley Fool) +5.03%
05:52AM	4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024 (Motley Fool)
Jan-05-24 10:04AM	Intellia Therapeutics Layoffs 2024: What to Know About the Latest NTLA Job Cuts (InvestorPlace)
Jan-04-24 04:01PM	Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones (GlobeNewswire)
12:47PM	Intellia to lay off staff, cut some early research (BioPharma Dive)
Dec-31-23 08:45AM	2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics (Motley Fool)
Dec-27-23 06:41PM	13 Most Promising Future Stocks To Buy According To Hedge Funds (Insider Monkey)
Dec-16-23 05:00AM	5 Beaten-Down Stocks That Could Soar in 2024 (Motley Fool)
Dec-13-23 05:20AM	3 Gene-Editing Stocks With the Potential to Mint Millionaires (InvestorPlace) +7.96%
Dec-12-23 06:00AM	Could Intellia Therapeutics Become the Next CRISPR Therapeutics? (Motley Fool)
Dec-10-23 11:57AM	5 Best Genomics Stocks To Buy Now (Insider Monkey)
Nov-28-23 05:30AM	2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market (Motley Fool)
Nov-24-23 07:00AM	Gene Editing Will Change Medicineand Maybe Health Investing Too (The Wall Street Journal)
Nov-15-23 11:07AM	Intellia (NTLA) Rises on EC's Orphan Drug Tag for HAE Candidate (Zacks)
Nov-14-23 07:30AM	Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (GlobeNewswire) +11.09%
Nov-10-23 05:38PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
06:30AM	Intellia (NTLA) Beats on Q3 Earnings, Provides Pipeline Update (Zacks)
Nov-09-23 04:06PM	Market Today: Tech Stocks Under Pressure Amid Mixed Earnings and Fed Remarks (GuruFocus.com) -12.27%
03:37PM	3 Biotech Stocks That Are Betting on the Future of Gene Editing (InvestorPlace)
08:29AM	Intellia Therapeutics Inc (NTLA) Reports Q3 2023 Financial Results and Progress in CRISPR Therapies (GuruFocus.com)
07:30AM	Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Nov-06-23 08:02AM	Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners (Investor's Business Daily)
Nov-02-23 07:00AM	Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting (GlobeNewswire)
06:45AM	1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years (Motley Fool)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
10:00AM	Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-28-23 07:30AM	Intellia Therapeutics Will Soon Make Biotech History. Is the Stock a Buy? (Motley Fool)
Oct-26-23 10:02AM	Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
07:30AM	Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November (GlobeNewswire)
Oct-23-23 09:40AM	Intellia (NTLA) Focuses on Developing Gene-Editing Therapies (Zacks)
08:45AM	3 Stocks Cathie Wood Is Buying That Should Be on Your List Too (Motley Fool)
Oct-21-23 05:00AM	Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time (Motley Fool)
Oct-19-23 11:46AM	Intellia's (NTLA) IND for Gene-Editing Therapy Gets FDA Clearance (Zacks)
Oct-18-23 04:10PM	Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing (Investor's Business Daily)
07:00AM	Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy (GlobeNewswire)
Oct-16-23 12:39PM	Intellia's (NTLA) HAE Candidate Gets EMA's PRIME Designation (Zacks)
10:43AM	16 Best Stocks to Buy and Hold for the Next 15 Years According to Cathie Woods Portfolio (Insider Monkey)
Oct-14-23 12:20PM	2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years (Motley Fool)
Oct-13-23 08:38AM	Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (GlobeNewswire)
Oct-12-23 08:57AM	2 Brilliant Growth Stocks to Buy and Hold Forever (Motley Fool)
Oct-10-23 02:00PM	Down 45%, Is Intellia a Buy? (Motley Fool)
10:07AM	This Cathie Wood Stock Is Poised to Double, Says Wall Street (Motley Fool)
Oct-06-23 04:59AM	The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna (Zacks)
Oct-05-23 09:15AM	This Market-Beating Stock Just Gave Investors More Reasons to Invest (Motley Fool) +5.43%
Oct-04-23 09:27AM	Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies (Zacks)
Oct-03-23 10:07AM	Intellia Therapeutics Could Rise 167%, Per Wall Street, But Is It a Buy? (Motley Fool)
07:58AM	UPDATE 1-Regeneron, Intellia to make gene editing therapies in expanded collaboration (Reuters)
07:08AM	Regeneron, Intellia Therapeutics expand research collaboration to make gene editing therapies (Reuters)
07:00AM	Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases (GlobeNewswire)
Sep-23-23 09:45AM	Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals (Motley Fool)
Sep-10-23 08:15AM	Cathie Wood Is Buying These 2 Biotech Stocks Hand Over Fist, and Wall Street Thinks They Could Double (Motley Fool)
Sep-09-23 03:59PM	10 Biotech Stocks with Biggest Upside (Insider Monkey)
Sep-06-23 02:00PM	Cathie Wood Is Buying This Stock Hand Over Fist. Should You? (Motley Fool)

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BASTA JAMES	EVP, General Counsel	Mar 04 '24	Sale	32.99	2,297	75,778	81,571	Mar 05 04:10 PM
Clark Eliana	EVP, Chief Technical Officer	Mar 04 '24	Sale	32.99	605	19,959	71,470	Mar 05 04:10 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Jan 08 '24	Sale	28.87	2,275	65,682	43,927	Jan 10 04:15 PM
LEONARD JOHN M	President and CEO	Jan 03 '24	Sale	29.46	19,223	566,310	846,486	Jan 05 04:51 PM
Lebwohl David	EVP, Chief Medical Officer	Jan 03 '24	Sale	29.46	5,843	172,135	54,372	Jan 05 04:50 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Jan 03 '24	Sale	29.46	5,532	162,973	46,202	Jan 05 04:50 PM
Goddard Glenn	EVP, Chief Financial Officer	Jan 03 '24	Sale	29.46	5,365	158,053	40,585	Jan 05 04:49 PM
Clark Eliana	EVP, Chief Technical Officer	Jan 03 '24	Sale	29.50	4,608	135,954	40,845	Jan 05 04:44 PM
Hicks Derek	EVP, Chief Business Officer	Jan 03 '24	Sale	29.46	3,877	114,216	36,987	Jan 05 04:46 PM
BASTA JAMES	EVP, General Counsel	Jan 03 '24	Sale	29.46	3,805	112,095	51,474	Jan 05 04:45 PM
Bhanji Muna	Director	Oct 31 '23	Sale	23.90	265	6,334	11,996	Nov 02 04:42 PM
Bhanji Muna	Director	Jul 31 '23	Sale	42.33	265	11,217	12,261	Aug 02 05:19 PM
Bhanji Muna	Director	Jul 06 '23	Sale	39.30	1,867	73,373	12,526	Jul 10 05:21 PM
Clark Eliana	EVP, Chief Technical Officer	Jul 03 '23	Sale	40.51	360	14,584	45,146	Jul 06 03:34 PM
Clark Eliana	EVP, Chief Technical Officer	Jun 20 '23	Option Exercise	12.27	5,000	61,350	50,146	Jun 22 05:52 PM
Clark Eliana	EVP, Chief Technical Officer	Jun 20 '23	Sale	45.00	5,000	225,000	45,146	Jun 22 05:52 PM

Open in Screener

TKNO

Alpha Teknova Inc

May 01 • 04:00PM ET

1.91

Dollar change +0.13
Percentage change 7.30	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

TKNO Alpha Teknova Inc daily Stock Chart

Held by: VTI VXF IWC DFAT DCOR

Index	-	P/E	-	EPS (ttm)	-1.17	Insider Own	74.29%	Shs Outstand	40.79M	Perf Week	11.70%
Market Cap	77.97M	Forward P/E	-	EPS next Y	-0.54	Insider Trans	0.04%	Shs Float	10.49M	Perf Month	-23.60%
Income	-36.78M	PEG	-	EPS next Q	-0.24	Inst Own	13.81%	Short Float	0.45%	Perf Quarter	-40.50%
Sales	36.68M	P/S	2.13	EPS this Y	33.62%	Inst Trans	-1.25%	Short Ratio	4.30	Perf Half Y	3.24%
Book/sh	2.21	P/B	0.87	EPS next Y	30.52%	ROA	-26.19%	Short Interest	0.05M	Perf Year	5.52%
Cash/sh	0.70	P/C	2.74	EPS next 5Y	-	ROE	-38.73%	52W Range	1.62 - 4.27	Perf YTD	-48.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-113.92%	ROI	-30.99%	52W High	-55.27%	Beta	0.39
Dividend TTM	-	Quick Ratio	3.84	Sales past 5Y	17.33%	Gross Margin	24.94%	52W Low	17.90%	ATR (14)	0.18
Dividend Ex-Date	-	Current Ratio	5.14	EPS Y/Y TTM	30.96%	Oper. Margin	-85.05%	RSI (14)	38.70	Volatility	9.26% 7.52%
Employees	211	Debt/Eq	0.34	Sales Y/Y TTM	-11.43%	Profit Margin	-100.26%	Recom	1.80	Target Price	5.50
Option/Short	No / Yes	LT Debt/Eq	0.32	EPS Q/Q	44.62%	Payout	-	Rel Volume	0.49	Prev Close	1.78
Sales Surprise	-5.58%	EPS Surprise	-8.33%	Sales Q/Q	-0.30%	Earnings	May 13 AMC	Avg Volume	11.04K	Price	1.91
SMA20	-12.15%	SMA50	-25.99%	SMA200	-28.37%	Trades		Volume	5,458	Change	7.30%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-12-24	Downgrade	BTIG Research	Buy → Neutral

Apr-29-24 04:01PM	Teknova to Report First Quarter 2024 Financial Results on May 13, 2024 (GlobeNewswire)
Apr-24-24 09:35AM	Down -28.04% in 4 Weeks, Here's Why Alpha Teknova (TKNO) Looks Ripe for a Turnaround (Zacks)
Mar-13-24 08:12AM	Alpha Teknova, Inc. (NASDAQ:TKNO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-11-24 05:35PM	Alpha Teknova Inc (TKNO) Faces Revenue Decline Amid Market Challenges (GuruFocus.com) +5.96%
04:24PM	Alpha Teknova: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Loading…
04:01PM	Teknova Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-21-24 04:01PM	Teknova to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024 (GlobeNewswire)
Nov-16-23 04:15AM	Alpha Teknova (TKNO) Posted Better Than Expected Results in Q3 (Insider Monkey)
Nov-12-23 11:53AM	Alpha Teknova, Inc. (NASDAQ:TKNO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:39PM	Alpha Teknova: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Teknova Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-26-23 08:00AM	Teknova to Report Third Quarter 2023 Financial Results on November 9, 2023 (GlobeNewswire)
Sep-27-23 08:00AM	Teknova Launches Latest Proprietary AAV-Tek Product and End-to-End Plasmid Workflow Solutions to Streamline Therapeutic Process Development (GlobeNewswire) +5.82%
Sep-26-23 09:56AM	Insiders Pour Millions Into These 2 Beaten-Down Stocks, Analysts Say They Could Be Ready to Bounce Back Heres Why You Should Take Notice (TipRanks) +26.41%
Sep-19-23 04:01PM	Teknova Announces Closing of $22.9 Million Concurrent Registered Direct Offering and Private Placement and Amends Credit Facility (GlobeNewswire)
08:00AM	Loading…
Sep-18-23 08:00AM	Teknova Announces Up to $22.9 Million Concurrent Registered Direct Offering and Private Placement (GlobeNewswire)
Aug-16-23 08:00AM	Teknova Announces New Board Member, Martha J. Demski (GlobeNewswire)
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Aug-14-23 09:12AM	Alpha Teknova, Inc. (NASDAQ:TKNO) Q2 2023 Earnings Call Transcript (Insider Monkey) -6.99%
Aug-10-23 04:31PM	Alpha Teknova: Q2 Earnings Snapshot (AP Finance) +6.87%
04:01PM	Teknova Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-09-23 08:00AM	Teknova Announces Opening of New GMP-Certified Facility, Increasing Manufacturing Capacity for Custom, High-Quality Life Sciences Reagents (GlobeNewswire) -10.88%
Jul-26-23 08:00AM	Teknova to Report Second Quarter 2023 Financial Results on August 10, 2023 (GlobeNewswire)
Jul-20-23 08:00AM	Teknova and Sartorius BIA Separations Share Data Demonstrating Reliable and Scalable Approach for the Enhancement of AAV Full Capsid Enrichment with an Optimized AEX Platform (GlobeNewswire) -6.35%
Jul-16-23 09:30AM	Despite Recent Gains, Alpha Teknova Insiders Are Still Down US$51k (Simply Wall St.)
Jul-11-23 08:00AM	Teknova Expands Proprietary AAV-Tek Solutions Product Line to Deliver End-to-End Solutions for Gene Therapy Process Development (GlobeNewswire) +7.09%
Jun-05-23 12:40PM	Amidst increasing losses, Investors bid up Alpha Teknova (NASDAQ:TKNO) 18% this past week (Simply Wall St.)
May-29-23 02:34AM	Should You Hold Alpha Teknova (TKNO)? (Insider Monkey)
May-25-23 08:00AM	Teknova to Participate in Upcoming Investor Conference (GlobeNewswire)
May-10-23 04:13PM	Alpha Teknova: Q1 Earnings Snapshot (AP Finance) +7.18%
04:01PM	Loading…
04:01PM	Teknova Reports First Quarter 2023 Financial Results (GlobeNewswire)
08:00AM	Teknova to Present Data on Novel Products to Accelerate the Development of AAV Therapies at ASGCT 2023 Annual Meeting (GlobeNewswire)
May-04-23 12:00PM	What Makes Alpha Teknova (TKNO) a New Strong Buy Stock (Zacks)
08:00AM	Teknova Announces Time Change for First Quarter 2023 Financial Results Conference Call on May 10, 2023 (GlobeNewswire)
May-02-23 08:00AM	Teknova Launches Proprietary AAV-Tek Solutions Gene Therapy Product Line to Accelerate the Development of AAV Therapies (GlobeNewswire)
Apr-26-23 08:00AM	Teknova to Report First Quarter 2023 Financial Results on May 10, 2023 (GlobeNewswire)
Apr-24-23 09:35AM	Alpha Teknova (TKNO) Loses -29.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Apr-17-23 06:12AM	Alpha Teknova, Inc. (NASDAQ:TKNO) Might Not Be As Mispriced As It Looks After Plunging 30% (Simply Wall St.)
Apr-07-23 09:35AM	Down -48.43% in 4 Weeks, Here's Why You Should You Buy the Dip in Alpha Teknova (TKNO) (Zacks)
Mar-18-23 02:55AM	Alpha Teknova, Inc. (NASDAQ:TKNO) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-15-23 04:01PM	Teknova Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
08:00AM	Teknova and Sartorius BIA Separations Announce Collaboration to Address Critical Pain Point in Gene Therapy Process Development (GlobeNewswire)
Feb-23-23 08:00AM	Teknova to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 (GlobeNewswire)
Feb-10-23 08:00AM	Teknova to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-06-23 07:06AM	Multiple insiders bought Alpha Teknova, Inc. (NASDAQ:TKNO) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Dec-27-22 10:02AM	Alpha Teknova (NASDAQ:TKNO) one-year losses have grown faster than shareholder returns have fallen, but the stock pops 11% this past week (Simply Wall St.)
Dec-18-22 04:42PM	Heres Why Alpha Teknova (TKNO) Stock Declined in Q3 (Insider Monkey)
Nov-16-22 05:44AM	Revenue Downgrade: Here's What Analysts Forecast For Alpha Teknova, Inc. (NASDAQ:TKNO) (Simply Wall St.)
Nov-12-22 08:07AM	Alpha Teknova Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Nov-09-22 04:01PM	Teknova Reports Third Quarter 2022 Financial Results (GlobeNewswire) -12.15%
08:00AM	Teknova Announces New WFI Quality Water Product Line for Bioprocessing Market (GlobeNewswire)
Nov-03-22 04:01PM	Teknova to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-26-22 04:01PM	Teknova to Report Third Quarter 2022 Financial Results on November 9, 2022 (GlobeNewswire)
Oct-18-22 09:03AM	10 Best Low Price Pharma Stocks To Buy Now (Insider Monkey)
Oct-13-22 08:00AM	Teknova Announces Early Access Program for Novel Products to Address Critical Pain Points in Gene Therapy Bioproduction (GlobeNewswire)
Oct-05-22 08:00AM	Teknova to Present at 2022 Cell & Gene Meeting on the Mesa (GlobeNewswire) +8.36%
Aug-31-22 04:01PM	Teknova to Participate in Upcoming Investor Conference (GlobeNewswire) -5.45%
Aug-17-22 06:08AM	The President of Alpha Teknova, Inc. (NASDAQ:TKNO), Stephen Gunstream, Just Bought A Few More Shares (Simply Wall St.) -11.23%
Aug-13-22 08:35AM	Analysts Have Lowered Expectations For Alpha Teknova, Inc. (NASDAQ:TKNO) After Its Latest Results (Simply Wall St.)
Aug-10-22 04:01PM	Teknova Reports Second Quarter 2022 Financial Results (GlobeNewswire) -5.24%
Aug-01-22 04:01PM	Teknova to Report Second Quarter 2022 Financial Results on August 10, 2022 (GlobeNewswire)
Jul-05-22 09:39AM	Loss-making Alpha Teknova (NASDAQ:TKNO) sheds a further US$57m, taking total shareholder losses to 65% over 1 year (Simply Wall St.) -10.91%
Jun-05-22 09:12AM	Multiple insiders bought Alpha Teknova, Inc. (NASDAQ:TKNO) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
May-25-22 04:01PM	Teknova to Participate in Upcoming Investor Conference (GlobeNewswire) -11.11%
May-11-22 04:01PM	Teknova Reports First Quarter 2022 Financial Results (GlobeNewswire) +17.04%
May-04-22 05:18PM	Teknova to Report First Quarter 2022 Financial Results on May 11, 2022 (GlobeNewswire)
Mar-15-22 04:01PM	Teknova Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-02-22 08:05AM	Teknova to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022 (GlobeNewswire)
Feb-28-22 08:15AM	Teknova Announces Preliminary Revenue of $10.0 to $10.1 Million for the Fourth Quarter 2021 (GlobeNewswire) +7.39%
Feb-14-22 08:00AM	Teknova to Participate in Upcoming Investor Conference (GlobeNewswire)
Jan-28-22 01:38PM	Roubaix Capital, LLC Buys Treace Medical Concepts Inc, Alpha Teknova Inc, EnerSys, Sells Rogers ... (GuruFocus.com)
Dec-27-21 11:38PM	Advisors' Inner Circle Fund III Buys SPDR Biotech ETF, Scientific Games Corp, Silvergate ... (GuruFocus.com)
11:56AM	One Alpha Teknova, Inc. (NASDAQ:TKNO) insider upped their stake by 0.5% in the previous year (Simply Wall St.)
Dec-15-21 06:02PM	Teknova to Join the Nasdaq Biotechnology Index (GlobeNewswire)
Nov-16-21 05:03PM	Teknova to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-10-21 04:01PM	Teknova Reports Third Quarter 2021 Financial Results (GlobeNewswire) -7.04%
07:00AM	Teknova Expands Leadership Team with the Appointments of Ken Gelhaus as Chief Commercial Officer and Jennifer Henry as Senior Vice President, Marketing (GlobeNewswire)
Nov-03-21 04:05PM	Teknova to Report Third Quarter 2021 Financial Results on November 10, 2021 (GlobeNewswire)
Oct-08-21 12:42PM	Most of this year's flood of new Bay Area public companies are 'under water' (American City Business Journals)
Aug-11-21 04:01PM	Teknova Reports Second Quarter 2021 Financial Results (GlobeNewswire) -6.40%
Aug-04-21 04:05PM	Teknova to Report Second Quarter 2021 Financial Results on August 11 (GlobeNewswire)
Jun-29-21 07:00PM	Teknova Announces Closing of Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire) -12.40%
Jun-24-21 10:00PM	Teknova Announces Pricing of its Upsized Initial Public Offering (GlobeNewswire)

Alpha Teknova, Inc. engages in the manufacture of cell culture media and supplements. It provides reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. The company was founded by Thomas E. Davis in 1996 and is headquartered in Hollister, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gelhaus Ken	Chief Commercial Officer	Nov 30 '23	Buy	1.73	3,587	6,220	22,924	Dec 01 05:44 PM
Telegraph Hill Partners IV, L.	10% Owner	Sep 19 '23	Buy	1.85	6,917,837	12,797,998	21,859,660	Sep 21 08:58 PM
Telegraph Hill Partners IV, L.	10% Owner	Sep 19 '23	Buy	1.85	1,190,270	2,202,000	3,761,132	Sep 21 08:58 PM
MACKOWSKI J MATTHEW	Director	Sep 19 '23	Buy	1.85	810,810	1,499,998	810,810	Sep 21 05:04 PM
Gunstream Stephen	President and CEO	Sep 19 '23	Buy	1.85	54,054	100,000	162,852	Sep 21 05:03 PM
Lowell Matthew	Chief Financial Officer	Sep 19 '23	Buy	1.85	54,054	100,000	88,054	Sep 21 05:03 PM
Terrill Damon	General Counsel and CCO	Sep 19 '23	Buy	1.85	27,027	50,000	41,027	Sep 21 05:04 PM
Hood Lisa	Chief People Officer	Jun 13 '23	Sale	3.80	11,400	43,268	33,834	Jun 14 04:55 PM
Davis Ted	Director	May 26 '23	Buy	3.21	2,000	6,430	1,888,419	May 31 05:16 PM
Davis Irene	Director	May 26 '23	Buy	3.21	2,000	6,430	1,888,419	May 31 05:16 PM
Hood Lisa	Chief People Officer	May 17 '23	Sale	2.04	3,119	6,351	45,234	May 17 06:17 PM
Gunstream Stephen	President and CEO	May 12 '23	Buy	1.67	4,665	7,772	108,798	May 16 07:07 PM
Gelhaus Ken	Chief Commercial Officer	May 12 '23	Buy	1.67	3,915	6,522	19,337	May 16 07:07 PM
Hood Lisa	Chief People Officer	May 12 '23	Buy	1.67	3,119	5,196	48,353	May 16 07:07 PM

Open in Screener

QDEL

QuidelOrtho Corporation

May 01 • 04:00PM ET

39.68

Dollar change -0.87
Percentage change -2.15	%

Healthcare • Medical Devices • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

QDEL QuidelOrtho Corporation daily Stock Chart

Held by: VTI IJH VB VXF VBK FXH IHI AVUV IJJ SCHA

Index	-	P/E	-	EPS (ttm)	-0.15	Insider Own	22.27%	Shs Outstand	66.70M	Perf Week	-2.79%
Market Cap	2.65B	Forward P/E	10.95	EPS next Y	3.62	Insider Trans	0.01%	Shs Float	51.96M	Perf Month	-5.86%
Income	-10.10M	PEG	-	EPS next Q	0.39	Inst Own	80.00%	Short Float	5.22%	Perf Quarter	-42.08%
Sales	2.99B	P/S	0.89	EPS this Y	-42.91%	Inst Trans	0.57%	Short Ratio	2.32	Perf Half Y	-34.03%
Book/sh	75.05	P/B	0.53	EPS next Y	53.72%	ROA	-0.12%	Short Interest	2.71M	Perf Year	-56.86%
Cash/sh	2.50	P/C	15.86	EPS next 5Y	7.20%	ROE	-0.20%	52W Range	37.78 - 95.02	Perf YTD	-46.16%
Dividend Est.	-	P/FCF	37.41	EPS past 5Y	-	ROI	-0.14%	52W High	-58.24%	Beta	0.17
Dividend TTM	-	Quick Ratio	0.88	Sales past 5Y	59.83%	Gross Margin	42.84%	52W Low	5.03%	ATR (14)	1.67
Dividend Ex-Date	-	Current Ratio	1.57	EPS Y/Y TTM	-101.18%	Oper. Margin	8.17%	RSI (14)	38.49	Volatility	4.32% 3.71%
Employees	7100	Debt/Eq	0.52	Sales Y/Y TTM	-8.34%	Profit Margin	-0.34%	Recom	2.38	Target Price	55.49
Option/Short	Yes / Yes	LT Debt/Eq	0.49	EPS Q/Q	-77.04%	Payout	-	Rel Volume	0.72	Prev Close	40.55
Sales Surprise	-6.81%	EPS Surprise	-42.60%	Sales Q/Q	-14.27%	Earnings	May 08 AMC	Avg Volume	1.17M	Price	39.68
SMA20	-3.50%	SMA50	-10.53%	SMA200	-38.93%	Trades		Volume	844,842	Change	-2.15%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-04-24	Downgrade	UBS	Neutral → Sell	$70 → $42
Feb-14-24	Downgrade	JP Morgan	Neutral → Underweight	$66 → $37
Dec-11-23	Downgrade	Citigroup	Buy → Neutral	$95 → $72
Dec-12-22	Upgrade	Citigroup	Neutral → Buy	$90 → $125
Dec-07-22	Initiated	RBC Capital Mkts	Outperform	$125
Oct-14-22	Upgrade	UBS	Sell → Neutral	$86
Sep-19-22	Initiated	Citigroup	Neutral	$90
Jul-20-22	Initiated	UBS	Sell	$86
Jun-17-22	Resumed	JP Morgan	Neutral	$80 → $110
Feb-22-22	Upgrade	Raymond James	Outperform → Strong Buy	$155 → $130
Jan-22-21	Upgrade	Raymond James	Mkt Perform → Outperform	$250
May-12-20	Downgrade	JP Morgan	Neutral → Underweight	$120 → $158
Mar-26-20	Downgrade	Barclays	Overweight → Equal Weight	$90
Oct-23-18	Resumed	Raymond James	Strong Buy	$80
Mar-08-18	Upgrade	Raymond James	Outperform → Strong Buy
Jan-22-18	Reiterated	Barclays	Overweight	$50 → $60
Jan-04-18	Upgrade	CL King	Neutral → Buy
Sep-19-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jul-18-17	Upgrade	William Blair	Mkt Perform → Outperform
Jul-18-17	Upgrade	Canaccord Genuity	Hold → Buy	$25 → $42

Show Previous Ratings

Today 10:01AM	Analysts Estimate QuidelOrtho (QDEL) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-30-24 08:15PM	QDEL Investors With Large Losses Should Contact Robbins LLP for Information About Their Rights in Connection With the QuidelOrtho Corporation Lawsuit (Business Wire)
Apr-17-24 07:00AM	QuidelOrtho To Report First Quarter 2024 Financial Results (Business Wire)
Apr-12-24 11:47AM	QuidelOrtho's (QDEL) New Test to Offer Enhanced Opioid Testing (Zacks)
Apr-10-24 07:00AM	QuidelOrtho Adds Fentanyl Test to Its Vitros Systems as a MicroTip Partnership Assay (Business Wire)
10:48AM	Loading…
Apr-03-24 10:48AM	QuidelOrtho's (QDEL) QuickVue Gets FDA Nod for COVID Testing (Zacks)
06:38AM	QuidelOrtho pulls FDA submission of 4-virus test (MedTech Dive)
Apr-02-24 09:00AM	QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue COVID-19 Test (Business Wire) -10.32%
Mar-14-24 07:23AM	QuidelOrtho to lay off employees after firing CEO (MedTech Dive)
Mar-07-24 10:44AM	QuidelOrtho's (QDEL) New Approval to Aid Pre-eclampsia Diagnosis (Zacks)
Mar-06-24 04:35PM	QuidelOrtho Receives Health Canada Approval for Quidel Triage PLGF Test for Laboratory Use in Canada (Business Wire)
Feb-26-24 04:30PM	QuidelOrtho to Participate in 45th Annual Raymond James Institutional Investor Conference (Business Wire)
Feb-21-24 07:30AM	QuidelOrtho Announces Changes in Executive Leadership (Business Wire) +6.20%
05:27AM	QuidelOrtho fires CEO Doug Bryant (MedTech Dive)
Feb-20-24 01:49PM	QuidelOrtho (QDEL) Stock Crashes After Posting YoY Revenue Decline, Analyst Downgrades - Hagens Berman (GlobeNewswire) +11.57%
08:34PM	Loading…
Feb-14-24 08:34PM	QuidelOrtho (QDEL) Stock Crashes After Posting YoY Revenue Decline, Analyst Downgrades - Hagens Berman (GlobeNewswire) -32.20%
10:05AM	QuidelOrtho (QDEL) Q4 Earnings and Sales Miss, Margins Fall (Zacks)
09:22AM	QuidelOrtho Corporation (NASDAQ:QDEL) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-13-24 07:30PM	QuidelOrtho (QDEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:30PM	QuidelOrtho (QDEL) Misses Q4 Earnings and Revenue Estimates (Zacks)
04:40PM	QuidelOrtho Corp (QDEL) Reports Mixed Results Amidst Respiratory Revenue Decline (GuruFocus.com)
04:05PM	QuidelOrtho Reports Fourth Quarter and Full-Year 2023 Financial Results (Business Wire)
Feb-12-24 09:16AM	Insights Into QuidelOrtho (QDEL) Q4: Wall Street Projections for Key Metrics (Zacks)
Jan-23-24 07:00AM	QuidelOrtho to Report Fourth Quarter and Full-year 2023 Financial Results (Business Wire)
Dec-22-23 07:00AM	QuidelOrtho to Present at 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-20-23 04:05PM	QuidelOrtho Receives 510(K) Clearance for Savanna Multiplex Molecular Platform and Savanna HSV 1+2/VZV PCR Assay (Business Wire)
Dec-13-23 05:10AM	Why is QuidelOrtho (QDEL) a Good Stock to Invest in? (Insider Monkey) +7.61%
Nov-16-23 05:05PM	QuidelOrtho to Participate in the Evercore ISI Conference (Business Wire)
Nov-01-23 05:56PM	QuidelOrtho Corp (QDEL) Reports Q3 2023 Financial Results: Revenue at $744 Million (GuruFocus.com)
04:05PM	QuidelOrtho Reports Third Quarter 2023 Financial Results (Business Wire)
03:43PM	Loading…
Oct-17-23 03:43PM	Powerful Lyme Disease Awareness PSA Featuring Christopher Meloni Illuminates Times Square (PR Newswire)
Oct-12-23 07:00AM	QuidelOrtho Reports Preliminary Revenue Results for the Third Quarter 2023 (Business Wire) -6.17%
Sep-21-23 04:05PM	QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIA (Business Wire)
07:02AM	Should You Add QuidelOrtho (QDEL) to Your Portfolio? (Insider Monkey)
Aug-28-23 04:05PM	QuidelOrtho to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-08-23 04:30PM	QuidelOrtho Reports Second Quarter 2023 Financial Results (Business Wire)
Jul-25-23 04:00PM	QuidelOrtho Ranks No. 1 in Customer Satisfaction for Six Years in a Row (Business Wire)
01:12PM	QuidelOrtho Partners With BYG4lab® to Strengthen Informatics Offerings (Business Wire)
Jul-19-23 08:15AM	The three-year shareholder returns and company earnings persist lower as QuidelOrtho (NASDAQ:QDEL) stock falls a further 3.2% in past week (Simply Wall St.)
Jul-18-23 04:05PM	QuidelOrtho to Report Second Quarter 2023 Financial Results (Business Wire)
Jun-21-23 08:00PM	QDEL: What does Argus have to say about QDEL? (Argus Research)
Jun-12-23 11:20AM	Declining Stock and Decent Financials: Is The Market Wrong About QuidelOrtho Corporation (NASDAQ:QDEL)? (Simply Wall St.)
May-23-23 07:00AM	QuidelOrtho to Participate in William Blair 43rd Annual Growth Stock Conference (Business Wire)
May-04-23 07:50AM	Q1 2023 QuidelOrtho Corp Earnings Call (Thomson Reuters StreetEvents) -6.53%
May-03-23 04:05PM	QuidelOrtho Reports First Quarter 2023 Financial Results (Business Wire)
Apr-26-23 08:00PM	QDEL: Lowering target price to $74.00 (Argus Research)
Apr-13-23 04:05PM	QuidelOrtho Reports Preliminary Revenue Results for the First Quarter 2023 (Business Wire)
Mar-28-23 11:05AM	QuidelOrtho Announces the Formation of the International QuidelOrtho Womens Leadership Network (QWLN) (Business Wire)
07:54AM	QuidelOrtho Corporation (NASDAQ:QDEL) Shares Could Be 36% Below Their Intrinsic Value Estimate (Simply Wall St.)
Mar-23-23 12:19PM	3 Reasons to Retain QuidelOrtho (QDEL) Stock in Your Portfolio (Zacks)
Mar-13-23 01:00PM	QuidelOrtho's (QDEL) Rapid Antigen Test Gets De Novo FDA Approval (Zacks)
Mar-08-23 04:05PM	QuidelOrtho Receives De Novo FDA Authorization for Sofia® 2 SARS Antigen+ FIA (Business Wire)
Mar-04-23 09:08AM	17 High Growth Low PE Stocks (Insider Monkey)
08:19AM	13 Most Undervalued Healthcare Stocks To Buy According To Hedge Funds (Insider Monkey)
Mar-02-23 02:01PM	QuidelOrtho to Participate in the Raymond James 44th Annual Institutional Investor Conference (Business Wire)
Feb-27-23 11:00AM	ImageMover and QuidelOrtho Partner to Simplify Test-to-Treat Process for Pharmacies (PR Newswire)
05:13AM	QuidelOrtho Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Feb-26-23 08:04AM	12 High Growth Healthcare Stocks to Buy (Insider Monkey)
Feb-18-23 07:14AM	QuidelOrtho Corporation Just Missed Revenue By 8.0%: Here's What Analysts Think Will Happen Next (Simply Wall St.)
Feb-16-23 06:18PM	QuidelOrtho Corporation (NASDAQ:QDEL) Q4 2022 Earnings Call Transcript (Insider Monkey) +5.66%
12:07PM	QuidelOrtho (QDEL) Q4 Earnings Top Estimates, Margins Down (Zacks)
Feb-15-23 04:05PM	QuidelOrtho Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-09-23 06:34AM	QuidelOrtho (NASDAQ:QDEL) pulls back 4.3% this week, but still delivers shareholders favorable 14% CAGR over 5 years (Simply Wall St.)
Jan-24-23 03:25PM	Top Healthcare Stocks (Investopedia)
Jan-06-23 04:05PM	QuidelOrtho Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022 (Business Wire)
Jan-03-23 09:53AM	Is QuidelOrtho Corporation's (NASDAQ:QDEL) Latest Stock Performance A Reflection Of Its Financial Health? (Simply Wall St.)
Dec-28-22 07:00AM	QuidelOrtho to Present at the J.P. Morgan Healthcare Conference (Business Wire)
Dec-20-22 06:08PM	Billionaire David Rubenstein Says Recession Is Likely, but Stays Heavily Invested in These 2 Stocks (TipRanks)
09:37AM	QuidelOrtho's (QDEL) Myocardial Infarction Test Cleared in Canada (Zacks)
Dec-19-22 03:15PM	Health Canada Grants License for Quidel® TriageTrue® High-Sensitivity Troponin I Test to Aid in the Diagnosis of Myocardial Infarction (Business Wire)
Dec-16-22 11:05AM	QuidelOrtho and Runda Medical Form Joint Venture to Develop and Manufacture Assays for VITROS® Platform (Business Wire)
09:21AM	13 Best Medical Device Stocks To Buy Now (Insider Monkey)
Dec-12-22 04:54PM	QuidelOrtho Announces Separation of Chairman and Chief Executive Officer Roles (Business Wire) +5.63%
Dec-08-22 02:13PM	Should You Invest in QuidelOrtho Corporation (QDEL) for a Long-Term Advantage? (Insider Monkey)
Nov-30-22 04:05PM	QuidelOrtho to Host Investor Day on December 13, 2022 (Business Wire) +5.15%
Nov-08-22 11:05AM	Will the Demand for QuidelOrtho Corporation (QDEL)s Products Increase in Near Term? (Insider Monkey)
Nov-03-22 06:38PM	Why QuidelOrtho Stock Slipped and Fell Today (Motley Fool)
Nov-02-22 04:05PM	QuidelOrtho Reports Third Quarter 2022 Financial Results (Business Wire)
Oct-19-22 06:54AM	Are Investors Undervaluing QuidelOrtho Corporation (NASDAQ:QDEL) By 49%? (Simply Wall St.)
Oct-12-22 04:05PM	QuidelOrtho Reports Preliminary Revenue Results for Third Quarter 2022 (Business Wire)
Oct-04-22 09:00AM	Development of New Drugs to Target Lyme and Other Infectious Diseases Subject of a New Webinar Now Available From Quidel Corporation (News Direct)
Sep-06-22 08:00AM	QuidelOrtho to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference (Business Wire)
Sep-03-22 09:00AM	The Fed Chief Speaks; Wall Street Reacts (Motley Fool)
Sep-02-22 06:46AM	QuidelOrtho (NASDAQ:QDEL) shareholders are still up 118% over 5 years despite pulling back 5.8% in the past week (Simply Wall St.)
Sep-01-22 12:00PM	Quidel and World Champion Los Angeles Rams Partner to Combat COVID-19 and Promote Health Awareness in the L.A. Community (Business Wire)
Aug-24-22 09:00AM	Bacterial Biofilms, Responsible for Up to 75% of All Infectious Diseases in America, Explored in New Webinar From Quidel Corporation (Business Wire)
Aug-17-22 04:30PM	QuidelOrtho Announces $300 Million Share Repurchase Authorization (Business Wire)
Aug-12-22 01:27PM	What You Need To Know About QuidelOrtho Corporation's (NASDAQ:QDEL) Investor Composition (Simply Wall St.)
Aug-09-22 12:08PM	QuidelOrtho (QDEL) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-04-22 04:10PM	QuidelOrtho Reports Second Quarter 2022 Financial Results (Business Wire)
Jul-27-22 07:24AM	QuidelOrtho Corporation (NASDAQ:QDEL) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? (Simply Wall St.)
Jul-26-22 09:35AM	ORTHO RANKS NO. 1 IN CUSTOMER SATISFACTION FOR 5 YEARS IN A ROW (PR Newswire)
Jul-24-22 05:30AM	Covid-19 Lab Companies Retrench as Rapid Tests Take Over (The Wall Street Journal)
Jul-18-22 04:05PM	QuidelOrtho to Report Second Quarter 2022 Financial Results on August 4, 2022 (GlobeNewswire)
Jul-04-22 03:57PM	Investors Don't See Light At End Of QuidelOrtho Corporation's (NASDAQ:QDEL) Tunnel (Simply Wall St.)
Jun-21-22 07:00PM	Quidel Corporation and the American Heart Association join forces to Advance Education and Awareness of Heart Disease in San Diego County (Business Wire)
Jun-09-22 09:00AM	QUIDEL CORP.DEVELOPER OF ONLY FDA-CLEARED FIA RAPID POINT-OF-CARE DIAGNOSTIC LYME DISEASE TESTTO PARTNER WITH RENOWNED GLOBAL LYME ALLIANCE TO DRAMATICALLY HEIGHTEN LYME DISEASE AWARENESS (News Direct)
Jun-03-22 11:32AM	Quidel (QDEL) Down 9.8% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-01-22 08:56AM	Here's Why We Think QuidelOrtho (NASDAQ:QDEL) Is Well Worth Watching (Simply Wall St.)
May-27-22 09:00AM	QuidelOrtho Formed by the Completion of Transaction Combining Quidel and Ortho Clinical Diagnostics (Business Wire)

QuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BUECHLER KENNETH F	Director	Apr 12 '24	Option Exercise	21.07	9,041	190,494	83,679	Apr 16 06:18 PM
Busky Joseph M	Chief Financial Officer	Feb 23 '24	Buy	46.35	2,150	99,663	2,150	Feb 26 06:48 PM

Open in Screener

IONS

Ionis Pharmaceuticals Inc

May 01 • 04:00PM ET

43.01

Dollar change +1.75
Percentage change 4.24	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

IONS Ionis Pharmaceuticals Inc daily Stock Chart

Held by: VTI VB VXF VBK ARKG IBB SCHA IWP VHT IWR

Index	-	P/E	-	EPS (ttm)	-2.56	Insider Own	8.11%	Shs Outstand	144.34M	Perf Week	1.32%
Market Cap	6.27B	Forward P/E	-	EPS next Y	-3.23	Insider Trans	-3.78%	Shs Float	133.94M	Perf Month	0.02%
Income	-366.02M	PEG	-	EPS next Q	-1.03	Inst Own	97.01%	Short Float	7.12%	Perf Quarter	-16.31%
Sales	788.14M	P/S	7.95	EPS this Y	-53.68%	Inst Trans	-4.53%	Short Ratio	8.93	Perf Half Y	-2.25%
Book/sh	2.68	P/B	16.05	EPS next Y	18.00%	ROA	-13.25%	Short Interest	9.53M	Perf Year	20.54%
Cash/sh	16.04	P/C	2.68	EPS next 5Y	-	ROE	-76.29%	52W Range	34.32 - 54.44	Perf YTD	-14.98%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-15.91%	52W High	-21.00%	Beta	0.41
Dividend TTM	-	Quick Ratio	5.83	Sales past 5Y	13.97%	Gross Margin	95.99%	52W Low	25.32%	ATR (14)	1.15
Dividend Ex-Date	-	Current Ratio	5.90	EPS Y/Y TTM	-34.71%	Oper. Margin	-44.87%	RSI (14)	53.90	Volatility	2.99% 2.55%
Employees	927	Debt/Eq	5.09	Sales Y/Y TTM	34.16%	Profit Margin	-46.44%	Recom	1.84	Target Price	57.61
Option/Short	Yes / Yes	LT Debt/Eq	4.95	EPS Q/Q	82.93%	Payout	-	Rel Volume	1.00	Prev Close	41.26
Sales Surprise	86.65%	EPS Surprise	92.53%	Sales Q/Q	113.82%	Earnings	May 07 BMO	Avg Volume	1.07M	Price	43.01
SMA20	2.45%	SMA50	-0.41%	SMA200	-5.19%	Trades		Volume	1,066,636	Change	4.24%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-10-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$58
Jan-02-24	Upgrade	BofA Securities	Neutral → Buy	$52 → $62
Oct-23-23	Upgrade	BofA Securities	Underperform → Neutral	$33 → $52
Sep-29-23	Initiated	Raymond James	Strong Buy	$63
Jul-31-23	Upgrade	Citigroup	Neutral → Buy	$36 → $60
Jun-07-23	Resumed	Piper Sandler	Overweight	$58
May-04-23	Upgrade	Citigroup	Sell → Neutral	$30 → $36
Mar-21-23	Initiated	Bernstein	Underperform	$31
Dec-21-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $40
Sep-09-22	Resumed	Morgan Stanley	Overweight	$57
Jul-18-22	Resumed	Oppenheimer	Outperform	$59
Mar-31-22	Resumed	Piper Sandler	Overweight	$54
Mar-01-22	Initiated	Guggenheim	Buy	$64
Mar-01-22	Initiated	Citigroup	Sell	$26
Feb-01-22	Downgrade	BofA Securities	Buy → Underperform	$40 → $30
Dec-14-21	Upgrade	William Blair	Mkt Perform → Outperform
May-07-21	Upgrade	UBS	Sell → Neutral	$33 → $37.50
Mar-01-21	Upgrade	Barclays	Underweight → Equal Weight	$50 → $52
Dec-16-20	Initiated	UBS	Sell	$34
Dec-15-20	Upgrade	Cowen	Market Perform → Outperform

Show Previous Ratings

Apr-30-24 10:00AM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-25-24 07:00AM	Ionis Publishes 2023 Corporate Responsibility Report (PR Newswire)
Apr-23-24 07:05AM	Ionis to hold first quarter 2024 financial results webcast (PR Newswire)
Apr-07-24 09:48AM	Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome (PR Newswire)
Apr-01-24 07:05AM	Ionis to present at upcoming investor conferences (PR Newswire)
07:05AM	Loading…
Mar-28-24 07:05AM	Ionis to hold olezarsen Phase 3 data webcast (PR Newswire)
Mar-25-24 09:09AM	Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs? (Zacks)
08:18AM	Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting (PR Newswire)
Mar-22-24 11:30AM	Ionis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-21-24 03:00PM	New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding (The Wall Street Journal)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-14-24 10:40AM	Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals (Zacks)
Mar-13-24 07:17AM	UPDATE 1-Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial (Reuters)
07:07AM	Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial (Reuters)
07:00AM	Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH (PR Newswire)
07:30AM	Loading…
Mar-06-24 07:30AM	New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy (GlobeNewswire)
Feb-29-24 09:05AM	Ionis announces new chief global product strategy officer to lead next phase of commercial growth (PR Newswire)
Feb-28-24 07:05AM	Ionis to present at upcoming investor conferences (PR Newswire)
Feb-22-24 12:12PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
10:59AM	Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2023 Earnings Call Transcript (Insider Monkey)
10:29AM	Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y (Zacks)
02:20AM	Q4 2023 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-21-24 11:31AM	Ionis Pharmaceuticals Inc (IONS) Surpasses Revenue Guidance for 2023, Sets Sights on 2024 Growth (GuruFocus.com)
09:30AM	Ionis Pharmaceuticals (IONS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:05AM	Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:06AM	Ionis Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ionis reports fourth quarter and full year 2023 financial results (PR Newswire)
Feb-15-24 09:15AM	Ionis Pharmaceuticals (IONS) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks) -7.72%
07:00AM	Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome (PR Newswire)
Feb-14-24 10:00AM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
10:44AM	Loading…
Feb-09-24 10:44AM	Ionis' (IONS) Eplontersen Gets Fast Track Tag for New Indication (Zacks)
Feb-08-24 07:00AM	Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy (PR Newswire)
Feb-07-24 07:05AM	Ionis to hold fourth quarter and full year 2023 financial results webcast (PR Newswire)
Jan-23-24 01:23PM	Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal (Zacks)
Jan-22-24 07:26AM	UPDATE 2-Ionis Pharma's genetic disease drug succeeds in late-stage study (Reuters)
07:09AM	Ionis Pharma's genetic disease drug succeeds in late-stage study (Reuters)
07:00AM	Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema (PR Newswire)
04:47AM	Ionis says rare disease drug succeeds in late-stage HAE study (BioPharma Dive)
Jan-18-24 07:58PM	Insider Sell: EVP CLO & General Counsel Patrick O'Neil Sells 7,744 Shares of Ionis ... (GuruFocus.com)
Jan-08-24 08:00AM	Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio (GlobeNewswire)
07:03AM	Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases (PR Newswire)
Jan-03-24 08:00AM	Alcyone Therapeutics Announces First Patient Implanted in PIERRE IDE Clinical Study of the ThecaFlex DRx System for Administration of SPINRAZA (nusinersen) (PR Newswire)
Dec-30-23 07:01AM	EVP CLO & General Counsel Patrick O'Neil Sells 20,825 Shares of Ionis Pharmaceuticals Inc (GuruFocus.com)
Dec-27-23 10:34PM	3 Stocks to Buy Now Before They Become Tomorrows Trillion-Dollar Companies (InvestorPlace)
Dec-24-23 11:01AM	Ionis Pharmaceuticals Inc EVP, Chief Scientific Officer C Bennett Sells 22,613 Shares (GuruFocus.com)
Dec-21-23 06:55PM	WAINUA (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (PR Newswire)
05:45PM	CORRECTED-UPDATE 2-US FDA approves Ionis-AstraZeneca's nerve disease drug (Reuters)
05:35PM	US FDA approves Ionis-AstraZeneca's nerve disease drug (Reuters)
Dec-20-23 01:50PM	12 Most Promising Gene Editing Stocks According to Hedge Funds (Insider Monkey)
07:05AM	Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-19-23 10:45AM	Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka (Zacks)
Dec-18-23 04:01PM	Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema (PR Newswire)
Dec-14-23 04:05PM	Ionis announces the appointment of Michael Yang to Board of Directors (PR Newswire)
Dec-07-23 08:47PM	Otera Capital Provides $136M Construction Loan for California Life Sciences Facility (Commercial Observer)
Nov-16-23 08:00AM	Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies (GlobeNewswire)
Nov-13-23 09:46AM	Ionis (IONS) Early-Stage Genetic Disorder Data Shows Promise (Zacks)
Nov-11-23 11:30AM	Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome (PR Newswire)
Nov-09-23 12:42PM	Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema (PR Newswire)
Nov-04-23 01:01PM	Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 06:36PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research) +7.91%
09:44AM	Ionis (IONS) Q3 Loss Wider Than Expected, Sales Beat Estimates (Zacks)
07:05AM	Ionis to present at upcoming investor conferences (PR Newswire)
05:09AM	Q3 2023 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-02-23 12:36PM	Ionis Pharmaceuticals Inc (IONS) Reports Q3 2023 Financial Results (GuruFocus.com)
09:30AM	Ionis Pharmaceuticals (IONS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:19AM	Ionis Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Ionis reports third quarter 2023 financial results (PR Newswire)
Oct-31-23 10:01AM	Amneal Pharmaceuticals (AMRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
Oct-26-23 10:02AM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-19-23 07:05AM	Ionis to hold third quarter 2023 financial results webcast (PR Newswire)
Oct-16-23 10:43AM	16 Best Stocks to Buy and Hold for the Next 15 Years According to Cathie Woods Portfolio (Insider Monkey)
Oct-05-23 10:26AM	Load Up, Says Raymond James About These 2 Strong Buy Stocks (TipRanks) +7.28%
Oct-04-23 07:00AM	Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization (PR Newswire)
Oct-02-23 01:17PM	Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day (GlobeNewswire)
Sep-30-23 05:10AM	Insider Sell: EVP, Chief Scientific Officer C Bennett Sells 4,460 Shares of Ionis ... (GuruFocus.com)
Sep-29-23 05:01AM	Insider Sell: Director B Parshall Sells 10,000 Shares of Ionis Pharmaceuticals Inc (GuruFocus.com)
Sep-28-23 12:02PM	Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit (PR Newswire)
10:06AM	Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs (Zacks)
Sep-27-23 09:58AM	Ionis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5% (Zacks)
08:00AM	Strength Seen in Ionis Pharmaceuticals (IONS): Can Its 8.5% Jump Turn into More Strength? (Zacks)
07:00AM	Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease (PR Newswire)
Sep-26-23 04:19PM	Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder (Investor's Business Daily) +8.49%
07:28AM	UPDATE 2-Ionis' metabolic disorder drug lowers high levels of a type of fat in study (Reuters)
07:10AM	Ionis Pharma's genetic disorder drug meets main goal in late-stage study (Reuters)
07:00AM	Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome (PR Newswire)
Sep-20-23 01:03PM	The 7 Most Hated Stocks by Institutional Traders (InvestorPlace)
Sep-12-23 07:05AM	Ionis to host investor and analyst day event (PR Newswire) +5.38%
Sep-08-23 11:30AM	Why Is Ionis Pharmaceuticals (IONS) Up 1.4% Since Last Earnings Report? (Zacks)
Aug-30-23 07:05AM	Ionis to present at upcoming investor conferences (PR Newswire)
Aug-11-23 12:37PM	Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 11:31AM	Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates (Zacks)
10:04AM	Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Revised) (Zacks)
09:55AM	Ionis Pharmaceuticals (IONS) Reports Q2 Results: What Key Metrics Have to Say (Revised) (Zacks)
04:56AM	Q2 2023 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
01:01AM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
Aug-09-23 09:30AM	Ionis Pharmaceuticals (IONS) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
08:15AM	Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Zacks)
07:09AM	Ionis Pharmaceuticals: Q2 Earnings Snapshot (AP Finance)
07:00AM	Ionis reports second quarter 2023 financial results (PR Newswire)

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Baroldi Joseph	EVP, Chief Business Officer	Apr 16 '24	Sale	41.60	4,006	166,641	19,631	Apr 17 05:19 PM
Birchler Brian	EVP, Corp and Development Ops	Apr 16 '24	Sale	41.66	905	37,698	46,156	Apr 17 05:16 PM
Baroldi Joseph	EVP, Chief Business Officer	Apr 15 '24	Option Exercise	0.00	10,838	0	23,637	Apr 17 05:19 PM
Birchler Brian	EVP, Corp and Development Ops	Apr 15 '24	Option Exercise	0.00	1,875	0	47,061	Apr 17 05:16 PM
Monia Brett P	Chief Executive Officer	Feb 16 '24	Sale	44.49	387	17,219	173,751	Feb 16 07:47 PM
Monia Brett P	Chief Executive Officer	Feb 02 '24	Sale	49.37	23,501	1,160,303	174,138	Feb 02 07:55 PM
Cadoret-Manier Onaiza	EVP, Chf GL Pdt Str & Oper Ofc	Feb 02 '24	Sale	49.60	2,125	105,404	35,825	Feb 02 07:54 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Feb 02 '24	Sale	49.54	2,125	105,272	92,905	Feb 02 07:55 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Feb 02 '24	Sale	49.59	2,071	102,701	49,812	Feb 02 07:55 PM
Geary Richard S	EVP, Chief Development Officer	Feb 02 '24	Sale	50.04	1,961	98,135	87,334	Feb 02 07:54 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Feb 02 '24	Sale	49.67	1,961	97,410	48,661	Feb 02 07:55 PM
Swayze Eric	EVP Research	Feb 02 '24	Sale	49.56	1,907	94,513	34,324	Feb 02 07:55 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Feb 02 '24	Sale	49.52	1,853	91,752	79,079	Feb 02 07:54 PM
Swayze Eric	EVP Research	Jan 31 '24	Sale	52.00	10,773	560,196	32,516	Feb 02 07:55 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 25 '24	Sale	51.75	6,450	333,788	46,802	Jan 29 05:34 PM
Monia Brett P	Chief Executive Officer	Jan 25 '24	Sale	51.75	2,285	118,249	151,851	Jan 29 05:34 PM
Monia Brett P	Chief Executive Officer	Jan 17 '24	Sale	50.42	32,059	1,616,319	154,136	Jan 18 05:48 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 17 '24	Sale	50.42	8,683	437,771	90,890	Jan 18 05:48 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 17 '24	Sale	50.42	7,744	390,429	53,252	Jan 18 05:59 PM
Geary Richard S	EVP, Chief Development Officer	Jan 17 '24	Sale	50.42	7,338	369,960	85,475	Jan 18 05:47 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jan 17 '24	Sale	50.42	6,745	340,063	77,323	Jan 18 05:44 PM
Swayze Eric	EVP Research	Jan 17 '24	Sale	50.42	6,296	317,425	43,289	Jan 18 05:49 PM
Cadoret-Manier Onaiza	EVP, Chf GL Pdt Str & Oper Ofc	Jan 17 '24	Sale	50.42	5,564	280,520	33,810	Jan 18 06:07 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 17 '24	Sale	50.42	5,482	276,386	47,850	Jan 18 05:48 PM
Birchler Brian	EVP, Corp and Development Ops	Jan 17 '24	Sale	50.42	4,497	226,725	44,582	Jan 18 05:55 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 17 '24	Sale	50.42	1,460	73,609	12,799	Jan 18 05:44 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 17 '24	Sale	50.42	564	28,435	1,640	Jan 18 05:44 PM
Swayze Eric	EVP Research	Jan 17 '24	Sale	50.42	9	454	85	Jan 18 05:49 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 16 '24	Option Exercise	0.00	1,353	0	2,204	Jan 18 05:44 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 16 '24	Option Exercise	0.00	3,688	0	14,259	Jan 18 05:44 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jan 16 '24	Option Exercise	0.00	18,314	0	84,068	Jan 18 05:44 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 16 '24	Option Exercise	0.00	22,487	0	99,573	Jan 18 05:48 PM
Monia Brett P	Chief Executive Officer	Jan 16 '24	Option Exercise	0.00	68,084	0	186,195	Jan 18 05:48 PM
Cadoret-Manier Onaiza	EVP, Chf GL Pdt Str & Oper Ofc	Jan 16 '24	Option Exercise	0.00	15,062	0	39,374	Jan 18 06:07 PM
Birchler Brian	EVP, Corp and Development Ops	Jan 16 '24	Option Exercise	0.00	12,080	0	49,079	Jan 18 05:55 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 16 '24	Option Exercise	0.00	20,641	0	60,996	Jan 18 05:59 PM
Geary Richard S	EVP, Chief Development Officer	Jan 16 '24	Option Exercise	0.00	19,852	0	92,813	Jan 18 05:47 PM
Swayze Eric	EVP Research	Jan 16 '24	Option Exercise	0.00	21	0	94	Jan 18 05:49 PM
Swayze Eric	EVP Research	Jan 16 '24	Option Exercise	0.00	17,069	0	49,585	Jan 18 05:49 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 16 '24	Option Exercise	0.00	15,162	0	53,332	Jan 18 05:48 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 12 '24	Option Exercise	32.60	8,000	260,800	46,170	Jan 17 08:51 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 12 '24	Sale	53.50	8,000	427,999	38,170	Jan 17 08:51 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Dec 28 '23	Option Exercise	47.34	45,225	2,140,952	120,884	Jan 02 05:54 PM
PARSHALL B LYNNE	Director	Dec 28 '23	Option Exercise	47.34	42,525	2,013,134	125,113	Dec 28 07:18 PM
Swayze Eric	EVP Research	Dec 28 '23	Option Exercise	47.34	27,100	1,282,914	59,616	Jan 02 05:54 PM
Birchler Brian	EVP, Corp and Development Ops	Dec 28 '23	Option Exercise	47.34	11,500	544,410	48,028	Jan 02 05:54 PM
PARSHALL B LYNNE	Director	Dec 28 '23	Sale	50.19	42,525	2,134,223	82,588	Dec 28 07:18 PM
Swayze Eric	EVP Research	Dec 28 '23	Sale	50.19	27,100	1,360,081	32,516	Jan 02 05:54 PM
PARSHALL B LYNNE	Director	Dec 27 '23	Option Exercise	47.34	50,000	2,367,000	132,588	Dec 28 07:18 PM
PARSHALL B LYNNE	Director	Dec 27 '23	Sale	50.23	50,000	2,511,515	82,588	Dec 28 07:18 PM
PARSHALL B LYNNE	Director	Dec 26 '23	Option Exercise	47.34	25,113	1,188,849	107,701	Dec 28 07:18 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Dec 26 '23	Option Exercise	47.34	25,000	1,183,500	61,052	Dec 28 07:18 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Dec 26 '23	Option Exercise	47.34	20,825	985,856	61,180	Dec 28 07:18 PM
PARSHALL B LYNNE	Director	Dec 26 '23	Sale	51.46	25,113	1,292,390	82,588	Dec 28 07:18 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Dec 26 '23	Sale	51.46	25,000	1,286,575	36,052	Dec 28 07:18 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Dec 26 '23	Sale	51.46	20,825	1,071,717	40,355	Dec 28 07:18 PM
Monia Brett P	Chief Executive Officer	Dec 21 '23	Option Exercise	47.34	17,500	828,450	135,611	Dec 22 07:11 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Dec 21 '23	Option Exercise	47.34	16,113	762,789	81,867	Dec 22 07:11 PM
Geary Richard S	EVP, Chief Development Officer	Dec 21 '23	Option Exercise	47.34	4,112	194,662	77,073	Dec 22 07:11 PM
Monia Brett P	Chief Executive Officer	Dec 21 '23	Sale	49.29	17,500	862,577	118,111	Dec 22 07:11 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Dec 21 '23	Sale	49.29	16,113	794,211	65,754	Dec 22 07:11 PM
Geary Richard S	EVP, Chief Development Officer	Dec 21 '23	Sale	49.29	4,112	202,681	72,961	Dec 22 07:11 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Dec 20 '23	Option Exercise	47.34	6,500	307,710	72,254	Dec 22 07:11 PM
Geary Richard S	EVP, Chief Development Officer	Dec 20 '23	Option Exercise	47.34	6,500	307,710	79,461	Dec 22 07:11 PM
Monia Brett P	Chief Executive Officer	Dec 20 '23	Option Exercise	47.34	6,500	307,710	124,611	Dec 22 07:11 PM
Monia Brett P	Chief Executive Officer	Dec 20 '23	Sale	49.64	6,500	322,643	118,111	Dec 22 07:11 PM
Geary Richard S	EVP, Chief Development Officer	Dec 20 '23	Sale	49.64	6,500	322,643	72,961	Dec 22 07:11 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Dec 20 '23	Sale	49.64	6,500	322,643	65,754	Dec 22 07:11 PM
Monia Brett P	Chief Executive Officer	Dec 14 '23	Option Exercise	47.34	24,000	1,136,160	132,971	Dec 18 04:56 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Dec 14 '23	Option Exercise	47.34	22,612	1,070,452	79,756	Dec 18 04:55 PM
Geary Richard S	EVP, Chief Development Officer	Dec 14 '23	Option Exercise	47.34	10,613	502,419	79,532	Dec 18 04:55 PM
Monia Brett P	Chief Executive Officer	Dec 14 '23	Sale	49.58	24,000	1,190,019	118,111	Dec 18 04:56 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Dec 14 '23	Sale	49.58	22,612	1,121,195	65,754	Dec 18 04:55 PM
Geary Richard S	EVP, Chief Development Officer	Dec 14 '23	Sale	49.58	10,613	526,236	72,961	Dec 18 04:55 PM
KLEIN JOSEPH III	Director	Nov 15 '23	Sale	50.00	2,000	100,000	16,346	Nov 17 04:58 PM
Swayze Eric	EVP Research	Oct 17 '23	Sale	47.95	52	2,493	73	Oct 18 06:40 PM
Swayze Eric	EVP Research	Oct 16 '23	Option Exercise	0.00	125	0	125	Oct 18 06:40 PM
Monia Brett P	Chief Executive Officer	Oct 12 '23	Sale	46.00	3,770	173,420	118,111	Oct 16 04:35 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Sep 28 '23	Sale	46.50	4,460	207,390	65,754	Sep 29 05:20 PM
PARSHALL B LYNNE	Director	Sep 26 '23	Sale	45.13	10,000	451,268	82,588	Sep 28 06:03 PM
KLEIN JOSEPH III	Director	Sep 26 '23	Sale	45.13	2,000	90,254	18,346	Sep 28 06:03 PM
Diaz Allene M.	Director	Aug 01 '23	Sale	41.05	657	26,970	12,676	Aug 03 05:20 PM
KLEIN JOSEPH III	Director	Jul 18 '23	Sale	42.00	3,555	149,310	20,346	Jul 19 06:05 PM
BERTHELSEN SPENCER R	Director	Jul 17 '23	Option Exercise	0.00	7,110	0	147,257	Jul 19 06:05 PM
WENDER JOSEPH H	Director	Jul 17 '23	Option Exercise	0.00	7,110	0	112,079	Jul 19 06:08 PM
Diaz Allene M.	Director	Jul 17 '23	Option Exercise	0.00	5,333	0	13,333	Jul 19 06:05 PM
Hayden Michael R	Director	Jul 17 '23	Option Exercise	0.00	7,110	0	30,219	Jul 19 06:05 PM
HERMAN JOAN E	Director	Jul 17 '23	Option Exercise	0.00	7,110	0	37,330	Jul 19 06:05 PM
KLEIN JOSEPH III	Director	Jul 17 '23	Option Exercise	0.00	7,110	0	23,901	Jul 19 06:05 PM
LOSCALZO JOSEPH	Director	Jul 17 '23	Option Exercise	0.00	7,110	0	41,082	Jul 19 06:06 PM
PARSHALL B LYNNE	Director	Jul 17 '23	Option Exercise	0.00	7,110	0	92,588	Jul 19 06:06 PM
Monia Brett P	Chief Executive Officer	Jul 07 '23	Sale	42.25	18,650	787,953	121,724	Jul 11 05:07 PM
BERTHELSEN SPENCER R	Director	Jun 20 '23	Option Exercise	28.47	11,250	320,288	140,147	Jun 22 05:17 PM
HERMAN JOAN E	Director	Jun 12 '23	Option Exercise	0.00	3,555	0	30,220	Jun 14 04:50 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	May 24 '23	Sale	41.70	1,527	63,676	40,355	May 24 08:25 PM
Monia Brett P	Chief Executive Officer	May 22 '23	Sale	40.14	4,931	197,907	140,374	May 24 08:25 PM

Open in Screener

AWH

Aspira Women's Health Inc

May 01 • 04:00PM ET

3.22

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

AWH Aspira Women's Health Inc daily Stock Chart

Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-1.78	Insider Own	45.51%	Shs Outstand	10.65M	Perf Week	-5.29%
Market Cap	39.77M	Forward P/E	-	EPS next Y	-0.86	Insider Trans	0.07%	Shs Float	6.73M	Perf Month	17.73%
Income	-16.18M	PEG	-	EPS next Q	-0.34	Inst Own	5.79%	Short Float	2.52%	Perf Quarter	-40.37%
Sales	9.15M	P/S	4.35	EPS this Y	28.27%	Inst Trans	60.31%	Short Ratio	7.42	Perf Half Y	-29.54%
Book/sh	-0.22	P/B	-	EPS next Y	34.08%	ROA	-136.91%	Short Interest	0.17M	Perf Year	-30.75%
Cash/sh	0.21	P/C	15.30	EPS next 5Y	-	ROE	-701.30%	52W Range	2.31 - 6.75	Perf YTD	-21.08%
Dividend Est.	-	P/FCF	-	EPS past 5Y	5.77%	ROI	-	52W High	-52.30%	Beta	1.57
Dividend TTM	-	Quick Ratio	0.99	Sales past 5Y	25.92%	Gross Margin	57.54%	52W Low	39.47%	ATR (14)	0.26
Dividend Ex-Date	Dec 16, 2016	Current Ratio	1.03	EPS Y/Y TTM	89.53%	Oper. Margin	-200.36%	RSI (14)	42.81	Volatility	7.41% 8.73%
Employees	64	Debt/Eq	-	Sales Y/Y TTM	11.85%	Profit Margin	-176.74%	Recom	2.33	Target Price	5.25
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	97.90%	Payout	-	Rel Volume	0.75	Prev Close	3.22
Sales Surprise	-15.91%	EPS Surprise	32.75%	Sales Q/Q	-1.07%	Earnings	Mar 28 BMO	Avg Volume	22.83K	Price	3.22
SMA20	-0.54%	SMA50	-9.46%	SMA200	-19.40%	Trades		Volume	17,118	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-12-22	Resumed	Cantor Fitzgerald	Overweight	$4
Mar-29-21	Initiated	Truist	Buy	$12
Jan-29-21	Initiated	Cantor Fitzgerald	Overweight	$10
Oct-30-20	Initiated	William Blair	Outperform

Apr-09-24 08:00AM	Aspira Women's Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California (GlobeNewswire) +9.93%
Apr-01-24 11:24AM	Aspira Women's Health Inc. (NASDAQ:AWH) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 11:53AM	AWH Stock Earnings: Aspira Womens Health Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace) -9.62%
07:30AM	Aspira Women's Health Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-25-24 08:00AM	Aspira Women's Health Announces New Time for its Fourth Quarter and 2023 Year End Earnings Results and Call (GlobeNewswire)
08:00AM	Loading…
Mar-21-24 08:00AM	Aspira Women's Health to Present at the MedInvest Biotech & Pharma Investor Conference (GlobeNewswire)
Mar-18-24 08:00AM	Aspira Women's Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President (GlobeNewswire)
Mar-11-24 08:00AM	Aspira Women's Health to Announce Fourth Quarter and 2023 Year End Earnings Results and Host a Conference Call on Thursday, March 28, 2024 (GlobeNewswire)
Feb-22-24 08:30AM	Aspira Women's Health to Present at The Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference (GlobeNewswire) -5.36%
Feb-12-24 08:00AM	Aspira Womens Health Announces Late-Breaking Poster Presentation at the Upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI) (GlobeNewswire)
Feb-06-24 08:00AM	Aspira Women's Health Announces OvaSuite(SM) Distribution Agreement in the Philippines (GlobeNewswire)
Jan-25-24 08:00AM	Aspira Women's Health Announces $5.5 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire)
07:30AM	OptimizeRx Announces Strategic Board Changes to Support Growth and Evolving Landscape (GlobeNewswire)
Dec-19-23 08:00AM	Aspira Women's Health to Host R&D Day With Updates on the Development of the Company's Ovarian Cancer and Endometriosis Tests on January 4, 2024 (GlobeNewswire)
Dec-14-23 08:00AM	Aspira Women's Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024 (GlobeNewswire)
09:46AM	Loading…
Dec-08-23 09:46AM	New to The Street TV Features Five Corporate Guest Interviews, Episode 537 Airs on the FOX Business Network, Monday, December 11, 2023, at 10:30 PM PT (GlobeNewswire)
Dec-07-23 09:20AM	New to The Street TV Announces Its Episode 536 Lineup, Five Corporate Guest Interviews, Broadcasted as Sponsored Program on Bloomberg TV, Tonight, Thursday, December 7, 2023, at 9:30 PM PT (GlobeNewswire) +12.84%
Dec-06-23 08:00AM	Aspira Women's Health Provides a Development Update on its Portfolio of Noninvasive Tests for Endometriosis (GlobeNewswire)
Nov-28-23 08:00AM	Aspira Women's Health Secures Reimbursement for Ova1Plus(R) from California Medicaid (Medi-Cal) (GlobeNewswire)
Nov-27-23 09:47AM	Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS) (GlobeNewswire)
Nov-13-23 04:05PM	Aspira Women's Health Reports Third Quarter 2023 Financial Results (GlobeNewswire) -8.82%
Nov-09-23 08:00AM	Aspira Women's Health Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Crosswalk Medicare Reimbursement Rate for OvaWatch (GlobeNewswire)
Oct-31-23 08:00AM	Aspira Womens Health to Announce Third Quarter Earnings Results and Host a Conference Call on Monday, November 13, 2023 (GlobeNewswire)
Oct-25-23 08:00AM	Aspira Women's Health Sees Poster on its miRNA-based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research (GlobeNewswire) -7.08%
Oct-23-23 08:00AM	Aspira Women's Health Establishes a New Clinical Advisory Board (GlobeNewswire) -8.12%
Oct-20-23 10:43AM	New to The Street Announces Six Business Interviews on its 524th Show, Airing on the Fox Business Network, Monday, October 23, 2023, at 10:30 PM PT (GlobeNewswire)
Sep-29-23 08:00AM	Aspira Women's Health to Present at the BioVenture Nexus Conference (GlobeNewswire)
Sep-13-23 08:00AM	Aspira Womens Health Regains Nasdaq Compliance (GlobeNewswire) +23.34%
Sep-11-23 08:00AM	Aspira Womens Health Announces Dr. Jody Berry as New Chief Scientific Officer (GlobeNewswire)
Aug-31-23 08:00AM	Aspira Womens Health Signs Exclusive Sample Procurement Agreement with The University of Oxford (GlobeNewswire) +14.57%
08:00AM	Loading…
Aug-29-23 08:00AM	Aspira Womens Health to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-28-23 08:00AM	Aspira Womens Health Announces Michelle Snider as Senior Vice President, Commercial Strategy and Operations (GlobeNewswire) +6.98%
Aug-14-23 04:01PM	Aspira Womens Health® Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-09-23 04:05PM	Aspira Womens Health Announces Transition of its Chief Scientific Officer/Chief Operating Officer (GlobeNewswire)
Jul-31-23 08:00AM	Aspira Womens Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 14, 2023 (GlobeNewswire)
Jul-20-23 08:30AM	Aspira Womens Health Announces $4.7 Million Registered Direct Offering (GlobeNewswire) -30.90%
Jun-28-23 08:00AM	Aspira Womens Health, Inc. Received a $1 MM Loan Forgiveness and 6-Month Payment Deferral from the CT DECD (GlobeNewswire) +8.33%
Jun-12-23 06:23PM	New to The Street Announces Five Corporate Interviews on its 478th Show, Airing on the Fox Business Network, Tonight, Monday, June 12, 2023, at 10:30 PM PT (GlobeNewswire)
Jun-08-23 01:23PM	New to The Street TV Announces its Four Business Guest Interviews, Episode 476 Airs on Bloomberg TV as A Sponsored Program, Tonight, Thursday, June 8, 2023, at 9:30 PM PT (GlobeNewswire)
01:23PM	New to The Street TV Announces its Five Business Guest Interviews, Episode 476 Airs on Bloomberg TV as A Sponsored Program, Tonight, Thursday, June 8, 2023, at 9:30 PM PT (GlobeNewswire)
Jun-05-23 08:00AM	Aspira Womens Health Appoints Dr. Winfred Parnell to its Board of Directors (GlobeNewswire)
Jun-02-23 09:35AM	New to The Street Announces its Corporate Guests TV Interviews, Airing as Episodes 474 and 475 with Shows Starting on Saturday, June 3, 2023, at 3:30 PM ET (GlobeNewswire)
08:00AM	Aspira Womens Health Regained Compliance with Nasdaqs Minimum Bid Price Requirement (GlobeNewswire)
May-31-23 08:00AM	Aspira Womens Health Announces the Publication of Three Abstracts by the American Society of Clinical Oncology (ASCO) Supporting the Clinical Utility of OvaSuite(SM) Ovarian Cancer Risk Assessment Tests (GlobeNewswire)
May-30-23 08:00AM	Aspira Womens Health to Participate at William Blairs 43rd Annual Growth Stock Conference (GlobeNewswire) -6.00%
May-26-23 09:15AM	New to The Street Announces the Televised Lineups for Shows 471, 472, and 473; Airings on Three Networks Will Begin on Saturday, May 27, 2023, at 3:30 PM ET (GlobeNewswire) -6.42%
May-19-23 09:38AM	New to The Street Announces its Televised Corporate Interviews Airing on Newsmax and The FOX Business Network, Episodes 469 and 470; Broadcastings Begin Saturday, May 20, 2023, at 3:30 PM ET (GlobeNewswire)
08:00AM	Aspira Womens Health to Present at the 2023 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Conference (GlobeNewswire)
May-16-23 04:05PM	Aspira Womens Health Names Torsten Hombeck as Chief Financial Officer (GlobeNewswire)
May-15-23 04:05PM	Aspira Womens Health to Host Investor Day on OvaWatch(SM) and EndoCheck Market Opportunities on May 23, 2023 (GlobeNewswire) +15.88%
09:00AM	Aspira Womens Health launches its New to The Street Media Series on May 8, 2023, World Ovarian Cancer Day (GlobeNewswire)
May-11-23 04:01PM	Aspira Womens Health® Reports First Quarter 2023 Financial Results (GlobeNewswire) -13.87%
12:33PM	Aspira Womens Health Announces 1-for-15 Reverse Stock Split (GlobeNewswire)
09:45AM	New to The Street Announces the Televised Lineups for Shows 466, 467, and 468; Airings on Three Networks, Starting Thursday, May 11, 2023, at 10:30 PM PT (GlobeNewswire)
08:00AM	Aspira Womens Health Signs an Exclusive Licensing Agreement with Dana Farber Cancer Institute for the Development of microRNA-based Ovarian Cancer Test (GlobeNewswire)
May-09-23 04:07PM	Aspira Womens Health Appoints Three New Members to its Board of Directors (GlobeNewswire)
Apr-27-23 04:05PM	Aspira Womens Health Announces Preliminary First Quarter 2023 OvaSuite Volume Increase of 29% and Plans to Announce Full Earnings Results on May 11, 2023 (GlobeNewswire)
Mar-27-23 07:12AM	Aspira Womens Health Inc. (NASDAQ:AWH) Q4 2022 Earnings Call Transcript (Insider Monkey) -11.70%
Mar-22-23 04:05PM	Aspira Womens Health Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-03-23 08:38AM	Aspira Womens Health to Announce Year End 2022 Financial Results and Host Conference Call on March 22, 2023 (GlobeNewswire) +19.14%
08:00AM	Aspira Womens Health Announces National Payer Coverage for OvaWatch (GlobeNewswire)
Jan-09-23 04:05PM	Aspira Womens Health Announces Preliminary Fourth Quarter 2022 Volume, Preliminary Results in Line with Cash Utilization Guidance, and Other Highlights (GlobeNewswire)
Jan-06-23 08:00AM	Aspira Womens Health Announces Publication of Real-World Data Validating Use of OvaWatch for the Management of Adnexal Masses (GlobeNewswire) +14.23%
Dec-27-22 08:00AM	Aspira Womens Health Announces Three Reimbursement Milestones that Improve Patient Access to its OvaSuite SM Testing Portfolio (GlobeNewswire)
Nov-29-22 04:01PM	Aspira Womens Health Announces the Commercial Launch of OvaWatch(SM) (GlobeNewswire)
Nov-10-22 07:00AM	Aspira Womens Health Reports Third Quarter 2022 Financial Results (GlobeNewswire) +6.23%
Nov-01-22 08:00AM	Aspira Womens Health to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10 (GlobeNewswire)
Oct-06-22 04:05PM	Aspira Womens Health to Participate at the Upcoming MicroCap Rodeo Windy City Roundup 2022 (GlobeNewswire) -11.85%
Oct-05-22 08:00AM	Aspira Womens Health Announces Formal Launch of Co-Marketing and Distribution Collaboration with BioReference (GlobeNewswire)
Sep-27-22 09:05AM	60+ Companies to Present at the 2nd Annual MicroCap Rodeo - Windy City Roundup Conference on October 12th - 13th, 2022 in Chicago (ACCESSWIRE)
Sep-12-22 04:28PM	Aspira Womens Health Announces Publication of its Second-Generation MultiVariate Index Assay, OVERA®, in the Detection of Cancer in Filipino Women (GlobeNewswire)
Aug-23-22 08:00AM	Aspira Womens Health Inc. Announces Pricing of $9.0 Million Public Offering (GlobeNewswire) -37.28%
Aug-22-22 04:02PM	Aspira Womens Health Inc. Announces Proposed Public Offering (GlobeNewswire) -5.92%
Aug-18-22 04:05PM	Aspira Womens Health Hosting Womens Health Webinar on Ovarian Cancer Risk Assessments Utilizing Multivariant Index Assay (GlobeNewswire)
Aug-10-22 07:30AM	Aspira Womens Health Reports Second Quarter 2022 Financial Results (GlobeNewswire) -9.35%
Aug-01-22 08:00AM	Aspira Womens Health to Announce Second Quarter 2022 Financial Results and Host Conference Call on Wednesday, August 10 (GlobeNewswire)
Jul-11-22 06:26AM	Aspira Women's Health (NASDAQ:AWH) adds US$31m to market cap in the past 7 days, though investors from a year ago are still down 81% (Simply Wall St.) -14.71%
Jun-23-22 04:05PM	Aspira Womens Health Announces Appointment of Two New Board Members (GlobeNewswire) -7.11%
Jun-16-22 04:01PM	Aspira Womens Health Announces Publication of Paper Validating OvaWatch Algorithm in the Detection of Ovarian Cancer (GlobeNewswire) -6.57%
May-18-22 07:31AM	Does Aspira Women's Health (NASDAQ:AWH) Have A Healthy Balance Sheet? (Simply Wall St.)
May-16-22 01:20PM	36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022 (ACCESSWIRE) +28.57%
May-12-22 04:01PM	Aspira Womens Health to Participate in the Upcoming Investor Conferences (GlobeNewswire)
May-11-22 07:30AM	Aspira Womens Health Reports First Quarter 2022 Financial Results (GlobeNewswire) -32.36%
Apr-29-22 08:00AM	Aspira Womens Health to Announce First Quarter 2022 Financial Results and Host Conference Call on Wednesday, May 11 (GlobeNewswire) -9.41%
Apr-02-22 01:40PM	What Kind Of Shareholders Hold The Majority In Aspira Women's Health Inc.'s (NASDAQ:AWH) Shares? (Simply Wall St.)
Mar-23-22 07:00AM	Aspira Womens Health Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire) -9.42%
Mar-15-22 08:00AM	Aspira Womens Health to Announce Year End 2021 Financial Results and Host Conference Call on Wednesday, March 23 (GlobeNewswire)
Feb-28-22 08:14AM	Aspira Womens Health Announces Appointment of Celeste Fralick, Ph.D., to its Board of Directors (GlobeNewswire) -5.22%
Feb-24-22 04:01PM	Valerie Palmieri Elevated to Executive Chair of the Board; Nicole Sandford Appointed President and CEO (GlobeNewswire) +9.00%
Feb-22-22 04:05PM	Aspira Womens Health, Inc. Expands Senior Leadership Team with Addition of Mr. Michael Newton as Head of Sales and Marketing (GlobeNewswire)
Feb-08-22 01:46PM	Aspira Womens Health to Participate in the Upcoming Winter Wonderland Best Ideas Conference (GlobeNewswire)
Feb-01-22 04:19AM	Aspira Women's Health (NASDAQ:AWH) shareholders have endured a 86% loss from investing in the stock a year ago (Simply Wall St.)
Jan-31-22 04:05PM	Aspira Womens Health Announces the Addition of 465,000 Covered Lives Through Medicaid Credentialing (GlobeNewswire) +12.04%
Jan-28-22 10:07AM	36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022 (ACCESSWIRE)
Jan-05-22 08:00AM	Aspira Womens Health Executes an Agreement with Axia Womens Health to Launch Aspira Synergy Genetics Platform (GlobeNewswire) -6.43%
08:00AM	Aspira Womens Health Appoints Minh Merchant as General Counsel (GlobeNewswire)
08:00AM	Aspira Womens Health Announces Fourth Quarter Operational Metrics and Provides Updates on Its OvaWatch and EndoCheck Programs (GlobeNewswire)
Dec-03-21 04:57AM	Is Aspira Women's Health (NASDAQ:AWH) Using Debt In A Risky Way? (Simply Wall St.) -9.95%
Nov-10-21 08:00AM	Aspira Womens Health Reports Third Quarter 2021 Financial Results (GlobeNewswire) -15.64%
Nov-03-21 03:01PM	Earnings Preview: Aspira (AWH) Q3 Earnings Expected to Decline (Zacks)

Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sandford Nicole	President & CEO	Dec 06 '23	Buy	3.36	5,000	16,800	58,703	Dec 06 05:21 PM
Merchant Minh Hoang	Secretary & General Counsel	Dec 06 '23	Sale	3.37	980	3,303	0	Dec 08 05:28 PM
Hombeck Torsten	Chief Financial Officer	Sep 08 '23	Buy	4.30	2,246	9,658	3,000	Sep 12 06:37 PM
SCHULER JACK W	10% Owner	Jul 24 '23	Buy	2.75	181,800	499,950	1,883,656	Jul 25 05:39 PM
Sandford Nicole	President & CEO	Jul 24 '23	Buy	3.98	12,563	50,001	134,665	Jul 25 05:16 PM
Herchuk Jannie Prestridge	Director	Jul 24 '23	Buy	3.98	8,794	35,000	23,833	Jul 24 06:49 PM
Parnell Winfred	Director	Jul 24 '23	Buy	3.98	6,281	24,998	31,513	Jul 25 05:03 PM
Cavanaugh Stefanie L.	Director	Jul 24 '23	Buy	3.98	6,281	24,998	34,904	Jul 25 05:20 PM
Jordan Veronica GH	Director	Jul 24 '23	Buy	3.98	3,769	15,001	34,575	Jul 24 06:58 PM
Vos Ellen O'Connor	Director	Jul 24 '23	Buy	3.98	3,769	15,001	32,878	Jul 26 04:28 PM
Merchant Minh Hoang	General counsel and secretary	Jul 24 '23	Buy	3.98	754	3,001	3,865	Jul 25 04:58 PM
Fralick Celeste Rachelle	Director	Jul 24 '23	Buy	3.98	754	3,001	12,032	Jul 26 07:28 PM
Hombeck Torsten	Chief Financial Officer	Jul 24 '23	Buy	3.98	754	3,001	754	Jul 24 06:53 PM
Phan Ryan Thinh	CSO & COO	Jul 24 '23	Buy	3.98	628	2,499	3,939	Jul 25 05:11 PM

Open in Screener

VNRX

VolitionRX Ltd

May 01 • 04:00PM ET

0.8660

Dollar change -0.0339
Percentage change -3.77	%

Healthcare • Diagnostics & Research • USA • AMEX

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Index	-	P/E	-	EPS (ttm)	-0.50	Insider Own	26.20%	Shs Outstand	81.90M	Perf Week	8.25%
Market Cap	71.07M	Forward P/E	-	EPS next Y	-0.31	Insider Trans	0.32%	Shs Float	60.56M	Perf Month	11.76%
Income	-35.32M	PEG	-	EPS next Q	-0.10	Inst Own	7.73%	Short Float	0.73%	Perf Quarter	-18.30%
Sales	0.78M	P/S	91.12	EPS this Y	26.50%	Inst Trans	-0.74%	Short Ratio	2.41	Perf Half Y	8.11%
Book/sh	-0.10	P/B	-	EPS next Y	15.65%	ROA	-152.75%	Short Interest	0.44M	Perf Year	-48.14%
Cash/sh	0.25	P/C	3.43	EPS next 5Y	-	ROE	-5396.85%	52W Range	0.55 - 2.10	Perf YTD	20.78%
Dividend Est.	-	P/FCF	-	EPS past 5Y	2.75%	ROI	-	52W High	-58.76%	Beta	1.26
Dividend TTM	-	Quick Ratio	0.69	Sales past 5Y	188.43%	Gross Margin	-82.07%	52W Low	57.45%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	0.69	EPS Y/Y TTM	8.32%	Oper. Margin	-4641.76%	RSI (14)	56.68	Volatility	13.80% 10.47%
Employees	110	Debt/Eq	-	Sales Y/Y TTM	153.04%	Profit Margin	-4555.53%	Recom	1.67	Target Price	3.63
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	14.31%	Payout	-	Rel Volume	0.78	Prev Close	0.90
Sales Surprise	-49.65%	EPS Surprise	3.19%	Sales Q/Q	103.79%	Earnings	Mar 26 BMO	Avg Volume	182.67K	Price	0.87
SMA20	17.22%	SMA50	2.96%	SMA200	-7.84%	Trades		Volume	142,429	Change	-3.77%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-01-23	Downgrade	The Benchmark Company	Buy → Hold
Feb-17-22	Resumed	Cantor Fitzgerald	Overweight	$8 → $7
Mar-10-21	Initiated	Cantor Fitzgerald	Overweight	$8
May-16-18	Initiated	Maxim Group	Buy	$6
May-14-18	Reiterated	The Benchmark Company	Buy	$7 → $5
Sep-07-16	Reiterated	Rodman & Renshaw	Buy	$12 → $10
Feb-01-16	Initiated	Rodman & Renshaw	Buy	$12

Apr-23-24 08:00AM	Nu.Q Vet Cancer Test launched in-clinic in U.S. and Europe through Antech (PR Newswire) +41.67%
Mar-27-24 12:31PM	VolitionRx Limited (AMEX:VNRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-25-24 04:10PM	VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update (PR Newswire)
Mar-21-24 08:30AM	VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update (PR Newswire) -8.75%
Mar-20-24 08:30AM	Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan (PR Newswire) -5.88%
04:30PM	Loading…
Mar-19-24 04:30PM	Volition appoints Dr Andrew Retter as Chief Medical Officer (PR Newswire)
Feb-02-24 08:00AM	Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar (PR Newswire)
Jan-18-24 04:54AM	Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances (InvestorPlace)
Jan-04-24 08:00AM	Volition Issues Business Review 2023 (PR Newswire) -18.10%
Dec-05-23 10:25AM	Sidoti Events, LLC's Virtual December Small-Cap Conference (ACCESSWIRE)
08:00AM	VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre (PR Newswire)
Nov-16-23 09:15AM	VolitionRx Limited (AMEX:VNRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-15-23 05:08AM	VolitionRX: Q3 Earnings Snapshot (Associated Press Finance)
Nov-14-23 04:10PM	VolitionRx Limited Announces Third Quarter 2023 Financial Results and Business Update (PR Newswire) -7.29%
Nov-08-23 08:00AM	VolitionRx Limited Schedules Third Quarter 2023 Earnings Conference Call and Business Update (PR Newswire) +6.00%
06:24AM	Loading…
Nov-06-23 06:24AM	Volition and VPG Launch Nu.Q® Vet Cancer Test in UK & Ireland (PR Newswire)
Nov-02-23 08:19AM	VNRX: Breakthrough Cancer Detection Method Disclosed at ESMO and in a Webinar - preliminary proof of concept work indicates simple blood test should be able to detect several types of cancer, potentially at Stages I & II (Zacks) +12.03%
Oct-23-23 08:00AM	Volition Presents Breakthrough Liquid Biopsy Blood Test Method for Early-stage Cancer (PR Newswire) +7.00%
Oct-19-23 08:00AM	Measuring Nucleosomes Using Nu.Q® NETs is a Promising Biomarker for Septic Shock (PR Newswire) -24.17%
Oct-18-23 12:00PM	US Ambassador Adler visits Belgian Volition (PR Newswire) +5.69%
Oct-16-23 08:00AM	Volition Presents Three Cancer Detection Abstracts at ESMO 2023 (PR Newswire)
Oct-13-23 08:00AM	Volition Publishes Key Opinion Leader Roundtable Report on NETs in Sepsis (PR Newswire) +6.45%
Oct-02-23 08:00AM	Volition to Reveal New Cancer Detection Method Insights at Upcoming Webinar (PR Newswire) +8.85%
Sep-13-23 08:00AM	Volition Hosts Key Opinion Leader Roundtable on Sepsis Management (PR Newswire)
Aug-25-23 04:30AM	VolitionRx (VNRX): Review of 2Q 2023; Distribution Footprint of Nu.Q Vet Cancer Test is expanding. Prolific Schedule of Clinical Papers & Posters. (Zacks)
Aug-14-23 05:27PM	VolitionRX: Q2 Earnings Snapshot (Associated Press Finance)
04:10PM	VolitionRx Limited Announces Second Quarter 2023 Financial Results and Business Update (PR Newswire)
Aug-09-23 08:00AM	VolitionRx Limited Schedules Second Quarter 2023 Earnings Conference Call and Business Update (PR Newswire)
Jun-23-23 04:10PM	VolitionRx Limited Announces Exercise of Over-Allotment Option by Underwriters (PR Newswire)
06:00AM	VNRX: Highlights of Capital Markets Day (Nu.Q NETs & Nu.Q Vet); Heska being acquired by Mars (increases Nu.Q Vet distribution footprint); 13 MM share offering completed (Zacks Small Cap Research)
04:10PM	Loading…
Jun-05-23 04:10PM	VolitionRx Limited Announces Closing of $16.5 Million Underwritten Public Offering of Common Stock (PR Newswire)
Jun-01-23 09:15AM	VolitionRx Limited Announces Pricing of $16.5 Million Underwritten Public Offering of Common Stock (PR Newswire)
May-31-23 04:01PM	VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock (PR Newswire) +8.41%
May-11-23 12:45PM	VolitionRX: Q1 Earnings Snapshot (AP Finance)
07:00AM	Volition Study shows Nucleosome Concentrations are a useful tool for Canine Cancer Treatment Monitoring (PR Newswire)
May-10-23 04:10PM	VolitionRx Limited Announces First Quarter 2023 Financial Results and Business Update (PR Newswire)
May-05-23 08:00AM	VolitionRx Limited Schedules First Quarter 2023 Earnings Conference Call and Business Update (PR Newswire)
Apr-26-23 07:30AM	VolitionRx Limited to Host Capital Markets Day at the NYSE on Thursday May 11. (PR Newswire)
Apr-24-23 09:00AM	Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV (ACCESSWIRE) -6.78%
Mar-15-23 04:10PM	VolitionRx Limited Announces Full Fiscal Year 2022 Financial Results and Business Update (PR Newswire) -15.38%
Mar-10-23 08:35AM	Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
08:00AM	VolitionRx Limited Schedules Full Year 2022 Earnings Conference Call and Business Update (PR Newswire)
Mar-07-23 08:35AM	Life Sciences Virtual Investor Forum Agenda Announced for March 9th (GlobeNewswire)
Mar-06-23 04:30PM	VolitionRx Limited to Webcast Live at VirtualInvestorConferences.com March 9th (GlobeNewswire)
Feb-27-23 04:42AM	VNRX: Nu.Q Vet Cancer Test Being Launched by Supply Agreement Partners Heska and IDEXX; 4.945 million Share Offering Completed to Help Fund Managements Initiatives (Zacks Small Cap Research)
Feb-22-23 04:10PM	VolitionRx Limited Announces Closing of $8.7 Million Underwritten Public Offering of Common Stock (PR Newswire)
Feb-17-23 08:30AM	VolitionRx Limited Announces Pricing of $7.525 Million Underwritten Public Offering of Common Stock (PR Newswire)
Feb-16-23 04:10PM	VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock (PR Newswire)
08:00AM	Volition's Nu.Q® Vet Cancer Test Now Available for Pre-Order at The Point-of-Care Through Heska Corporation (PR Newswire)
Jan-23-23 08:00AM	Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on January 25, 2023 (GlobeNewswire)
Jan-20-23 08:30AM	Volition to Take Part in Nu.Q® Vet Commercial Strategy Webinar (PR Newswire)
Jan-17-23 10:00AM	Sidoti's January Micro-Cap Conference (ACCESSWIRE)
Jan-12-23 08:00AM	Volition Announces Expansion of Availability of the Nu.Q® Vet Cancer Test Through IDEXX's Reference Laboratory Network (PR Newswire)
Jan-08-23 12:00PM	Volition Issues Business Review 2022 (PR Newswire)
Dec-05-22 08:30AM	Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022 (ACCESSWIRE) -6.70%
Nov-14-22 04:10PM	VolitionRx Limited Announces Third Quarter 2022 Financial Results and Business Update (PR Newswire)
08:30AM	Volition Announces Clinical Research Study with Oncovet (PR Newswire)
Nov-10-22 08:30AM	Volition to Participate in a Lung Cancer Screening Study in France (PR Newswire)
Nov-03-22 08:30AM	Volition Announces the Launch of the Nu.Q® Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories (PR Newswire)
08:10AM	VNRX: Global Supply Agreement for Nu.Q Vet Cancer Test with a market leader in pet healthcare. U.S. Clinical studies for Nu.Q NETs are planned to pave the way for FDA approval. (Zacks Small Cap Research)
Oct-20-22 08:00AM	Volition Signs Global Supply Agreement for Nu.Q® Vet Cancer Test (PR Newswire) +22.76%
Oct-11-22 08:05AM	Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics (ACCESSWIRE) -5.63%
Oct-04-22 07:30AM	UPDATE - Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on October 4, 2022 (GlobeNewswire) +5.04%
Sep-30-22 09:00AM	Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on October 4, 2022 (GlobeNewswire) -5.56%
Sep-16-22 08:35AM	Life Sciences Virtual Investor Conference: Presentations Now Available for On-Demand Viewing (GlobeNewswire) -5.14%
Sep-12-22 08:35AM	VolitionRx Limited to Webcast Live at VirtualInvestorConferences.com September 15th (GlobeNewswire)
08:35AM	Life Sciences Virtual Investor Conference Agenda Announced for September 15th (GlobeNewswire)
Aug-16-22 03:00PM	Sidoti's August Micro-Cap Virtual Conference (ACCESSWIRE)
08:00AM	Volition Appoints Mickie Henshall as an Independent Director (PR Newswire)
Aug-10-22 04:10PM	VolitionRx Limited Announces Second Quarter 2022 Financial Results and Business Update (PR Newswire)
08:00AM	Volition Announces U.S. Clinical Study for NETs (PR Newswire)
Aug-08-22 08:00AM	Volition Appoints DXOCRO to Spearhead U.S. FDA Strategy (PR Newswire)
Aug-03-22 08:00AM	VolitionRx Awarded $1.5 Million in Non-Dilutive Funding (PR Newswire)
07:00AM	VolitionRx Limited to Present at Investor Summit Group's Q3 Virtual Conference (Newsfile)
Aug-02-22 04:10PM	VolitionRx Limited Announces Closing of $6.9 Million Underwritten Public Offering of Common Stock (PR Newswire)
08:30AM	Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement (GlobeNewswire)
08:05AM	Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer (ACCESSWIRE)
Jul-29-22 08:30AM	VolitionRx Limited Announces Pricing of $6 Million Underwritten Public Offering of Common Stock (PR Newswire) -10.96%
Jul-28-22 04:10PM	VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock (PR Newswire) +5.07%
Jul-25-22 06:05AM	VNRX: Nu.Q NETs receives CE mark in Europe with a broad claim for detecting & monitoring diseases with a NETs component. Nu.Q Vet test launched in Singapore through SAGE Healthcare. Nu.Q Discover - six contracts signed. (Zacks Small Cap Research)
Jul-13-22 08:00AM	New NETs Data Presented at International Society on Thrombosis and Haemostasis (ISTH) Congress (PR Newswire)
Jun-21-22 08:43AM	UPDATE -- Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on June 23, 2022 (GlobeNewswire)
08:00AM	Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on June 23, 2022 (GlobeNewswire)
May-31-22 08:00AM	Volition Achieves CE Mark for Nu.Q® NETs Test (PR Newswire)
May-11-22 04:10PM	VolitionRx Limited Announces First Quarter 2022 Financial Results and Business Update (PR Newswire) -5.26%
May-06-22 08:00AM	VolitionRx Limited Schedules First Quarter 2022 Earnings Conference Call and Business Update (PR Newswire)
May-05-22 08:03AM	VolitionRx Limited to Host Capital Markets Day on Friday May 13 (PR Newswire) -5.94%
Apr-27-22 09:00AM	Keynotes, Educational Panels and 88 Companies to Present at the Planet MicroCap Showcase on May 3-5, 2022 at Bally's Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-25-22 08:00AM	Volition Launches its Nu.Q® Vet Cancer Test in Asia Through its Appointed Distributor SAGE Healthcare (PR Newswire)
Apr-11-22 05:52AM	VNRX: VolitionRx Enters into Global License & Supply Agreement with Heska Corp. for Nu.Q Vet Cancer Screening Test. Financial Review of 2021 and Expectations in 2022. (Zacks Small Cap Research)
Apr-06-22 08:00AM	Volition appoints Sharon Ballesteros as U.S. Head of Quality and Development Process (PR Newswire)
Mar-30-22 04:10PM	VolitionRx Limited Announces Full Fiscal Year 2021 Financial Results and Business Update (PR Newswire) +5.19%
Mar-29-22 08:00AM	Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q® Vet Cancer Screening Test at the Point of Care (PR Newswire)
08:00AM	Heska Corporation Signs Exclusive Agreement to Introduce Nu.Q® Vet Cancer Screening Test, First-Ever Point of Care Cancer Screen (PR Newswire)
Mar-28-22 04:25PM	VolitionRx Limited Schedules Full Fiscal Year 2021 Earnings Conference Call and Business Update (PR Newswire)
Mar-22-22 09:50AM	Sidoti March Virtual Small Cap Investor Conference (ACCESSWIRE)
Mar-14-22 08:35AM	Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing (GlobeNewswire)
Mar-08-22 08:35AM	UPDATE Life Sciences Investor Forum: Company Executives Present Live March 10th (GlobeNewswire)
Mar-07-22 08:35AM	Life Sciences Virtual Investor Conference: Company Executives Present Live March 10th (GlobeNewswire)
Feb-15-22 09:00AM	Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on February 24, 2022 (GlobeNewswire)

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Eight Corp Ltd	10% Owner	Jan 02 '24	Sale	0.90	20,000	18,000	298,419	Jan 03 10:41 AM
Butera Salvatore Thomas	CEO - Volition Veterinary	Dec 18 '23	Buy	0.83	10,000	8,300	99,350	Dec 19 10:59 AM
Butera Salvatore Thomas	CEO - Volition Veterinary	Dec 15 '23	Buy	0.77	10,000	7,700	89,350	Dec 18 09:38 AM
Eight Corp Ltd	10% Owner	Dec 15 '23	Sale	0.75	20,000	15,000	318,419	Dec 20 10:31 AM
Rootsaert Rodney Gerard	Secretary	Dec 13 '23	Buy	0.60	10,000	6,000	78,652	Dec 14 09:11 AM
Reynolds Cameron John	President and CEO	Dec 08 '23	Buy	0.67	10,000	6,700	1,704,518	Dec 11 08:51 AM
Innes Guy Archibald	Director	Nov 27 '23	Buy	0.77	20,000	15,400	627,161	Nov 28 09:39 AM
Futcher Edward	Director	Nov 27 '23	Buy	0.80	9,000	7,200	71,936	Nov 28 09:39 AM
Innes Guy Archibald	Director	Nov 24 '23	Buy	0.76	10,000	7,600	607,161	Nov 27 10:28 AM
Innes Guy Archibald	Director	Nov 22 '23	Buy	0.71	20,000	14,200	597,161	Nov 24 11:06 AM
Butera Salvatore Thomas	CEO - Volition Veterinary	Nov 16 '23	Buy	0.81	10,000	8,100	79,350	Nov 17 10:01 AM
Barnes Phillip	Director	Sep 05 '23	Buy	1.30	5,000	6,500	24,686	Sep 06 10:01 AM
Faulkes Martin Charles	Director	Aug 31 '23	Buy	1.28	9,716	12,436	1,673,532	Sep 01 09:41 AM
Henshall Mickie	Director	Aug 31 '23	Buy	1.25	3,706	4,632	18,706	Sep 19 04:05 PM
Micallef Jacob Vincent	Chief Scientific Officer	Aug 30 '23	Buy	1.27	8,750	11,112	55,000	Aug 31 09:35 AM
Micallef Jacob Vincent	Chief Scientific Officer	Aug 29 '23	Buy	1.24	11,250	13,950	46,250	Aug 31 09:35 AM
Micallef Jacob Vincent	Chief Scientific Officer	Aug 25 '23	Buy	1.24	20,000	24,800	235,140	Aug 28 10:07 AM
Michel Gaetan	Chief Operating Officer	Aug 24 '23	Buy	1.23	5,000	6,150	212,997	Aug 24 12:00 PM
Futcher Edward	Director	Aug 24 '23	Buy	1.22	5,000	6,100	62,936	Aug 25 11:49 AM
Kway Jasmine	CEO - Singapore Volition	Aug 24 '23	Buy	1.20	5,000	6,000	10,400	Aug 25 11:49 AM
Reynolds Cameron John	President and CEO	Aug 16 '23	Buy	1.22	10,000	12,200	1,494,518	Aug 16 12:28 PM
Butera Salvatore Thomas	CEO - Volition Veterinary	Aug 16 '23	Buy	1.21	8,000	9,680	69,350	Aug 17 09:40 AM
Butera Salvatore Thomas	CEO - Volition Veterinary	Jun 02 '23	Buy	1.59	10,000	15,900	61,350	Jun 06 10:14 AM

Open in Screener

MYGN

Myriad Genetics, Inc.

May 01 • 04:00PM ET

19.47

Dollar change -0.10
Percentage change -0.51	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

MYGN Myriad Genetics, Inc. daily Stock Chart

Held by: IJR VTI VB IWM VBR VXF IWN IBB IJS IJT

Index	RUT	P/E	-	EPS (ttm)	-3.20	Insider Own	4.29%	Shs Outstand	89.90M	Perf Week	4.51%
Market Cap	1.75B	Forward P/E	78.14	EPS next Y	0.25	Insider Trans	-1.53%	Shs Float	86.02M	Perf Month	-2.65%
Income	-263.30M	PEG	-	EPS next Q	-0.10	Inst Own	101.81%	Short Float	6.39%	Perf Quarter	-8.98%
Sales	753.20M	P/S	2.32	EPS this Y	109.26%	Inst Trans	1.69%	Short Ratio	8.72	Perf Half Y	34.46%
Book/sh	8.71	P/B	2.23	EPS next Y	896.67%	ROA	-20.54%	Short Interest	5.50M	Perf Year	-10.28%
Cash/sh	1.58	P/C	12.31	EPS next 5Y	-8.20%	ROE	-31.55%	52W Range	13.82 - 24.21	Perf YTD	1.72%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-28.65%	52W High	-19.58%	Beta	1.97
Dividend TTM	-	Quick Ratio	1.87	Sales past 5Y	4.63%	Gross Margin	62.96%	52W Low	40.88%	ATR (14)	0.82
Dividend Ex-Date	-	Current Ratio	2.01	EPS Y/Y TTM	-131.34%	Oper. Margin	-19.33%	RSI (14)	47.50	Volatility	4.76% 3.77%
Employees	2700	Debt/Eq	0.19	Sales Y/Y TTM	11.03%	Profit Margin	-34.96%	Recom	2.85	Target Price	23.33
Option/Short	Yes / Yes	LT Debt/Eq	0.17	EPS Q/Q	30.17%	Payout	-	Rel Volume	1.55	Prev Close	19.57
Sales Surprise	0.92%	EPS Surprise	181.69%	Sales Q/Q	10.57%	Earnings	Feb 27 AMC	Avg Volume	630.82K	Price	19.47
SMA20	0.54%	SMA50	-7.20%	SMA200	1.83%	Trades		Volume	977,780	Change	-0.51%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-21-23	Resumed	Piper Sandler	Neutral	$23
Dec-19-23	Initiated	Wells Fargo	Equal Weight	$20
Dec-14-23	Initiated	Guggenheim	Buy	$23
Dec-13-23	Initiated	Wolfe Research	Outperform	$28
Jul-05-23	Resumed	JP Morgan	Underweight	$18
May-23-23	Upgrade	Goldman	Sell → Buy	$18 → $25
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform	$25
Oct-06-22	Initiated	Stephens	Equal-Weight	$22
Oct-15-21	Resumed	Cowen	Market Perform	$33
Jun-15-21	Initiated	Raymond James	Mkt Perform
Jun-03-21	Initiated	Goldman	Sell	$25
Sep-26-19	Downgrade	BofA/Merrill	Neutral → Underperform	$30 → $28
Aug-14-19	Downgrade	Piper Jaffray	Overweight → Neutral	$45 → $40
Aug-02-19	Upgrade	BofA/Merrill	Underperform → Neutral
Aug-01-19	Upgrade	Barclays	Underweight → Equal Weight	$18 → $40
Jul-29-19	Downgrade	Needham	Strong Buy → Hold
Jul-09-19	Downgrade	Cowen	Outperform → Market Perform
Mar-12-19	Reiterated	Needham	Strong Buy	$37 → $41
Jan-03-19	Initiated	Needham	Strong Buy	$36
Nov-30-18	Upgrade	Goldman	Sell → Neutral

Show Previous Ratings

Apr-30-24 04:05PM	Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-24-24 10:01AM	Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-17-24 08:00AM	Nearly Half of Americans Say They've Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor (GlobeNewswire)
Apr-16-24 09:15AM	New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel Prenatal Screen (GlobeNewswire)
Apr-11-24 10:00AM	Myriad Genetics (MYGN) Announces Favorable Research Results (Zacks)
09:10AM	Loading…
Apr-09-24 09:10AM	Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now (Zacks)
08:00AM	Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing (GlobeNewswire)
Mar-28-24 11:30AM	Why Is Myriad (MYGN) Down 1% Since Last Earnings Report? (Zacks)
Mar-27-24 07:51AM	Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay (Zacks)
Mar-21-24 09:40PM	Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date (GlobeNewswire)
Mar-20-24 04:05PM	Myriad Genetics Announces Patent Granted for SneakPeek Snap Device (GlobeNewswire)
Mar-01-24 09:41AM	Myriad Genetics (MYGN) to Evaluate MRD Testing With New Pact (Zacks) +5.97%
Feb-28-24 02:45PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research) -8.04%
11:24AM	Q4 2023 Myriad Genetics Inc Earnings Call (Thomson Reuters StreetEvents)
10:24AM	Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:50AM	Loading…
07:50AM	Myriad Genetics (MYGN) Q4 Earnings Top Estimate, Margins Down (Zacks)
Feb-27-24 07:00PM	Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
06:30PM	Myriad Genetics (MYGN) Tops Q4 Earnings and Revenue Estimates (Zacks)
04:42PM	Myriad Genetics Inc (MYGN) Reports 11% Revenue Growth in Q4 and Full-Year 2023 (GuruFocus.com)
04:05PM	Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance (GlobeNewswire)
09:15AM	Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3 (GlobeNewswire)
Feb-26-24 09:16AM	Wall Street's Insights Into Key Metrics Ahead of Myriad (MYGN) Q4 Earnings (Zacks)
Feb-21-24 04:05PM	Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (GlobeNewswire)
Feb-16-24 07:05AM	Larry Robbins' Glenview Capital Management Bolsters Stake in Myriad Genetics Inc (GuruFocus.com)
Feb-15-24 04:05PM	Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women's Health (GlobeNewswire)
Feb-01-24 09:25AM	Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics (GlobeNewswire)
Jan-30-24 05:00PM	Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology (GlobeNewswire)
Jan-25-24 07:05PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
Jan-22-24 08:55AM	Myriad's (MYGN) New Acquisition to Boost Precision Oncology Arm (Zacks) +5.17%
Jan-18-24 06:10PM	Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics (GlobeNewswire)
04:05PM	Loading…
Jan-09-24 04:05PM	Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO (GlobeNewswire)
Jan-04-24 11:10AM	Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now (Zacks)
Jan-03-24 04:05PM	Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-23 03:05PM	Genetic Testing Pioneer Myriad Genetics' Evolution Draws Analyst Attention Amid New Product(s) Anticipation (Benzinga)
09:17AM	Myriad Genetics' (MYGN) New Platform to Advance Cancer Care (Zacks)
08:30AM	Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance (GlobeNewswire)
Dec-20-23 08:00AM	Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care (GlobeNewswire)
Dec-14-23 08:22AM	Myriad Genetics' (MYGN) New Partnerships Aid Amid FX Woes (Zacks)
Dec-06-23 11:30AM	Why Is Myriad (MYGN) Up 3% Since Last Earnings Report? (Zacks)
Nov-21-23 10:54AM	Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now (Zacks)
Nov-20-23 04:05PM	Myriad Genetics Celebrates One Million SneakPeek Results Shared with Expectant Parents (GlobeNewswire)
11:18AM	Myriad Genetics (MYGN) Expands Pharma Services With New Pact (Zacks)
Nov-16-23 04:05PM	Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers (GlobeNewswire)
Nov-09-23 07:00AM	Myriad Genetics to Participate in Stephens Annual Investment Conference (GlobeNewswire) -8.94%
Nov-08-23 09:20PM	Myriad Genetics Announces Pricing of Upsized Offering of Common Stock (GlobeNewswire)
04:10PM	Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock (GlobeNewswire)
Nov-07-23 02:30PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research) +8.69%
10:24AM	Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:09AM	Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q3 (Zacks)
Nov-06-23 07:00PM	Myriad (MYGN) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
04:59PM	Myriad Genetics Inc (MYGN) Reports 23% YoY Revenue Growth in Q3 2023 (GuruFocus.com)
04:36PM	Myriad: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance (GlobeNewswire)
Nov-04-23 03:02AM	Insider Sell: CFO Richard Riggsbee Sells 30,000 Shares of Myriad Genetics Inc (GuruFocus.com)
Nov-03-23 07:04PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research) +6.51%
Nov-01-23 09:00AM	Myriad Genetics Appoints Sam Raha as Chief Operating Officer (GlobeNewswire)
Oct-31-23 04:05PM	Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023 (GlobeNewswire) +7.60%
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
Oct-26-23 08:00AM	QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer (GlobeNewswire)
Oct-20-23 10:31AM	Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research (PR Newswire)
Oct-09-23 06:56PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
Sep-29-23 11:44AM	Is Myriad Genetics (MYGN) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap (GuruFocus.com)
Sep-28-23 04:59PM	BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD (PR Newswire)
07:00AM	New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood (GlobeNewswire)
Sep-22-23 11:51AM	Is Myriad Genetics (MYGN) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap (GuruFocus.com)
Sep-20-23 07:42AM	Myriad Genetics (MYGN) Secures Key Milestones in Illumina Tie-Up (Zacks)
Sep-19-23 09:00AM	Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials (GlobeNewswire)
07:00AM	Myriad Genetics Issues 2022 Environmental, Social and Governance Report (GlobeNewswire)
Sep-18-23 08:00AM	Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer (GlobeNewswire)
Sep-12-23 11:41AM	Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now (Zacks)
Sep-08-23 11:49AM	Is Myriad Genetics (MYGN) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap (GuruFocus.com)
Sep-07-23 11:30AM	Why Is Amicus Therapeutics (FOLD) Down 6.8% Since Last Earnings Report? (Zacks)
Sep-06-23 04:05PM	Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work (GlobeNewswire)
07:00AM	New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women (GlobeNewswire)
Sep-05-23 08:00AM	Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-23-23 09:48AM	Myriad Genetics (MYGN) Teams Up to Assess Breast Cancer Risk (Zacks)
Aug-22-23 09:00AM	Myriad Genetics and Onsite Womens Health Partner to Help More Women Understand Breast Cancer Risk (GlobeNewswire)
Aug-17-23 04:05PM	Myriad Genetics to Host Investor Day on September 19, 2023 (GlobeNewswire)
Aug-16-23 08:36AM	Myriad Genetics (MYGN) Adds ARR to Prolaris Biomarker Test (Zacks)
Aug-15-23 07:05AM	Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris® (GlobeNewswire)
Aug-11-23 10:34AM	Myriad Genetics (MYGN) Unveils GeneSight Test Enhancement (Zacks) +7.19%
Aug-08-23 04:05PM	Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment (GlobeNewswire)
Aug-07-23 04:05PM	Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status (GlobeNewswire) -9.53%
12:12PM	Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Q2 Loss (Zacks)
Aug-05-23 08:29AM	Myriad Genetics, Inc. (NASDAQ:MYGN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-04-23 09:00PM	Myriad (MYGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -6.98%
07:08PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
07:09AM	Q2 2023 Myriad Genetics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-03-23 06:35PM	Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth (GlobeNewswire)
Jul-27-23 04:05PM	Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023 (GlobeNewswire)
Jul-24-23 08:00AM	Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment (GlobeNewswire)
Jul-06-23 08:30AM	Myriad Genetics Announces New $90 Million Asset-Based Credit Facility (GlobeNewswire)
Jun-30-23 11:16AM	Myriad Genetics (MYGN) Test Volume Rises Amid Margin Woe (Zacks)
Jun-28-23 09:32AM	Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now (Zacks)
Jun-21-23 08:00PM	MYGN: What does Argus have to say about MYGN? (Argus Research)
Jun-17-23 07:00AM	3 Gene Testing Stocks to Buy Before They Take Off (InvestorPlace)
Jun-13-23 08:16AM	Myriad Genetics' (MYGN) New Pact to Use MRD Testing Platform (Zacks)
Jun-12-23 08:00AM	Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform (GlobeNewswire)
Jun-07-23 04:05PM	Myriad Genetics to Participate in Goldman Sachs Healthcare Conference (GlobeNewswire)

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Riggsbee Richard Bryan	Chief Financial Officer	Dec 01 '23	Sale	19.09	30,000	572,835	291,812	Dec 05 04:19 PM
Riggsbee Richard Bryan	Chief Financial Officer	Nov 01 '23	Sale	15.69	30,000	470,622	321,812	Nov 03 05:12 PM
SPIEGELMAN DANIEL K	Director	Jun 02 '23	Sale	23.01	8,638	198,760	40,493	Jun 02 06:15 PM

Open in Screener

CDIO

Cardio Diagnostics Holdings Inc

May 01 • 04:00PM ET

0.6980

Dollar change +0.0130
Percentage change 1.90	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

CDIO Cardio Diagnostics Holdings Inc daily Stock Chart

Held by: VXF

Index	-	P/E	-	EPS (ttm)	-0.73	Insider Own	18.66%	Shs Outstand	20.54M	Perf Week	-6.93%
Market Cap	15.07M	Forward P/E	-	EPS next Y	-0.34	Insider Trans	0.00%	Shs Float	17.56M	Perf Month	-32.23%
Income	-8.38M	PEG	-	EPS next Q	-0.09	Inst Own	7.67%	Short Float	2.91%	Perf Quarter	-67.98%
Sales	0.02M	P/S	753.49	EPS this Y	34.09%	Inst Trans	-2.73%	Short Ratio	1.05	Perf Half Y	227.39%
Book/sh	0.14	P/B	4.85	EPS next Y	21.84%	ROA	-156.40%	Short Interest	0.51M	Perf Year	-68.70%
Cash/sh	0.06	P/C	11.77	EPS next 5Y	-	ROE	-230.77%	52W Range	0.17 - 3.56	Perf YTD	-71.97%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-231.33%	52W High	-80.39%	Beta	5.25
Dividend TTM	-	Quick Ratio	3.29	Sales past 5Y	850.88%	Gross Margin	-554.09%	52W Low	308.19%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	3.29	EPS Y/Y TTM	-46.44%	Oper. Margin	-42440.43%	RSI (14)	29.60	Volatility	9.68% 11.00%
Employees	9	Debt/Eq	0.43	Sales Y/Y TTM	-	Profit Margin	-49087.81%	Recom	1.00	Target Price	4.67
Option/Short	No / Yes	LT Debt/Eq	0.22	EPS Q/Q	84.50%	Payout	-	Rel Volume	0.30	Prev Close	0.69
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	484.20K	Price	0.70
SMA20	-27.16%	SMA50	-44.56%	SMA200	-44.26%	Trades		Volume	144,571	Change	1.90%

Today 08:30AM	3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation (News Direct)
Apr-29-24 08:31AM	Cardio Diagnostics Announces Publication of Study Showing That its PrecisionCHD Test Could Save Health Insurers Over $113 Million Annually (Business Wire)
Apr-24-24 08:30AM	As the Use of AI In Healthcare Grows, Cardio Diagnostic Is Using It In Quest to Help Prevent Cardiovascular Disease (News Direct)
Apr-12-24 08:45AM	Cardio Diagnostics Inks Groundbreaking Telehealth Agreement With Navierre And Expands Access To Cardiovascular Tests (News Direct)
Apr-09-24 08:31AM	Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan (Business Wire)
08:31AM	Loading…
Apr-04-24 08:31AM	Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre (Business Wire)
Mar-14-24 08:31AM	Cardio Diagnostics Holdings, Inc. to Showcase HeartRisk and Actionable Clinical Intelligence Version 3 at the American College of Cardiologys 73rd Annual Scientific Session (Business Wire) -5.76%
Mar-05-24 08:31AM	Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease (Business Wire) +22.09%
Feb-15-24 08:46AM	Cardio Diagnostics Holdings, Inc. Expands HeartRisk Platform Offering to Diverse Markets in Conjunction with Nationwide Rollout (Business Wire)
Feb-07-24 08:31AM	Cardio Diagnostics Holdings, Inc. Expands Partnership with Family Medicine Specialists to Bring Its Specialty Cardiology Tests to Select Walmart Supercenters (Business Wire) -5.13%
Feb-05-24 08:31AM	Houston-Based resTOR Longevity Clinic to Offer Cardio Diagnostics' AI-Driven Epigenetic-Genetic Heart Disease Tests (Business Wire)
Jan-24-24 08:31AM	Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor (Business Wire)
Jan-08-24 08:31AM	Cardio Diagnostics Holdings, Inc. Announces the Grant of a Patent in India (Business Wire) +9.13%
Jan-04-24 11:36AM	CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk (Business Wire)
08:31AM	Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk (Business Wire)
08:31AM	Loading…
Jan-03-24 08:31AM	American Medical Association (AMA) Grants Cardio Diagnostics a Dedicated CPT PLA Reimbursement Code for Epi+Gen CHD, an AI-powered Test for Assessing the Probability of a Heart Attack or Coronary Heart Disease Event (Business Wire)
Jan-02-24 08:31AM	American Medical Association (AMA) Grants Cardio Diagnostics Holdings, Inc.s AI-Powered Coronary Heart Disease Detection Test, PrecisionCHD, a Dedicated CPT PLA Reimbursement Code (Business Wire) +22.89%
Dec-21-23 09:21AM	Cardio Diagnostics Holdings, Inc. Appoints Biotechnology Investor, Executive & Serial Entrepreneur Paul Burton to its Board of Directors (Business Wire) +5.48%
Dec-06-23 08:31AM	Cardio Diagnostics Holdings, Inc. Regains Nasdaq Minimum Bid Price Requirement (Business Wire)
Dec-04-23 05:38PM	CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Convenes Cardiovascular Care & Risk Roundtable at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) -7.74%
08:31AM	Cardio Diagnostics Holdings, Incs Convenes Cardiovascular Care & Risk Roundtable at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-28-23 08:31AM	American Medical Association is Reviewing Cardio Diagnostics Holdings, Incs Integrated Epigenetic-Genetic Cardiovascular Medicine Tests for CPT PLA Codes (Business Wire) +5.75%
Nov-20-23 09:00AM	Cardio Diagnostics Establishes A New Partnership To Facilitate Global Footprint And Expansion Beyond North America With India-Based Aimil Ltd. (News Direct) +123.23%
08:31AM	Cardio Diagnostics Holdings, Inc. Announces Breakthrough in Coronary Heart Disease Detection with PrecisionCHD Test, Published in the Journal of the American Heart Association (Business Wire)
Nov-14-23 09:25AM	With New Lab/Operations Hub, Cardio Diagnostics Says its Prepared To Meet Uptake In Demand, Announces New Partner Initiative (News Direct) -5.36%
Nov-07-23 09:01AM	Family Medicine Specialists Selects Cardio Diagnostics Epigenetic-Genetic Tests for Assessing Heart Attack Risk for its BlueCross BlueShield Patients (Business Wire) +102.94%
Oct-31-23 09:15AM	Cardio Diagnostics Leverages AI To Combat Cardiovascular Disease (News Direct) +41.46%
09:01AM	Cardio Diagnostics Holdings, Inc Receives Innovative Technology Contract from Vizient for Its Novel AI-Driven Precision Heart Disease Tests Epi+Gen CHD & PrecisionCHD (Business Wire)
Oct-17-23 09:01AM	Cardio Diagnostics Holdings, Inc and Aimil Ltd Join Forces to Introduce Cardiovascular Epigenetic Technologies to India (Business Wire)
Oct-12-23 08:30AM	Cardio Diagnostics Holdings, Inc Launches New Lab and Fulfillment Center, Paving Way for Expanded Testing Capacity, Reduced Costs, Reduced Turnaround Time and Improved Margins (Business Wire)
09:01AM	Loading…
Sep-20-23 09:01AM	Cardio Diagnostics Publishes Novel and Scalable Pathways to Enhance Global Coronary Heart Disease Care through Precision Epigenetics in Epigenomics (Business Wire) -10.90%
Sep-07-23 09:01AM	Cardio Diagnostics Holdings, Inc. and Truckers Health Network Enter Into a Strategic Collaboration to Accelerate Cardiovascular Health Initiatives in the Trucking Industry (Business Wire) -14.63%
Sep-06-23 09:16AM	Cardio Diagnostics Holdings, Inc Partners with Ascension Borgess Hospitals Heart Attack Prevention Clinic on Coronary Artery Disease Study (Business Wire)
Sep-05-23 09:01AM	Cardio Diagnostics Holdings, Inc to Participate in Upcoming Investor Conferences (Business Wire)
Aug-18-23 08:30AM	Cardio Diagnostics Partners With FRSTeam of East Kansas and West Missouri to Host First Onsite Heart Disease Fair in Kansas Using Epigenetic-Genetic Technologies (Business Wire)
Aug-02-23 08:30AM	Cardio Diagnostics Holdings, Inc Announces Expansion of IP Portfolio in Australia with Notice of Allowance of Patent Application (Business Wire) -6.61%
Jul-26-23 01:30PM	Northland Capital Markets Institutional Investor Conference (ACCESSWIRE)
Jul-06-23 09:05AM	Cardio Diagnostics Holdings, Inc and RiverRock Medical Partner to Bring Epigenetic-Genetic Heart Disease Testing to Austin, Texas (Business Wire)
Jun-21-23 08:45AM	Cardio Diagnostics Holdings, Inc Democratizes CHD Detection with Nationwide Launch of PrecisionCHD (Business Wire)
Jun-13-23 09:01AM	Cardio Diagnostics Publishes Research Highlighting the Reversibility of Epigenetic Signatures of Coronary Heart Disease (Business Wire) +5.93%
May-16-23 10:35AM	Cardio Diagnostics Holdings, Incs Actionable Clinical IntelligenceTM (ACI) Platform Offers New Epigenetic and Genetic Insights to Inform Coronary Heart Disease Management (Business Wire) -15.93%
May-10-23 09:01AM	Transforming Heart Disease Prevention for Self-Insured Employers in Oklahoma, Missouri, Kansas, and Arkansas: A Strategic Alliance between Connect Clinic and Cardio Diagnostics (Business Wire)
May-04-23 08:30AM	Cardio Diagnostics Holdings, Inc Unveils The CardioInnovate360TM BioPharma Research System (Business Wire) +5.45%
Apr-26-23 08:30AM	Juniper Research Awards Cardio Diagnostics Holdings, Inc Future Digital Award for Best Digital Diagnostics Solution (Business Wire)
Apr-12-23 08:30AM	Cardio Diagnostics Holdings, Inc to Attend 22nd Annual AHOU Conference (Business Wire) +14.94%
Apr-05-23 08:30AM	Cardio Diagnostics Holdings, Inc Announces Strategic Engagement with Lifespan.io to Drive Longevity & Heart Disease Research and Education (Business Wire) -17.43%
Apr-03-23 06:15AM	7 Cheap Stocks That Are Worth Your Attention (InvestorPlace) -9.46%
Mar-31-23 06:30AM	7 Risky Stocks That Are Worth the Stretch (InvestorPlace)
Mar-29-23 09:27AM	Cardio Diagnostics Holdings, Inc Sponsors Beckers Hospital Review 13th Annual Meeting (Business Wire)
Mar-08-23 04:15PM	Cardio Diagnostics Holdings, Inc Announces Financing Agreement with Yorkville Advisors Global, LP of up to $11.2 Million (Business Wire) -7.96%
09:27AM	Cardio Diagnostics Holdings, Inc Welcomes Dr. Damon Broyles, MD, as Strategic Advisor for Precision Cardiovascular Medicine Strategy (Business Wire)
Mar-02-23 08:00AM	Cardio Diagnostics Holdings Inc Announces Expansion of IP Portfolio with Notice of Allowance of Patent Application (Business Wire) +19.70%
Feb-28-23 08:00AM	Cardio Diagnostics Holdings Inc Launches Revolutionary Blood Test for Early Detection of Coronary Heart Disease (Business Wire) +158.47%
Feb-22-23 08:01AM	Cardio Diagnostics Holdings Inc to Debut PrecisionCHD at the American College of Cardiologys 72nd Annual Scientific Session (Business Wire)
Jan-05-23 08:00AM	Healing Sanctuary Clinic Partners With Cardio Diagnostics Holdings Inc to Offer the Epi+Gen CHD Test in their Medical Practice in Idaho (Business Wire)
Jan-04-23 04:15PM	Cardio Diagnostics Holdings Inc to Attend 41st Annual JP Morgan Healthcare Conference (Business Wire)
Dec-28-22 08:00AM	Houston Concierge Medicine Partners With Cardio Diagnostics to Offer the Epi+Gen CHD Test in Their Executive Health Program (Business Wire)
Nov-21-22 08:00AM	Cardio Diagnostics to Present at the Benchmark Companys Upcoming Discovery One-on-One Investor Conference (Business Wire) +40.34%
Nov-17-22 07:01AM	Cardio Diagnostics Named to Fast Companys Second Annual List of the Next Big Things in Tech (Business Wire)
Nov-16-22 04:15PM	Cardio Diagnostics Holdings Inc Sponsors the Illinois Association of Medicaid Health Plans Annual Conference (Business Wire) -7.99%
Nov-14-22 08:13AM	Cardio Diagnostics Holdings Inc CEO Meesha Dogan, Accepted into Forbes Technology Council (Business Wire) +10.29%
Nov-08-22 07:12AM	Cardio Diagnostics Holdings Inc Sponsors Beckers Hospital Review 11th Annual Meeting - The CEO + CFO Roundtable (Business Wire)
Oct-26-22 08:30AM	Cardio Diagnostics Holdings, Inc. to List on Nasdaq Following Successful Business Combination with Mana Capital Acquisition Corp. (Business Wire) -36.23%

Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. It also develops and commercializes a series of products for major types of cardiovascular disease and associated co-morbidities including coronary heart disease (CHD), stroke, heart failure, and diabetes. The company was founded in 2007, and is headquartered in Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burton Paul Frederick	Director	Mar 31 '24	Option Exercise	1.42	8,803	12,500	8,803	Apr 08 03:28 PM
Lau Stanley K.	Director	Mar 31 '24	Option Exercise	1.42	8,803	12,500	100,325	Apr 08 03:22 PM
Intrater James	Director	Mar 31 '24	Option Exercise	1.42	8,803	12,500	71,596	Apr 08 03:07 PM
Levy Oded	Director	Mar 31 '24	Option Exercise	1.42	8,803	12,500	71,596	Apr 08 02:59 PM
Lau Stanley K.	Director	Jan 31 '24	Option Exercise	2.18	917	1,999	91,522	Feb 05 04:50 PM
Lau Stanley K.	Director	Dec 31 '23	Option Exercise	2.49	6,626	16,499	90,605	Jan 02 05:40 PM
Sim Brandon	Director	Dec 31 '23	Option Exercise	2.49	5,020	12,500	62,793	Jan 02 06:04 PM
Intrater James	Director	Dec 31 '23	Option Exercise	2.49	5,020	12,500	62,793	Jan 02 05:58 PM
Levy Oded	Director	Dec 31 '23	Option Exercise	2.49	5,020	12,500	62,793	Jan 02 05:49 PM
Lau Stanley K.	Director	Oct 31 '23	Option Exercise	0.30	6,631	2,000	83,979	Nov 03 04:24 PM
Lau Stanley K.	Director	Sep 30 '23	Option Exercise	0.34	42,647	14,500	77,348	Oct 04 12:15 PM
Levy Oded	Director	Sep 30 '23	Option Exercise	0.34	36,765	12,500	57,773	Oct 03 06:01 PM
Sim Brandon	Director	Sep 30 '23	Option Exercise	0.34	36,765	12,500	57,773	Oct 03 05:45 PM
Intrater James	Director	Sep 30 '23	Option Exercise	0.34	36,765	12,500	57,773	Oct 03 05:53 PM
Lau Stanley K.	Director	Aug 31 '23	Option Exercise	0.55	3,637	2,000	34,701	Oct 04 12:15 PM
Dogan Timur	Chief Technology Officer	Aug 31 '23	Buy	0.55	16,481	8,982	128,345	Sep 08 12:12 PM
Dogan Meeshanthini	Chief Executive Officer	Aug 31 '23	Buy	0.55	16,481	8,982	128,345	Sep 08 12:18 PM
Philibert Robert	Chief Medical Officer	Aug 28 '23	Buy	0.60	18,000	10,795	1,649,792	Sep 05 04:14 PM
Dogan Timur	Chief Technology Officer	Aug 25 '23	Buy	0.56	1,770	982	111,864	Sep 08 12:12 PM
Dogan Meeshanthini	Chief Executive Officer	Aug 25 '23	Buy	0.56	1,770	982	111,864	Sep 08 12:18 PM
Philibert Robert	Chief Medical Officer	Aug 24 '23	Buy	0.60	16,000	9,600	1,631,792	Sep 05 04:14 PM
Lau Stanley K.	Director	Jul 31 '23	Option Exercise	1.21	1,653	2,000	31,064	Oct 04 12:15 PM
Lau Stanley K.	Director	Jul 01 '23	Option Exercise	1.19	8,403	10,000	29,411	Jul 05 01:55 PM
Lau Stanley K.	Director	Jun 30 '23	Option Exercise	1.19	21,008	25,000	21,008	Jul 05 01:55 PM
Intrater James	Director	Jun 30 '23	Option Exercise	1.19	21,008	25,000	21,208	Jul 05 01:19 PM
Sim Brandon	Director	Jun 30 '23	Option Exercise	1.19	21,008	25,000	21,008	Jul 05 01:13 PM
Levy Oded	Director	Jun 30 '23	Option Exercise	1.19	21,008	25,000	21,008	Jul 05 01:04 PM

Open in Screener

MYMD

MyMD Pharmaceuticals Inc

May 01 • 04:00PM ET

3.20

Dollar change +0.12
Percentage change 3.90	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

MYMD MyMD Pharmaceuticals Inc daily Stock Chart

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-5.65	Insider Own	8.22%	Shs Outstand	2.02M	Perf Week	11.89%
Market Cap	6.91M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.98M	Perf Month	44.14%
Income	-8.22M	PEG	-	EPS next Q	-	Inst Own	9.53%	Short Float	19.85%	Perf Quarter	-28.89%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-79.54%	Short Ratio	1.74	Perf Half Y	-74.62%
Book/sh	6.06	P/B	0.53	EPS next Y	-	ROA	-22.60%	Short Interest	0.39M	Perf Year	-94.47%
Cash/sh	2.28	P/C	1.40	EPS next 5Y	-	ROE	-29.12%	52W Range	2.00 - 70.50	Perf YTD	-58.77%
Dividend Est.	-	P/FCF	-	EPS past 5Y	67.29%	ROI	-64.34%	52W High	-95.46%	Beta	2.18
Dividend TTM	-	Quick Ratio	1.17	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	60.00%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	1.17	EPS Y/Y TTM	52.05%	Oper. Margin	0.00%	RSI (14)	63.93	Volatility	8.13% 11.70%
Employees	6	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	32.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-3.10%	Payout	-	Rel Volume	0.60	Prev Close	3.08
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	225.22K	Price	3.20
SMA20	26.38%	SMA50	13.20%	SMA200	-75.22%	Trades		Volume	134,838	Change	3.90%

Apr-09-24 08:21AM	Why Is MyMD Pharmaceuticals (MYMD) Stock Up 35% Today? (InvestorPlace)
Mar-05-24 09:15AM	MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing (Business Wire)
Feb-13-24 11:45AM	MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing (Business Wire) -14.49%
Dec-29-23 12:45PM	MyMD Pharmaceuticals Releases Positive Clinical Trial Results For Sarcopenia Treatment Drug (ACCESSWIRE)
Dec-06-23 09:15AM	MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis (Business Wire) -5.75%
09:00AM	Loading…
Oct-19-23 09:00AM	MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain (Business Wire)
Oct-04-23 07:30AM	MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF- Market Disrupter, at BioFuture 2023 (Business Wire)
Aug-14-23 08:30AM	FDA Accepts MyMD Pharmaceuticals Investigational New Drug Application (IND) for Phase 2 Study of oral TNF- inhibitor MYMD-1® in Rheumatoid Arthritis (RA) (Business Wire) -7.64%
Aug-02-23 08:30AM	MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results (Business Wire)
Jul-31-23 09:00AM	MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF- Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty (Business Wire) +31.82%
Apr-12-23 08:30AM	MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire) -8.54%
Mar-20-23 08:55AM	MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF- Inhibitor MYMD-1® in Rheumatoid Arthritis (Business Wire) -5.00%
Mar-08-23 08:30AM	MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls (Business Wire)
Mar-02-23 08:30AM	MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD is not a Controlled Substance or Listed Chemical (Business Wire) +5.62%
Feb-28-23 08:30AM	MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF- Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting (Business Wire)
08:45AM	Loading…
Feb-21-23 08:45AM	MyMD Announces $15 Million Offering with Existing Investors (Business Wire) -7.32%
Dec-06-22 09:40AM	ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022 (Business Wire) -9.74%
Nov-17-22 08:00AM	MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress (Business Wire)
Nov-14-22 08:00AM	MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research (Business Wire) -5.96%
Sep-20-22 08:00AM	MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire) -6.25%
Aug-30-22 08:30AM	MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD Compound (Business Wire) -7.27%
Aug-03-22 09:45AM	Data Showing MyMD Pharmaceuticals MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences (Business Wire)
Jul-29-22 09:19AM	Is MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) Popular Amongst Insiders? (Simply Wall St.) +5.79%
Jul-26-22 07:30AM	MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire) -11.44%
Jul-12-22 09:30AM	MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions (Business Wire) +17.10%
Jun-21-22 10:30AM	MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire)
Apr-05-22 09:15AM	MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire) -8.79%
Mar-24-22 09:26AM	MyMD Pharmaceuticals Announces Live Appearance on Cheddar News Network Today March 24 (Business Wire)
Feb-23-22 09:15AM	MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire) -9.49%
Feb-20-22 08:37AM	We're Keeping An Eye On MyMD Pharmaceuticals' (NASDAQ:MYMD) Cash Burn Rate (Simply Wall St.)
09:15AM	Loading…
Feb-08-22 09:15AM	MyMD Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan (Business Wire) -5.13%
Feb-07-22 08:38PM	NorthRock Partners, LLC Buys PepsiCo Inc, iShares MSCI EAFE ETF, iShares MSCI Emerging Markets ... (GuruFocus.com)
Jan-05-22 09:15AM	MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia (Business Wire) -5.26%
Dec-29-21 09:15AM	MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia (Business Wire)
Dec-16-21 10:50AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating MyMD Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors (PR Newswire)
Dec-01-21 10:05AM	MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021 (Business Wire)
Nov-23-21 09:25AM	MyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending Lifespan (Business Wire)
Nov-18-21 09:15AM	MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America (Business Wire) -9.76%
Nov-16-21 09:25AM	MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan (Business Wire) -11.75%
Nov-15-21 09:45AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating MyMD Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors (ACCESSWIRE)
Oct-26-21 10:30AM	MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation (Business Wire)
Oct-19-21 10:30AM	MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21 (Business Wire) +6.56%
Oct-05-21 10:00AM	MyMD Pharmaceuticals to Detail its Two Upcoming Phase 2 Trials at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7 (Business Wire)
Sep-22-21 11:00AM	MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD (Business Wire)
Sep-13-21 10:00AM	MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan (Business Wire) -9.30%
Sep-09-21 10:15AM	MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15 (Business Wire)
Aug-24-21 10:17AM	MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and Asthma (Business Wire)
Aug-23-21 08:47AM	We Think MyMD Pharmaceuticals (NASDAQ:MYMD) Can Afford To Drive Business Growth (Simply Wall St.) +5.02%
Aug-10-21 02:30PM	MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases (Business Wire) +13.75%
10:30AM	MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine (Business Wire)
Aug-05-21 10:30AM	MyMD Pharmaceuticals Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study (Business Wire) +8.46%
Jul-27-21 09:15AM	MyMD Pharmaceuticals Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and Dermatitis (Business Wire)
Jul-07-21 09:00AM	MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1 (Business Wire) -12.50%
Jun-07-21 10:02AM	MyMD Pharmaceuticals Set to Join Russell Microcap® Index (Business Wire)
May-17-21 09:00AM	MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory Board (Business Wire)
May-12-21 09:00AM	MyMD Pharmaceuticals Schedules Business Update Conference Call (Business Wire)
May-10-21 09:00AM	MyMD Pharmaceuticals: Invitation to the Benzinga Global Small Cap Conference (Newsfile)
Apr-28-21 10:13AM	Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit (Business Wire) +10.92%
Apr-22-21 09:20AM	MyMD Pharmaceuticals Announces Issuance of Allowance from United States Patent and Trademark Office for Synthetic Cannabinoid Compounds (Business Wire)

MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. It focuses on developing and commercializing the MyMD-1 and SUPERA-CBD therapeutic platforms. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune diseases. Supera-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in Baltimore, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rivard Paul	Chief Legal Officer	Aug 24 '23	Buy	1.11	150,000	166,500	400,000	Aug 24 05:58 PM
Rivard Paul	Chief Legal Officer	Aug 17 '23	Buy	1.12	25,000	28,080	250,000	Aug 18 04:21 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

LNTH

NEOG

OCX

CATX

IDXX

ACHV

NTLA

TKNO

QDEL

IONS

AWH

VNRX

MYGN

CDIO

MYMD

Upgrade your FINVIZ experience